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Abstract  I 
Partly presented at AACR 2018 
Abstract 
With the help of a patient-derived clear cell renal cell carcinoma (ccRCC) model system 
previously established in our laboratory, which recapitulates the heterogeneity of the 
originating tumor, we were able to study ccRCC on a functional level
1,2
. In five rounds and in 
four biological replicates of an in vivo selection, we transplanted lung metastases of 
orthotopically transplanted tumor cells into the renal capsules of NOD scid gamma (NSG) 
mice. The tumor was enriched for cells with increased growth and higher metastatic potential 
compared to the initial heterogeneous population. Comparative gene expression analysis 
revealed candidate genes associated with enhanced malignant growth and metastasis. Least 
absolute shrinkage and selection operator (LASSO) regression identified a gene signature that 
can robustly predict cancer specific patient survival. The prognostic power of our signature 
was additionally verified in independent patient cohorts suggesting that this approach 
leverages efficient stratification of patients into distinctive risk groups. Intra- and intertumor 
heterogeneity remains a clinical challenge as estimated survival rates could vary substantially 
when comparing different tumor regions.  
Tetraspanin-8 (TSPAN8) was identified as one of the hallmark genes in the generated ccRCC 
signature and is known to alter cellular signaling. Therefore, we hypothesized that TSPAN8 
contributes to tumor aggressiveness and thus to growth and metastasis of ccRCC. In fact, in 
knockdown and overexpression xenografts experiments, we could confirm an essential role 
for tumor aggressiveness in vivo suggesting that TSPAN8 is an attractive target for treatment 
of clear cell renal cell carcinoma. 
  
 
Zusammenfassung  II 
Zum Teil auf der AACR 2018 präsentiert 
Zusammenfassung 
Ein zuvor in unserem Labor etabliertes patientenbasiertes Modellsystem des klarzelligen 
Nierenzellkarzinoms (ccRCC), welches die Heterogenität des Ursprungtumors widerspiegelt, 
ermöglichte es uns, ccRCC auf funktioneller Ebene zu untersuchen
1,2
. In vier biologischen 
Replikaten und in jeweils fünf in vivo Selektionsrunden wurden Lungenmetastasen 
orthotopisch transplantierter Tumorzellen in die Nierenkapseln von NOD scid gamma (NSG)-
Mäusen retransplantiert. Dabei wurde der Tumor, verglichen mit der anfänglich heterogenen 
Population, für Zellen mit erhöhtem Wachstums- und Metastasierungspotenzial angereichert. 
Durch eine vergleichende Genexpressionsanalyse wurden Kandidatengene identifiziert, die 
mit bösartigen Tumorwachstum und Metastasierung assoziiert werden. Wir konnten mit Hilfe 
einer LASSO-Regression (Least Absolute Shrinkage and Selection Operators) eine 
Gensignatur erstellen, die das krebsspezifische Patientenüberleben zuverlässig vorhersagen 
kann. Die prognostische Aussagekraft unserer Signatur wurde zusätzlich in unabhängigen 
Patientenkohorten überprüft, was darauf hindeutet, dass ihr Einsatz eine effiziente 
Stratifizierung der Patienten in unterschiedliche Risikogruppen ermöglicht. Die 
Tumorheterogenität zwischen den Patienten und innerhalb des Tumors selbst bleibt jedoch 
eine klinische Herausforderung, da die geschätzten Überlebensraten beim Vergleich 
verschiedener Tumorregionen stark variieren können.  
Tetraspanin-8 (TSPAN8) ist eines der wichtigsten Gene in der ccRCC-Signatur und dafür 
bekannt, die zellulären Signalwege zu modulieren. Daher haben wir angenommen, dass 
TSPAN8 zur Tumoraggressivität und damit zum Wachstum und Metastasierung von ccRCC 
beiträgt. Tatsächlich konnten wir durch den Knockdown und die Überexpression des Gens im 
Xenograft Modell dessen wesentlichen Einfluss auf die Aggressivität des Tumors in vivo 
bestätigen. Dies deutet darauf hin, dass TSPAN8 ein attraktives Ziel für die Behandlung von 
klarzelligem Nierenkrebs ist. 
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1 Introduction 
1.1 Kidney Cancer – Epidemiology and Subtypes 
Kidney cancer is the 14
th
 most common cancer worldwide
3
. Approximately 400 000 new 
cases of kidney cancer were registered worldwide, an age-standardized risk of 4.4 per 100 000 
inhabitants, with a mortality of approximately 175 000 every year. In countries with a high 
human development index (developed countries), incidence rates are higher (Figure 1a, b). 
The highest age-standardized incidence rate has been reported in the Eastern European 
countries Belarus, Latvia and Lithuania with 16.8, 15.2 and 14.8 cases per 100 000 
inhabitants, respectively
3
. Two-third of the patients are male and average age of diagnosis is 
64  
(Figure 2a). The epidemiological data in Germany is comparable to other Western countries, 
with an incidence of 16.5 per 100 000 males and 7.8 per 100 000 females. Therefore, kidney 
cancer is the 8
th
 and 10
th
 most common cancer type in Germany, respectively
4
. In Germany, 
the relative 5-year survival rate that represents the cancer-specific survival (CSS) is 77 % and 
relative 10-year survival rate 71 % (see section 1.3.1). 
Kidney cancer incidence has been reported to rise in the future (Figure 2b)
5,6
. This rise has 
been linked to an aging population
7
, an increased prevalence of the main risk factors, such as 
obesity
8
, smoking
9
 and hypertension
10
. However, a detection bias has been discussed, which 
arises by improvements in screening methods and increasing awareness of kidney cancer
11
. 
 Renal Cell Carcinoma 1.1.1
Approximately 90-95 % of kidney cancers are renal cell carcinomas (RCC)
12
. The classical 
clinical symptoms of RCC are a combined symptom triad of flank pain, hematuria and flank 
mass. These symptoms are present in only 10 % of the patients and only in advanced tumors. 
Other symptoms of renal cell carcinomas are anemia, weight loss, fever and hypertension. 
Many patients present themselves additionally with paraneoplastic syndromes that may 
mislead a correct diagnosis, such as hypercalcemia, erythrocytosis, Stauffer syndrome, 
amyloidosis and anemia. The complex clinical presentation of renal cell carcinoma explains 
late diagnosis, when 15-25 % of the patients have already developed local or distant 
metastases (Figure 2c)
4,13,14
. 
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a 
 
 
b 
 
Figure 1 –Cancer Statistics 
GLOBOCAN 2018 age-standardized cancer incidence and mortality rates between (a) men and (b) woman in 
regions of high/very-high human development index (HDI) and regions of low/medium HDI regions in 2018. In 
the 2018 edition of the Global Cancer Statistics, Bray et al. present the worldwide estimates of incidence and 
mortality for 36 types of cancer in a bar chart of descending order of the overall age-standardized rate
3
. 
400 000 new cases of kidney cancer were registered worldwide with a mortality of approximately 175 000 
every year. Countries with high human development index (developed countries) have higher incidence rates 
than countries with a low human development index. 
Figure reprinted with kind permission of John Wiley and Sons (License Number 4494191362627). 
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a 
 
b 
 
c  
 
Figure 2 – Kidney Cancer Statistics 
(a) Cancer Research UK reported age-specific mortality rate and average number of death by kidney 
cancer per year, UK, 2014-2016. Rates of kidney cancers in the UK are comparable with high HDI 
countries. This plot illustrates that kidney cancer is an age and gender related tumor. Credit: Cancer 
Research UK. 
(b) Cancer Research UK reported increasing incidence rates of kidney cancer between 1990 and 2015. 
Credit: Cancer Research UK. 
(c) Distribution of T-Stages of RCC at first diagnosis by gender, Germany 2013-2014. 
Adapted from “Krebs in Deutschland”, 2017, with kind permission of Zentrum für Krebsregisterdaten, 
Robert Koch-Institut
4
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Correct diagnosis is accomplished by ultrasonography, computed tomography scan or 
magnetic resonance imaging (MRI) and provides necessary information for surgical 
resections. Preoperative biopsy may validate diagnosis but is not used in German general 
practice
15,16
.  
 Histologic Subtypes of RCC 1.1.2
RCC is subtyped into five major distinct histological subtypes. The most common subtype is 
the clear cell type with 60-70 % of the renal cell carcinomas. Other types are papillary (10-
15 %), chromophobe (3-5%), oncocytomas (3 %) and tumors originating from the collecting 
duct (1 %). Additionally, some rare subtypes of RCC have been identified: Cystic-solid (1 %), 
Medullary (< 1 %), Xp11 translocations, “Mucinous tubular and Spindle cell”, and 
“Associated with neuroblastoma”17,18. 
The RCCs of the different histological phenotypes differ in growth, aggressiveness, metastatic 
patterns, cell of origin and cytogenetics among others (Table 1). 
Table 1 – Pathologic classification of the most common types of renal cell carcinoma
17,19
 
 
Type Features Growth Pattern Cell of Origin 
Common 
Cytogenetics 
Clear cell Most common, majority 
sporadically 
Acinar or 
sarcomatoid 
Proximal tubule 3p-, 5q+, 8p-, 9p-, 14q- 
Papillary Bilateral and multifocal Papillary or 
sarcomatoid 
Proximal tubule +7, +17, -Y, 12+, 16+, 20+ 
Chromophobe Indolent course Solid, tubular, or 
sarcomatoid 
Cortical collecting duct Hypodiploid 
Oncocytic Rarely metastasize Tumor nests Cortical collecting duct Undetermined 
Collecting 
duct 
Very aggressive Papillary or 
sarcomatoid 
Medullary collecting duct Undetermined 
 
 Clear Cell Renal Cell Carcinoma 1.1.3
Clear cell Renal Cell Carcinoma (ccRCC), the most common histologic variant of RCC, 
displays the worst prognosis in comparison to other histologic subtypes
20
. The most 
prominent feature of this subtype is the vast accumulation of lipids and glycogen in the 
cytoplasm of the epithelial cells. These molecules are washed out during the fixation process 
for the histological examination and therefore the cells appear “clear” (Figure 3a)21. ccRCCs 
may also contain various amounts of cells with granular eosinophilic cytoplasm (Figure 
3b)
22
. 
ccRCCs grow in acinar, nested compact-alveolar and/or microcystic patterns, often in a 
combination in one single tumor. Typically, the epithelial cells are surrounded by a branched 
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network of connective tissue and blood vessels separated by a well-defined basal lamina  
(Figure 3a,c)
22
. 
Additional cells of the microenvironment are tumor-infiltrating immune cells, mainly T cells 
(51 %), tumor-associated macrophages (31 %), natural killer cells (9 %) and B cells (4 %)
23
. 
Also granulocytes are found in the ccRCC tumor microenvironment at low levels.  
a 
 
 
 
b 
 
c 
 
Figure 3 – Typical Histological Appearance of Clear Cell Renal Cell Carcinoma 
(a) Histology of a ccRCC, fixated and stained with hematoxylin and eosin. The carcinoma is characterized by 
a clear, name-giving cytoplasm of the epithelial cells. The tumor is highly infiltrated by a branched network of 
vasculature. 
(b) Variant of ccRCC with eosinophilic granules 
(c) The extensive network of vasculature can be observed by staining for CD31 
Image reproduced with permission from Medscape Drugs & Diseases (https://emedicine.medscape.com/),  
Pathology of Clear Cell Renal Cell Carcinoma, 2016, available at: 
https://emedicine.medscape.com/article/1612043-overview 
Macroscopically, ccRCCs are generally solid and solitary tumors. In early stages they are 
often well surrounded by a capsule or a so called pseudocapsule comprised of compressed 
normal renal parenchyma and fibrous tissue
24
. Intracellular accumulation of lipids gives 
ccRCCs a yellow-golden color, which may be intersected by brown hemorrhages and grey 
fibrotic areas or necrotic areas
22
. Tumor sizes can range from microscopic lesions < 0.3 cm to 
maximal diameters large as 30 cm 
25
. In average, patients present themselves with a tumor 
size of 6-7 cm at diagnosis. Modern imaging technologies and a higher awareness allow 
earlier tumor detection and therefore tumors are diagnosed at smaller sizes
20
. 
1.2  Pathophysiology of ccRCC 
 The role of VHL and HIF in ccRCC 1.2.1
ccRCC arises from proximal convoluted tubular epithelium of the nephron
26,27
. The majority 
of ccRCCs are sporadic cancers, but approximately 2-4 % of ccRCCs are caused by hereditary 
syndromes such as the rare Von Hippel-Lindau (VHL) syndrome and tuberous sclerosis
26
. In 
about 90 % of the tumors, the VHL pathway is affected: Mutations (53-37 %) of the tumor 
suppressor gene VHL, hypermethylation of its promoter (5-10 %), mutations in genes of the 
6  Introduction 
VHL complex or loss of the short arm of chromosome 3, on which the VHL gene is located at 
3p25 have been reported
28-31
. 
The gene product of VHL is part of the E3 ubiquitin ligase complex VCB-CR that targets 
hydroxylated proteins for proteasomal degradation
32
. Under normoxic conditions, prolyl 
hydroxylases (PHD) enzymes hydroxylate proline residues of the hypoxia-inducible 
transcription factors HIF-1α and HIF-2α, which are subsequently recognized by pVHL of the 
VCB-CR complex to start the ubiquitination and degradation process (Figure 4a)
33-35
. 
Deprivation of oxygen suppresses PHD dependent hydroxylation of HIFα resulting in HIFα 
stabilization and accumulation. Together with HIF-1β, HIF-α forms a heterodimer, which is 
shuttled into the nucleus, binds hypoxia response elements (HREs) and induces the 
transcription of more than 500 hypoxic target genes (Figure 4b)
36-38
. Thereby, pathways of 
glycolysis, lipogenesis, cell-cycle and angiogenesis are activated and apoptosis is inhibited
39-
46
. 
Defective VCB-CR complexes lead to normoxic accumulation of HIF-α, irrespectively of its 
proline residue hydroxylation status. As a consequence, HIF-α-HIF-1β complexes become 
stabilized resulting in non-physiological HREs activation (Figure 4c)
35,47
. Although not 
expressed in normal tubular kidney epithelium, the expression and stabilization of the isoform 
HIF-2α plays an essential role as an early event in the tumorigenesis of ccRCCs48-51. In this 
aspect, ccRCC differs from other cancer types in which both subunits of HIF-α are associated 
with tumor progression
52
. In ccRCC, it has been noted that HIF-1α could even act as a tumor 
suppressor. HIF-1α loss of function mutations have been identified and additionally, 
knockdown and mutations in HIF-1α promote tumor growth in mouse models53-55. On the 
contrary, overexpression of HIF-2α in mouse ccRCC-xenograft models increases tumor 
formation
48,56
, whereas its inhibition stops tumor progression in vivo
57
. Both isoforms share 
common DNA binding regions like the ubiquitous HIF target genes CA9 and GLUT1. One of 
the target genes that is exclusively regulated by the heterodimeric HIF-2α-HIF-1β complex is 
Cyclin D1, a cell cycle promoting protein, which is expressed in early ccRCC lesions
48
. 
Moreover, c-Myc activity is solely enhanced by tumors only expressing HIF-2α58,59. HIF-2α 
stabilizes c-Myc/Max complexes post-transcriptionally due to direct binding, while HIF-1α 
represses c-Myc transcription factor activity by disrupting c-Myc/Max and c-Myc/Sp1 
complexes. Hence, c-Myc promotes tumor progression by enhanced transcription of cell cycle 
activators such as cyclin D2, E2F1 and inhibition of cell cycle repressors such as cyclin-
dependent kinase inhibitor 1 (p21) and cyclin-dependent kinase inhibitor 1B (p27)
60
. Another 
gene that is upregulated by HIF-2α is the embryonic stem cell factor POU5F1 (Oct-4)61. 
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The tumor-suppressor gene TP53, a hallmark gene of many tumor entities, is mutated in only 
2.6 % of ccRCCs
62,63
. However, HIF-2α inhibition has been shown to promote p53 pathway 
activity
64
. Nevertheless, the crosstalk between HIF and TP53 is complex and its role in tumor 
progression controversially discussed
65
. 
a 
 
b 
c 
Figure 4 – pVHL and HIF in physiological conditions and disease 
(a) In normoxic conditions, all isoforms of hypoxia inducible factor alpha (HIF-α) are oxygen dependent 
hydroxylated by prolyl hydroxylases (PHD). Subsequently, HIF-α is bound by pVHL and the E3 ubiquitin 
ligase complex VCB-CR is recruited. The complex ubiquitinates HIF-α and targets it for ubiquitin-mediated 
proteolysis. 
(b) In hypoxic conditions, HIF-α is not degraded. It accumulates, forms a heterodimer with HIF1-β and 
translocates to the nucleus where it binds to hypoxia response elements (HREs) and regulates the 
transcription of more than 500 genes. 
(c) Mutated pVHL is unable to bind hydroxylated HIF-α, which thereby accumulates and non-physiologically 
regulates HREs. 
8  Introduction 
 Genomic evolution of ccRCC 1.2.2
In many ccRCC patients, loss of chromosomal arm 3p, which harbors VHL, is a hallmark 
event that occurs early in childhood to adolescence (Figure 5)
62,66,67
. Often, a chromothriptic 
rearrangement between 3p and 5q is followed by 3p loss and 5q gain. This unbalanced 
translocation can be found in up to 60 % of all ccRCC patients
67-70
. Following Knudson’s 
two-hit hypothesis for tumor suppressor genes
71
, the subsequent mutation or epigenetic 
inactivation of the second VHL gene on the other allele of 3p is often found on the trunk of the 
phylogenetic tree that describes the ccRCC tumor evolution
72,73
.  
 
Figure 5 – Chronologic sequence of 
genomic events in ccRCC development 
Already in childhood and adolescence, loss of the 
short arm of chromosome 3 by a chromotrypsis 
event is often the initial event of ccRCC 
development. Loss of 3p leads to a loss of 
heterozygosity for many tumor suppressors. Years 
later, inactivation of the second VHL allele is found 
clonal in most tumors, followed by subclonal 
mutations. From Mitchell et al.
67
 
The chromosomal deletion of 3p leads to a loss of heterozygosity (LOH) of many genes. Next 
to VHL, 3p harbors genes like Polybromo-1 (PBRM1), BRCA1-associated protein (BAP1), 
and Su(var), Enhancer of zeste, Trithorax-domain containing 2 (SETD2), which are mutated 
in ~50 %, ~15 % and ~15 % of the patients, respectively (Figure 6a)
74-77
. While 3p loss and 
inactivation of VHL are ubiquitously found in ccRCC, mutations in PBRM1, BAP1 and 
SETD2 are often found in spatial separated subclones. They are subclonal driver mutations of 
branches of a phylogenetic tree describing the tumor evolution
73,78-82
. The branched evolution 
of the tumor leads to a vast intratumor heterogeneity (ITH) with a median of 4 subclones per 
tumor that complicates stratification of patients for targeted treatment according to a single 
biopsy (Figure 7). In fact, the number of subclones correlates with tumor stage and grade but 
only with a tumor of a size up to ~10 cm 
28
.  
Turajilic et al. identified seven major evolutionary subtypes of ccRCC subclones by 
multiregion sequencing
28
. The first subtype, often found in early stage tumors, is solely driven 
by VHL inactivation and has a stable genome (Figure 6b-1). The second subtype has an 
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additional BAP1 mutation driving tumor progression to high grade tumors with increased 
genome instability (Figure 6b-2).  
Instead of BAP1, PBRM1 drives progression of three other distinct evolutionary subtypes with 
high subclonal heterogeneity. Subsequent mutation of SETD2, often mutated in parallel 
evolution, results in slow tumor progression with high intratumor heterogeneity (> 10 clones 
per tumor) (Figure 6b-3). Evolutionary subtypes that show PI3K/AKT/mTOR pathway 
activation (Figure 6b-4) or subclonal somatic copy number aberrations following PBRM1 
mutation are often low grade and have a good prognosis (Figure 6b-5). Common subclonal 
chromosomal events are 14q loss (with HIF1A), 9p loss (with CDKN2A) and 4q loss (with 
CXXC4) (Figure 6c). 
In the subtypes described so far, BAP1 and SETD2 or PBRM1 mutations are mutually 
exclusive
28,77
. However, such mutations are found together in advanced tumors of the last 
evolutionary subtype defined by Turajulic et al. This “multiple clonal driver” subtype with 
VHL, BAP1, PBRM1, SETD2 or PTEN clonal mutations shows low intratumor heterogeneity 
but high chromosomal complexity (Figure 6b-6). 
The last evolutionary subtype is a highly proliferative VHL wild-type tumor with high genome 
instability (Figure 6b-7). This rare subtype (10-18 %) is characterized by a hyperdiploid 
karyotype with common amplifications of chromosome 2, 3q, 7, 8q, 12, 16, 20, 21 and loss of 
9p
83
. It often lacks the classic 3p21-25 deletion and shows rapid tumor progression as well as 
sarcomatoid differentiation
84
. 
The different evolutionary subtypes were grouped by Mitchell et al. according to their 
evolution into: “Punctuated Evolution” with rapid progression (“multiple clonal driver”, 
“BAP1 driven” and “VHL wildtype”), “Branched Evolution” with attenuated progression 
(PBRM1 driven tumors) and “Linear Evolution” that may represent early tumor stages 
(Figure 6b)
67
. 
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Figure 6 – Somatic drivers of ccRCC 
(a) Mutation frequency of somatic drivers of ccRCC in the TRACERx Renal cohort, TCGA-KIRC, Sato et al.
31
 
and Scelo et al.
85
 ccRCC studies. Dark shaded columns indicates clonal and light shade subclonal mutations 
in the TRACERx study. Adapted from Turajilic et al.
28
 
(b) Evolutionary subtypes of primary tumors of ccRCC subclones, grouped according to chromosomal 
complexity. Exemplary chronology sequence of mutations and somatic copy number alterations (SCNA) is 
annotated from the bottom to the top. Genomic alterations and driver mutations found in one exemplary tumor 
subclone are colored in blue for each evolutionary subtype. BAP1-driven tumors for example harbor clonal 
VHL inactivation, following subclonal BAP1 mutation, 9p and 14q loss. ccRCC subclones that contain the 
sequence of VHL→PBRM1 mutations tend to have higher intratumor heterogeneity. The length of the path 
that describes a tumor subclone is meaningless. Adapted from Turajilic et al.
86
 
(c) Frequencies of somatic copy number alterations (SCNAs) in the TRACERx renal cohort. Red marks clonal 
copy number gains and blue marks clonal copy number losses. Light shades are subclonal changes in copy 
numbers. The dotted line indicates SCNAs in the TCGA KIRC dataset. Adapted from Turajilic et al.
28
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PBRM-1, the second most common mutated gene in ccRCC, encodes for the nucleosome 
remodeling protein BAF180. It is part of the chromatin-remodeling complex Switch/Sucrose 
nonfermentable (SWI/SNF) and associated with cell cycle control
87,88
. Unchecked cell cycle 
control can also result from mutations in the tumor suppressor gene BAP-1 that together with 
the host cell factor-1 (HCF-1) inhibits cell proliferation
75
. 
The chromatin remodeler SETD2 has a dual function. On the one hand, SETD2 is important 
for nucleosome stabilization, RNA polymerase II-mediated transcriptional elongation and 
splicing by trimethylation of H3 histones on lysine 36
89,90
. On the other hand, the loss of 
SETD2 mediated microtubule methylation during mitosis results in mitotic defects with 
increased genomic instability
91
. 
 
Figure 7 – Schematic overview of intertumor and intratumor heterogeneity 
ccRCCs show vast genetic and phenotypic heterogeneity between patients (intertumor heterogeneity). 
Although the majority of patients (~90 %) harbor the trunk mutation VHL, subsequent tumor development 
varies greatly between them. Tumor evolution of patients is never identical, even though they are all classified 
histologically as ccRCC. The tumors themselves may consist of several subclones (intratumor heterogeneity), 
of which cells of the subclones may be mixed (subclone 1 and 2) or separated spatially from other subclones 
(subclone 3). Figure reprinted with kind permission of Springer Nature (License Number: 4514240325627) 
 mTOR signaling in ccRCC 1.2.3
In many ccRCCs, activation of the PI3K/AKT/mTOR pathway plays a central role in 
enhancing cell growth and metabolism (Figure 8). Phosphatidylinositol-3-kinase (PI3K or 
p110-α) is phosphorylated by receptor tyrosine kinases (RTKs), such as epidermal growth 
factor (EGF) receptor, Platelet-derived growth factor (PDGF) receptor or vascular endothelial 
growth factor (VEGF) receptor family members after extracellular stimulation
92
. PI3K 
phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) in the plasma membrane to 
phosphatidylinositol-3,4,5-triphosphate (PIP3) recruiting protein kinase B (PKB/Akt) to the 
membrane. After successful recruitment, PKB/Akt is activated by phosphorylation by 
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mammalian target of rapamycin complex 2 (mTORC2 or PDK2) and subsequently by 
phosphoinositide dependent kinase 1 (PDPK1)
93-95
. This process is antagonized by 
dephosphorylation of PIP3 by phosphatase and tensin homolog (PTEN). PKB/Akt is a 
serine/threonine protein kinase that promotes proliferation and cell growth but inhibits 
apoptosis via various substrates. Through PKB dependent phosophorylation of tuberous 
sclerosis complex 2 (TSC2), the GTPase function of the heterodimer TSC1/TSC2 is 
inactivated. Subsequently, the Ras homolog enriched in brain (RHEB)-GTP complex is not 
hydrolyzed to RHEB-GDP and can activate the mechanistic target of rapamycin complex 1 
(mTROC1)
96
. This in turn activates many processes required for cell growth and proliferation, 
such as increased lipid and protein synthesis
97
.  
HIF molecules are mTOR dependently transcribed and translated, promoting tumorigenesis of 
ccRCC
98,99
. As a negative feedback loop, they usually regulate the expression of regulated in 
development and DNA damage responses 1 (REDD1) by a HRE. REDD1 activates TSC2 and 
inhibits mTORC1
99,100
. Nevertheless, TSC1 and TSC2 are downregulated in VHL and PBRM1 
deficient kidney tumors in a JAK/STAT3 dependent manner and therefore, the negative 
feedback loop is inactive in ccRCCs
101
. Moreover, mTORC1 signaling in ccRCC is indirectly 
activated due to a HIF-2α specific upregulation of the amino acid carriers SLC7A5 and 
SLC43A1, leading to an increased uptake of branched chain amino acids
102
.  
Glycolysis in ccRCC is increased by elevated import of glucose into the cell via HIF 
dependent upregulation of GLUT1 and HIF-2α dependent c-Myc activation103,104. Increased 
glycolysis can activate mTORC1 via pyruvate kinase muscle isoform 2 (PKM2) dependent 
phosphorylation of the mTORC1 inhibitor proline-rich AKT substrate 1 (PRAS40)
105
. 
PRAS40 is also inactivated by PKB signaling
99
. 
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Figure 8 – Interplay of PI3K/AKT/mTOR and VHL signaling in ccRCC 
Activation of the PI3K/AKT/mTOR pathway plays a central role in the development of ccRCC. Extracellular 
stimuli activate receptor tyrosine kinases (RTKs) that activate phosphatidylinositol-3-kinase (PI3K) by 
phosphorylation. PI3K in turn phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to 
phosphatidylinositol-3,4,5-triphosphate (PIP3), which recruits protein kinase B (PKB/Akt) to the membrane 
where it gets activated by mechanistic target of rapamycin complex 2 (mTORC2/PDK2) and phosphoinositide 
dependent kinase 1 (PDPK1/PDK1). Phosphatase and tensin homolog (PTEN) dephosphorylates PIP3 again 
to PIP2 and inhibits activation of PKB. Activated PKB induces proliferation, cell growth and inhibits apoptosis. 
It activates the mTOR pathway by inhibiting tuberous sclerosis complex 2 (TSC2). Thereby, the Ras homolog 
enriched in brain (Rheb) is not inactivated anymore and can activate mTORC1. In a hypoxic environment, 
mTORC1 is regulated by a negative feedback loop via upregulation of HIF and regulated in development and 
DNA damage responses 1 (REDD1). This negative control slows down tumorigenesis of VHL mutated 
patients. Using small molecule inhibitors to chemically inhibit FK506 Binding Protein 1A (FKBP1A/FKBP12), 
mTORC1 signaling can be specifically blocked. Brown-colored oncogenes are commonly activated in ccRCC; 
blue-labeled tumor-suppressor genes are commonly inactivated in ccRCC. Dotted line indicates indirect 
activation of mTORC1 by HIF-mediated signaling pathways. 
Adapted from Kucejova et al.
99
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 Angiogenesis in ccRCC 1.2.4
Angiogenesis is the process of blood vessel formation. In physiological settings angiogenesis 
is tightly controlled and only active during embryogenesis, wound healing processes and 
menstruation
106
. New vessel formation can be induced by hypoxia and HIF signaling, via 
secretion of mitogens like the vascular endothelial growth factor (VEGF) and the platelet-
derived growth factor (PDGF). VEGF binds to VEGF receptors on endothelial cells and 
induces proliferation and tube formation of the forming capillaries
107,108
. PDGF stimulates 
recruitment of vascular smooth muscle cells and pericytes to cover the newly formed 
vessels
109-111
. 
In 2000, Hanahan and Weinberg postulated sustained angiogenesis as one of the hallmarks of 
cancer
112
. As growing tumors need constant oxygen and nutrient supply, they initiate de novo 
angiogenesis by activating pro-angiogenic activators, such as VEGF, which is secreted from 
the tumor, and by suppressing the expression angiogenesis inhibitors like thrombospondin-1 
(TSP-1)
113
. 
Harboring a hyperactive HIF signaling, VHL mutant ccRCC exhibit increased VEGF and 
PDGF secretion resulting in hyper-vascularization of the tumor (Figure 3c)
114
. This is further 
enhanced by an activation of the PI3K/Akt/mTOR signaling pathway, which leads to a 
downregulation of the anti-angiogenic factor TSP-1
115
. In late tumor development, 
hyperactivated angiogenesis signaling induces an undifferentiated microvasculature with bad 
prognosis
116
. 
 Metastasis of ccRCC 1.2.5
Metastasis is a multi-step process by which a localized tumor disseminates into distant parts 
of the body
92
. First, the primary tumor invades the local tissue and breaches through the 
basement membrane. Next, single tumor cells or groups of cells intravasate into blood or 
lymphatic vessels and get transported through the body. Eventually, the tumor cells get 
trapped in microvessels and may extravasate into the surrounding tissue. These 
micrometastases can stay dormant for a long period of time or proliferate at one point to form 
macrometastases. 
Metastasis of ccRCC follows the path of least resistance, most frequent along renal veins and 
the renal sinus, as migrating tumor cells do not have to cross connective tissue
117
. Lymphatic 
metastasis is less frequent in renal cell carcinoma than hematogenous
118
 explaining the 
distribution of distant metastatic sites: Lung (45 %), bone (30 %), lymph node (22 %), liver 
(20 %), adrenal (9 %), brain (8 %) and retroperitoneum (7 %)
119
. With only 16.6 % relative 
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survival probability, metastasis deteriorates the relatively good prognosis of kidney cancer 
(see section 1.3.1).  
Turajlic et al. analyzed the metastatic potential of ccRCCs
86
. They found that tumors of the 
“punctuated evolution” type (tumors with low ITH and elevated SCNAs) were more prone to 
metastasize rapidly, whereas tumors of the “branched evolution” type (tumors with high ITH 
but low SCNAs) showed an attenuated progression (Figure 9a). The authors identified driver 
events of many metastasis seeding subclones, mainly of the “punctuated evolution” subtype, 
in copy-number losses of either chromosome 9p or 14q (Figure 9b). Furthermore, 9p loss was 
pre-determining the prognosis of patients’ survival. This chromosome encodes for the cell 
cycle inhibitor CDKN2A and 14q hosts the ccRCC tumor suppressor HIF1A gene among 
others. Tumors of the “linear evolution” did not metastasize in their analysis. However, more 
research needs to be done to identify genes and pathways associated with metastases (see 
chapter 1.2.1). 
Early dissemination of metastases has been observed in breast cancer
120-122
. This process, by 
which already early lesions seed cells that form subsequent metastases has in general not been 
observed in ccRCCs
86
. Usually, metastatic clones develop from late subclones of the primary 
tumor or from already seeded metastases (Figure 9b). However, Turajlic et al. identified 
patients with late pancreatic metastases that appeared in median 15 years after the first 
presentation. The clones that seeded these metastases most likely developed already from 
primitive ancestral clones and lacked the metastatic 9p loss. Therefore, the pancreas may 
represent a more permissive metastatic niche for dormant ccRCC cells than other organs
123
. 
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Figure 9 – The evolution of ccRCC metastases 
(a) Schematic of the evolutionary subtypes and their potential to metastasize. The “punctuated evolution” 
subtype depicts rapid progression with many metastases at various locations and the “branched evolution” 
subtype shows slow progression with only few, singular metastases. The “linear evolution” subtype 
metastasizes rarely. 
(b) Summary of two selected cases of the metastatic route of ccRCC. The fishplots illustrate disease 
evolution by annotating driver events. For example, the BAP1 driven route of metastasis of patient K153 
(punctuated evolution) shows that a subclonal BAP1 mutation together with a loss of 9p and 14q and a gain 
of 8q and 12 led to the growth of a distinct subclone. This subclone had already metastasized into two 
lymphnodes (aorto-caval (AC) and para-aortic (PA)) when the patient underwent surgery. 8.4 month later, this 
subclone was found in the lung. The patient K029 with a PBRM1  P13K evolutionary subtype (branched 
evolution) showed a slower progressing metastasis development. At 6the time of the first surgery, no 
metastases where found. After a period of 16.6 month, the patient had a metastasis in the ribs, which 
originated from an mTOR driven subclone of the primary tumor. Twice more metastasis where excised, both 
from the spine and both of the metastases originated from the primary metastasis. 
Figures adapted from Turajlic et al.
86
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In many tumors, hypoxia is a key microenvironmental factor that drives migration and 
metastasis
124
. HIF activation regulates many steps of the metastatic cascade. For example, it 
induces the epithelial to mesenchymal transition (EMT) pathway
125,126
.  
EMT is essential in early embryogenesis for processes such as gastrulation and neural crest 
formation, but also for early steps of tumor cell dissemination
127,128
. Thereby, epithelial cells 
lose contact to their neighboring cells and the basal lamina, mainly due to a loss of 
E-cadherin-mediated adherens junctions. Subsequent loss of cellular polarity and gain of a 
mesenchymal phenotype allows the tumor cells to migrate and invade into surrounding tissue. 
Important transcriptional regulators of this process are Twist Family BHLH Transcription 
Factor 1 (TWIST1), Snail Family Transcriptional Repressor 1 (SNAI1 or SNAIL) and Zinc 
finger E-box-binding homeobox 1/2 (ZEB1/2). 
Other processes next to EMT of the metastatic cascade are also mediated via hypoxia 
signaling. Local invasion of migrating tumor cells, both at the primary tumor and metastatic 
site, is supported by modifying the extracellular matrix. Key enzymes of this process are HIF-
1α dependent secretion of the extracellular lysyl oxidase (LOX)129, matrix-metalloproteinase-
1 and -2 (MMP1/2), urokinase-type plasminogen-activator receptor (uPAR) and cathepsin D 
(CTSD)
130
. 
Hypoxia induced overexpression of VEGF not only stimulates angiogenesis, but also 
increases vascular permeability and interstitial fluid pressure
131
. Thereby, tumor cells can 
intra- and extravasate more easily. It has been shown that organ specific homing of metastatic 
tumor cells can be explained by chemokine-receptor interactions. Hypoxia dependent 
upregulation of the chemokine receptor CXCR4 allow the tumor cells to home to organs that 
express the ligand stromal cell-derived factor-1alpha (SDF-1α), such as the lung and the 
bones
132
. 
In summary, many steps of the multi-step process of metastases are regulated by HIF and the 
hypoxia pathway which is omnipresent in VHL deficient ccRCCs. Nevertheless, the period 
until the first metastasis appears in ccRCC is relatively long in comparison to other tumors 
and except for pancreatic metastases, additional mutations and genomic events have to occur 
before the tumor metastasizes to distant organs. Especially the loss of chromosome 9p and 
CDKN2A seems to play a pivotal role in the initiation of metastasis in ccRCC. 
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1.3 Management of clear cell Renal Cell Carcinoma 
 Prognostic stages, grades and signatures 1.3.1
In most classification systems, assessing patients’ survival no distinction is made between 
different kidney cancers and histological subtypes. In the following, the most common 
systems in clinical use are summarized. 
1.3.1.1 Staging of kidney cancer:  
The American Joint Committee on Cancer (AJCC) makes use of the TNM classification to 
stage kidney cancer into four stages. The system differentiates primary tumor size and extent 
(T), lymph node infiltration (N) and distant metastasis (M). The 8
th
 edition of the TNM 
classification uses the system shown in Table 2
133,134
. 
Table 2 – 8
th
 edition of the AJCC TNM classification system for kidney cancer 
T 
TX Tumor size of the primary tumor cannot be evaluated 
T0 No evidence of primary tumor 
T1a Primary Tumor diameter < 4cm 
T1b Primary Tumor diameter > 4cm but ≤ 7cm 
T2a Primary Tumor diameter > 7cm but ≤ 10cm 
T2b Primary Tumor diameter > 10cm, limited to the kidney 
T3a 
Primary tumor extends into the renal vein or its segmental branches, or invades the pelvicalyceal system, or 
invades perirenal and/or renal sinus fat but not beyond Gerota’s fascia 
T3b Primary tumor extends into vena cava below the diaphragm 
T3c Primary tumor grossly extends into vena cava above diaphragm or invades wall of vena cava 
T4 Tumor invading beyond Gerota’s fascia 
N 
NX Lymph node involvement cannot be evaluated 
N0 No regional lymph node metastases 
N1 Single or multiple regional lymph nodes involved (regional lymph nodes: hilar, caval, aortic) 
M M0 No distant metastases 
M1 Distant metastasis, including noncontiguous adrenal involvement 
 
With the help of the TNM classification, the kidney tumor can be assigned to a prognostic 
cancer stage (Table 3), which, in most cases, determines the treatment decision and is one of 
the best prognostic factors for treatment success. 
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Table 3 – AJCC Prognostic Groups, stage specific 5-year relative survival probability kidney 
cancer 1998-2016, Munich Cancer Registry
135
 
Stage TNM  Alternative TNM 5-year Relative Survival Probability 
I T1, N0, M0  97.6 % 
II T2, N0, M0  88.6 % 
III T1-2, N1, M0 T3a-c, N0-1, M0 71.9 % 
IV T4 Any T, any N, M1 16.6 % 
 
1.3.1.2 Fuhrman nuclear grading system 
ccRCCs are graded based on the microscopic findings of nuclear morphology
136
 (Table 4). 
Nevertheless, interobserver reproducibility of the Fuhrman grading is low. Therefore, 
researchers tried to simplify the system by combining Fuhrman grade 1 and 2 as well as grade 
3 and 4 into a 2-tiered grading system
137
 or by combining grade 1 and 2 with unchanged grade 
3 and 4 into a 3-tiered system
138
. The simplified systems have the same accuracy relatively to 
the conventional grading system
139-141
. 
Table 4 – Fuhrman nuclear grading system, grade specific 5-year Cancer-Specific Survival 
Probability assessed by Gudbiartsson
25
 
Grade Nuclear characteristics 
5-year Cancer-Specific 
Survival Probability 
1 Nuclei < 10µm, finely round, granular chromatin, small nucleoli 87.3 % 
2 Nuclei < 15 µm, finely granular chromatin, small nucleoli 70.5 % 
3 Nuclei < 20 µm, oval, coarsely granular chromatin, prominent nucleoli 45.9 % 
4 Pleomorphic nuclei, open chromatin, single/multiple macronucleoli 14.9 % 
 
1.3.1.3 SSIGN Score:  
To predict outcome of ccRCCs after radical nephrectomy, Frank et al. proposed a scoring 
system termed SSIGN score based on TNM stage, tumor size, nuclear grade and histological 
tumor necrosis (Table 5)
142
. Zigeuner et al. validated the SSIGN score on an external, single 
center cohort and suggest to apply the system routinely
143
. 
Table 5 – Estimated Cancer-Specific Survival rates according to SSIGN Scores
142
 
 
% estimated cancer-specific survival rates 
SSIGN Score Year 1 Year 3 Year 5 Year 7 Year 10 
0 - 2 99.7 98.7 97.3 96 93.6 
3 - 4 98.1 93.4 89.8 84 77.9 
5 - 6 92.9 83.8 74.1 65 57.3 
7 - 9 76.5 46.9 38.6 29 25.9 
≥ 10 43.3 21.9 19.2 19.2 19.2 
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 Prognostic survival factors (MSKCC Score) 1.3.2
In addition to tumor stage and grade information, Motzer et al. categorized metastatic renal 
cell carcinoma patients according to five clinical risk factors
144
. Patients with limited levels of 
self-sufficiency (assessed by a so called Karnofsky performance status), increased serum 
lactate dehydrogenase (LDH) level, low hemoglobin levels, increased serum calcium levels 
and patients already nephrectomized displayed reduced survival expectations (Table 6). The 
risk assessment of the MSKCC Score is used to give patients with advanced tumors the 
optimal first line treatments taking adverse effects into account
16
. 
Table 6 – Relative survival rates of patients with metastasized ccRCC according to risk 
stratification by Motzer et al.
144
 
 % survival rates 
Number of risk factors Year 1 Year 2 Year 3 
0 71 45 31 
1-2 42 17 7 
3-5 12 3 0 
 
An interesting finding regarding an additional prognostic survival factor was observed by 
Albiges et al. They showed that obese patients (BMI >25) with metastatic RCC and targeted 
treatment showed improved survival
145
. 
1.4 Treatment of ccRCC 
The gold standard treatment of localized renal cell carcinoma is surgical resection with 
potential curative outcome
16,146
. Depending on tumor size, stage, location and patient 
performance, either radical or partial nephrectomy (also called nephron-sparing) surgery is 
preferred.  
Early stage Ia/b tumors are preferably laparoscopically or robotically resected while keeping 
most of the surrounding kidney intact
147,148
. Stage II and stage III tumors are generally 
removed by radical nephrectomy
16,146
. An adjuvant therapy is not recommended when 
imaging gave unsuspicious findings
149-151
. 
Advanced ccRCCs (stage IV, relapsed or recurrent disease) cannot be completely surgically 
removed. Therefore, patients have to undergo systemic treatment. 
ccRCC tumors are highly resistant to chemotherapy with cytotoxic or cytostatic agents, 
showing only 5-10 % response rates and no improved overall survival
152-154
. Only isolated 
cases with sarcomatoid differentiated tumors show limited benefit of chemotherapeutics. The 
resistance to chemotherapy has been correlated to a high HIF-2α dependent expression of the 
ABC-transporter Multidrug resistance protein 1 (MDR1/p-glycoprotein)
155-158
. Another 
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resistance mechanism may be a PTEN dependent inhibition of p53-mediated apoptosis in 
ccRCC
159
. 
Besides chemotherapy, ccRCCs are also highly resistant to radiotherapy
160,161
, which has been 
associated with HIF-2α mediated resistance to DNA damage and interferon signaling via 
STAT1
162-165
. As operations in the brain are complicated and risky, brain metastases are 
nevertheless treated with high doses of radiation to overcome potential resistance 
mechanisms
16,146
. Furthermore, radiotherapy of metastases is a palliative option with possible 
symptom reduction
166-168
. 
The guidelines for patients with advanced ccRCCs recommend a cytoreductive nephrectomy 
to reduce primary tumor mass as much as possible prior systemic treatment with additional 
resection of metastases
16,146,169
. However, a new trial result suggests that perioperative risks 
may outweigh the benefit of this intervention and recommend targeted therapy alone
170
.  
 First generation of systemic treatment in advanced RCC: 1.4.1
Immunotherapy 
As chemo- and radiotherapy have been proven to give unsatisfactory results in the 
management of advanced ccRCC, patients were historically treated with interferon-alpha 
(IFNα) and high dose interleukin-2 (IL-2). This treatment option was considered, as some 
tumors were anecdotally found to regress in the absence of systemic treatment, implying that 
the immune system might have recognized them
171,172
. However, this immunotherapy has 
been found to be effective in only 15-25 % of the patients and some of them experienced 
strong adverse effects
173,174
. 
 Second generation of systemic treatment in ccRCC: Tyrosine Kinase 1.4.2
Inhibitors and mTOR inhibitors 
A new era for the treatment of renal cell carcinoma emerged from the study of the role of 
VHL in ccRCC. Sorafenib was the first broad acting tyrosine kinase inhibitor (TKI) that 
blocks receptors of the pro-angiogenic factors VEGF and PDGF (Figure 11). This therapy 
doubled progression free survival of patients from 2.8 to 5.5 months and improved overall 
survival from 14.3 to 17.8 months
175
. Sorafenib was approved as first line treatment of 
advanced renal cell carcinoma by the FDA and the EMA in 2005 and 2006, respectively
176,177
. 
In the following years, more and more TKIs were approved by the regulatory authorities and 
especially sunitinib and pazopanib have emerged as the first choice in first line treatment of 
advanced renal cell carcinoma. Their efficacy is similar but pazopanib may show a better 
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safety profile
178
. Other approved TKIs are axitinib, cabozantinib, lenvatinib and tivozanib, all 
with slightly different tyrosine kinase binding capabilities. 
Bevacuzimab is a monoclonal antibody that directly targets VEGF-A. It has been approved in 
the EU and 2009 in the US as combination therapy together with IFN-α2a as first line 
treatment option. However, an improvement over the traditional IFN monotherapy was only 
notable in the extended progression free survival time, whereas overall survival remained 
unchanged
179
. 
Another overstimulated signaling pathway in ccRCC is the PI3K/Akt/mTOR pathway. 
Blockage of the mTORC1 complex using temsirolimus and everolimus has been shown to 
improve patients’ progression free survival for both agents from 1.9 months to 5.5 
months
180,181
. Especially temsirolimus has been shown to be effective in high risk patients, 
whereas single-agent everolimus has been relegated back in the line. 
The current approved treatment options for advanced RCC according to the German kidney 
cancer guidelines (2/2017) are summarized in Figure 10. 
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Figure 10 – Sequence of treatment approaches for the advanced renal cell carcinoma 
according to the German kidney cancer guidelines 2/2017 
16
 
* Risk assessment according to the MSKCC Score (see chapter 1.3.2) 
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 New treatment options on the horizon: Immune checkpoint inhibitors, 1.4.3
combinational treatments and vaccines 
Blockage of tyrosine kinases and the mTOR pathway has been shown to significantly improve 
survival of metastatic renal cell carcinoma patients. Nevertheless, clinical guidelines in the 
USA and Europe suggest to enroll patients into ongoing clinical trials instead of using current 
treatment options in order to identify more effective therapy options
16,146
.  
In 1992 PD-1 was identified as an inhibitory surface molecule on T cells
182
 as binding of the 
ligand PD-L1 or PD-L2 leads to inhibition of T cell receptor (TCR) signaling
183
. A variety of 
tumors have been found to express PD-L1 on their surface
184
, thereby repressing the 
anticancer T cell response. In renal cell carcinoma, PD-L1 is higher expressed on advanced 
tumors and associated with reduced survival
185
. 
Another checkpoint inhibitor under investigation is CTLA-4. CTLA-4 is expressed on T cells 
and T regulatory cells as response to TCR activation
186
. It binds CD80 and CD86 on antigen 
presenting cells with higher affinity than CD28, which acts as second signal for T cell 
activation, thereby reducing the signal amplitude of T cell priming
187,188
. Furthermore, 
CTLA-4 plays an essential role in the development of memory function and tolerance to self-
antigens. There are further targets for immunotherapy in clinical development, such as CD25, 
OX40 
189
. 
The first approved monoclonal antibody as second line treatment for advanced renal cell 
carcinoma was the immune checkpoint inhibitor nivolumab, targeting PD-1
190
. It outcompeted 
the mTOR inhibitor everolimus in the Checkmate 025 phase III study, even though only in 
high risk MSKCC patients. In these patients, it could nearly double the median overall 
survival from 7.9 (everolimus) to 15.3 months (nivolumab)
191
. 
Already included in the most recent ESMO guidelines as first line treatment recommendation 
for intermediate and poor risk metastatic ccRCC, the immune checkpoint inhibitors are not 
yet recommended in the German treatment guidelines
192
. In the following paragraphs, current 
or recently finished clinical trials of substances with various cellular targets are summarized 
that may increase treatment options in the future. 
The Checkmate 214 clinical phase III trial was the first first-line treatment trial with immune 
checkpoint inhibitors to show prolonged overall survival in advanced ccRCC
193
. Additionally, 
it was the first co-treatment trial in ccRCC with two different immune checkpoint inhibitors: 
Nivolumab (mAB αPD-1) together with ipilimumab (mAB αCTLA4) against a monotherapy 
with sunitinib (TKI). Especially high risk patients showed improved response rates and 
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overall survival (18-months OS 75 % vs 60 %). Still, adverse effects led to discontinuation of 
treatments in 22 % of the patients. 
The IMmotion151 clinical phase III trial combined two compounds with different mode of 
action: The immune checkpoint inhibitor atezolizumab (mAB αPD-L1) with the anti-
angiogenic bevacuzimab (mAB αVEGF-A). This combination of drugs was also compared to 
sunitinib in advanced ccRCCs as first line treatment option and progression free survival was 
significantly improved from 7.7 (sunitinib alone) to 11.2 months (atezolizumab + 
bevacuzimab)
194
. 
A combination of avelumab (mAB αPD-L1) and axitinib (TKI) in the treatment of naïve 
metastatic RCCs was tested in the JAVELIN Renal 101 trial
195
. This trial may have set a new 
standard in the management of advanced RCC: Compared to sunitinib, this combination 
nearly doubled the patients’ progression free survival in all risk groups (13.8 vs 8.4 months), 
regardless the PD-L1 status. Interestingly, the safety of this combination showed fewer 
adverse events than treating patients with sunitinib alone. 
A similar combination of drug targets is currently being tested in the KEYNOTE-426 trial 
with pembrolizumab (mAB αPD-1) and axitinib (TKI). Also in this trial, interim results 
suggested that PD-L1 expression on tumor cells had no effect on the efficacy of immune 
checkpoint inhibitor treatment, as progression free and overall survival did not significantly 
differ so far
196
. 
Currently, more clinical trials are ongoing, testing the efficacy of other monoclonal PD-1 and 
PD-L1 antibodies in the advanced renal cell carcinoma setting alone or in combination 
therapy
197-199
. 
Another treatment approach has been opened by testing vaccines in the metastatic renal cell 
carcinoma setting. However, IMA901, a multipeptide cancer vaccine as co-treatment to 
sunitinib in a first line setting tested in the IMPRINT trial did not improve patients overall 
survival
200
. 
The ADAPT trial was maybe the most personalized immunotherapy that has been tested in 
the renal cell carcinoma context so far. The trial tested, whether sunitinib in combination with 
patient derived tumor neoantigens primed dendritic cells would improve patients’ survival. 
These cells (called AGS-003) were then given back to the patient. This trial failed, as it did 
not improve patients’ survival201,202. 
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At the time of this thesis, 166 interventional clinical trials were running for the metastatic 
RCC alone, with many new therapy approaches in early phases of clinical development
203
. In 
phase III studies are currently only immune checkpoint inhibitors as mono- and 
combinational-therapies in various combinations with already approved drugs to treat RCC. 
However, in phase I and II studies a broad variety of other compounds is being tested. One 
example is the specific inhibition of HIF-2α with the compound PT2977204,205 (see chapter 
1.2.1).  
 
 
Figure 11 – Mechanism of therapies of advanced RCC (approved or successful clinical 
phase III studies) 
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1.5 Model Systems of ccRCC 
In order to study various aspects of ccRCC in the laboratory, different model systems have 
been established including conventional cell lines, primary patient derived cell lines, genetic 
engineered mouse models and patient derived xenografts. 
 Conventional cell lines 1.5.1
Supplementation of cell culture medium with fetal calf serum (FCS) allowed the generation of 
hundreds of cancer cell lines. With the help of these homogenous cell lines, fundamental 
insights into cellular and molecular biology were gained as they are fast and easy to 
manipulate. Conventional cell lines allowed for drug screenings in large scale before testing 
them in vivo, complying with the main principle of animal research: Replacement, Reduction 
and Refinement (3Rs)
206
.  
However, the cell culture setting oversimplifies the complex tissue architecture of the human 
system. In general, cells are cultured in a two-dimensional monolayer of adherent cells 
without mechanic and biochemical interactions of normal tissue environments, which are 
essential to maintain cellular differentiation fates
207
. Some cell lines have already been 
cultured for decades, like the commonly used HeLa cell line, which has been established in 
1951 and passaged since then
208
. This long-term passage of cells with FCS leads to an 
acquisition of mutations with alterations in gene expression and pathways over time
209,210
. 
Media supplemented with FCS is not a fully defined medium and concentrations of growth 
factors vary from batch to batch
211
. Therefore, it is not surprising that long-term passage lead 
to a high clonal and genetic variability of the cell lines between different laboratories and 
studies
212
. Re-injection of cancer cell lines into immunodeficient mice led to tumors that do 
not resemble the primary tumor
213-216
. In summary, usage of conventional cell lines can 
complicate the reproducibility and significance of preclinical studies
217-219
.  
Brodaczewska et al. discuss the usage of cell lines as model systems for ccRCC
220
. Many of 
the established cell lines are described to be tumorigenic in immunodeficient mice, some even 
metastatic, whereas others fail to implant
221
. Commonly used ccRCC cell lines are 786-O 
(VHL mutant), UM-RC-2 (VHL mutant) and the metastatic Caki-1 cell line (VHL wild type). 
Often also papillary RCC cell lines, such as ACHN, A-498 or Caki-2, are used as model 
system to examine the clear cell phenotype. Various more cell line collections are available, 
such as one from the Memorian Sloan Kettering Cancer Center and the National Cancer 
Institute in Bethesda. Nevertheless, gene expression patterns and CNAs of most of the 
conventional cell lines differ often from primary patient derived tumors
222
. Additionally, only 
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few conventional ccRCC cell lines are able to recapitulate the distinct clear cell phenotype in 
vivo. 
 Genetically engineered mouse models 1.5.2
Genetically engineered mouse models (GEMMs) are an excellent tool to study tumor-
microenvironment interactions in an immune competent setting (Figure 12). Tissue specific 
overexpression of tumor oncogenes, dominant negative tumor-suppressor genes, the knockout 
of tumor-suppressor genes, the insertion of targeted mutations or complex combinations of all 
those methods can induce de novo tumorigenesis
223
. With the help of inducible promoters, this 
process can be timely adjusted and controlled
224
. 
However, the usage of GEMMs is limited as long as the complex process of tumorigenesis, 
which differs among the various cancer types, is poorly understood. Increased length of 
telomeres in mice hamper the development of an instable genome, a common feature of 
human cancers
225
. The mayor drawback of GEMMs is that a simplified tumorigenesis model 
in the mouse is used to draw conclusions for the human counterpart, bearing the risk of 
unreliable results. 
Thus, GEMMs are required to study the effect of distinct genes on the development of tumors 
but cannot reproduce the complex genetic human landscape of a cancer.  
Knockout of the ccRCC hallmark gene Vhl in mice is embryonic lethal
226
. Heterozygous VHL 
patients are predisposed to develop ccRCCs but mice with heterozygous Vhl, even with 
additional treatment of the renal carcinogen streptozotocin, do not develop renal cancers
227
. 
An organ specific conditional inativation of Vhl in renal epithelial cells has no tumorigenic 
effect either but shows renal cyst formation
228
. The first mouse model that led to carcinomas 
in the kidney had a constitutively overexpression of a mutant active HIF-1α in the proximal 
tubules of the kidney
229
.  
In 2017, the combined homozygous knockout of Vhl, Rb1 and Trp53 (encoding for p53) in 
renal epithelial cells led to the formation of advanced ccRCCs
230
. However, both Rb1 and p53 
are only altered in 0.8 % and 3 % of human ccRCC, respectively (cBioportal, TCGA, 
PanCancer Atlas), which limits the use of this model. 
One month later, another clear cell renal cell carcinoma model in mice was presented by Gu et 
al.
231
. They followed the pathogenesis of ccRCC and conditionally deleted Vhl and either 
Bap1 (the driver of the punctuated evolution type) or Pbrm1 (the driver of the branched 
evolution type). Bap1 deletion gave rise to a more aggressive, high grade tumor and deletion 
of Pbrm1 gave rise to a slow progressing tumor. An additional heterozygous inactivation of 
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the mTORC1 inhibitor Tsc1 in the Vhl and Pbrm1 deficient kidney cells increased the tumor 
aggressiveness. At the time of this thesis, this mouse model resembles the development of 
ccRCC best. An interesting finding of this mouse model were pre-neoplastic lesions found in 
the parietal epithelial cells of the Bowman capsule (the lining of the glomerulus, the 
functional unit of the kidney), which challenges the current view that proximal tubule cells are 
the cell of origin of ccRCC. 
 Xenograft and Syngeneic ccRCC Models 1.5.3
A xenograft is a heterologous transplant of cells, tissue or organs, for example human material 
into a mouse. Xenotransplantation has to be performed with immunocompromised mouse 
models, as the foreign material would be rejected by the hosts’ immune system (Host-versus-
Graft reaction). The ability of the foreign material to engraft into the new host depends on the 
functionality of the host immune system. Athymic nude mice, lacking the thymus and thus 
functional T cells, were the first mice to receive xenotransplants
232
. Engraftment efficiency 
was low and therefore a new mouse model was established: The non-obese diabetic mouse 
strain with severe combined immunodeficiency (NOD/SCID)
233,234
. These mice are unable to 
rearrange T cell receptor and immunoglobulins, which leads to a combined B and T cell 
deficiency in those mice. A derivative of this mouse strain is the NOD.Cg-Prkdc
scid
 Il2rg
tm1Wjl
 
(NSG) mouse strain
235
. The nonfunctional interleukin-2 receptor γ-chain impairs B and T cell, 
natural killer cell and lymph node development, but improved engraftment efficiency
234
. 
Xenograft mouse models allow the study of cell lines and primary patient tumor material in 
vivo. Samples can be transplanted ectopically, for example subcutaneously or orthotopic at the 
native site of the originating tumor (Figure 12). The microenvironment of the orthotopic site 
in the mouse resembles tumor-originating tissue in matrix composition, nutrient availability 
and growth factors. Such a surrounding is impossible to emulate in a cell culture setting
236
. 
Regarding RCCs, the tumor material can be injected orthotopically into the renal 
subcapsule
237,238
. This method is technically very challenging and may lead to increased 
animal morbidity. Also tumor take and growth rates may vary in between experiments. 
A unique feature of mouse models in cancer research is their ability to study metastasis. 
While subcutaneous transplantation of tumor material shows very low metastatic 
capacity
238,239
, orthotopic injection has been reported to be the best method to study 
metastasis. With the help of this method, researchers are able to study metastases 
development in lung, bone and peritoneal organs (Figure 12), which resembles the human 
route of metastases in renal cancer (see chapter 1.2.5). 
30  Introduction 
In addition to conventional cell lines used for orthotopic transplantation
237
, various xenograft 
models of ccRCC were generated from primary patient material with varying engraftment 
potentials
240-244
. These mouse xenograft in vivo models are increasingly used in preclinical 
studies to test the efficacy of new drugs
245
. 
A disadvantage of xenograft models is the mouse strain itself as these mice lack a functional 
immune system, which plays a crucial role in tumor and metastasis control. New treatment 
strategies targeting the immune system of a patient, cannot be tested in a xenograft 
transplantation setting and therefore, syngeneic mouse models are used. 
Syngeneic mouse models are mouse tumor allografts meaning that they have the same genetic 
background as the mouse strain in which the tumor is transplanted (Figure 12). For renal cell 
carcinomas, the syngeneic mouse model Renca is available
246,247
. The renal tumor arose 
spontaneously in a BALB/c mouse and a cell line was established from this tumor. When 
orthotopically re-transplanted into the renal capsule of BALB/c mice, the tumor develops and 
forms metastasis. However, the tumor is not mutated in Vhl and its mouse origin makes it 
complicated to compare to the human system. 
 
Figure 12 – In vivo tumor models of ccRCC 
Several different approaches have been developed to study tumor formation in vivo. In the syngeneic mouse 
model a mouse tumor is transplanted as allograft. In this mode, mice have a full functional immune system 
and orthotopic transplantation often leads to metastases. However, the number of tumor models is limited 
and the comparison to the human system is hampered. 
In subcutaneous xenograft experiments, primary patient tumor material is injected into immunodeficient mice 
subcutaneously. This is an easy handling to study primary tumor formation. To study the physiological tumor 
formation, tumor cells are injected orthotopically. 
Genetic engineered mouse models (GEMM) with mutations in oncogenes and/or tumor suppressor genes, 
often organ specific, have been generated. Thereby, spontaneous tumors arise and the influence of single 
genes on the tumor formation process can be studied. Often, GEMMs oversimplify the tumor development 
and no metastases develop. 
In the figure by Katie Vicari the different tumor mouse models at the example of lung cancer are shown.  
With kind permission of Springer Nature, License Number: 4511280297518 
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 Advanced primary serum-free cultured cell lines and xenografts 1.5.4
In our laboratory, novel patient-derived in vivo and in vitro ccRCC models were 
developed
1,248
 (Figure 13a). In short, primary tumor material was mechanically and 
enzymatically dissociated, and orthotopically transplanted into immunodeficient NSG mice. 
Engraftment efficiency of primary patient material correlated with tumor size and tumor 
stage. Engraftment time and metastatic capacity showed great intertumor heterogeneity.  
Subsequently, tumor-initiating serum free cell culture models, termed KIKA, were isolated. 
With our chemically defined cell culture medium (adapted from Vermeulen et al.
249
), 
disadvantages of the conventional cell lines were avoided
216
 (see chapter 1.5.1). To preserve 
tumorigenicity of the cell lines, various cell culture conditions were tested. Except for one 
line, 3D spheroid conditions showed best tumor initiating capacity. 
The xenografts and KIKA cell line derived tumors were able to recapitulate both the intra- 
and inter heterogeneity of the original ccRCC (Figure 13b)
1
. The histological hallmark 
phenotype of ccRCCs, the clear cells, were retained and additional renal cell carcinoma and 
epithelial markers such as AE1/3, CD10, Vimentin, CK18 and Kl1 stained positively
1
. Human 
origin of the material was verified by positive staining of the proliferation marker hKi67 and 
negative staining for the mouse marker H2kD.  
With our approach to establish novel ccRCC models, we are able to amplify limited starting 
material of primary patient material, check for tumorigenicity and use it as a tool to study the 
tumor both in vitro and in vivo. 
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Figure 13 – Novel patient derived ccRCC xenograft and serum free cell culture model 
(a) Schema describes the establishment of our ccRCC models. Adapted from Watermeier
1
 
(b) HE-staining of the primary patient tumor material, the respective xenograft and cell line derived tumor 
models used in this study. DT = derived tumor 
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1.6 Survival analysis 
Survival analysis is a method to analyze time dependent outcomes and is mostly used to 
estimate the survival time of a cohort
250
. However, the outcomes can be any event, from the 
death of a person, marriage to the birth of a child. The time from a well-defined starting point 
until an event occurs can be measured in any appropriate timescale, for example days, years, 
generations or atom oscillations. 
In medical research, studies that analyze survival data are in general prospective cohort 
studies following patients over a period of time. In these studies, it is common that the 
outcome of an observation is not known for every event. These events are so called censored 
events. There are several types of censoring, but in survival analysis, we have usually right 
censored events. Meaning that either an event occurs or the event has not occurred and is 
censored at the end of the observation period (Figure 14a). 
With the help of the survival function 𝑆(𝑡), it is possible to calculate the probability to survive 
longer than time t, as long as the time is t ≥ 0. Let T be the non-negative variable that stands 
for the time until an event occurs: 
𝑆(𝑡) = 𝑃({𝑇 > 𝑡}) (1) 
With the help of the hazard function ℎ(𝑡), one can calculate the hazard rate: The risk that an 
event occurs in the next period of time, in case the event has not occurred until then. In the 
context of survival, the function describes the risk of dying at a specific time t, in case, the 
subject survived that long: 
ℎ(𝑡) = lim
∆𝑡→0
(
𝑃(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡|𝑇 ≥ 𝑡)
∆𝑡
) 
(2) 
The complexity of this analysis is that common regression methods cannot handle censored 
data. Therefore, Edward L. Kaplan and Paul Meier formulated their product-limit estimator in 
1958
251
. 
Let i be the individuals of the cohort, and events (not censored observations) be ordered along 
the time 𝑡(1) < 𝑡(2) < ⋯ < 𝑡(𝑖). Let 𝑑𝑖 be the events that occur at time 𝑡(𝑖) and 𝑛𝑖 be the total 
number of observations in risk right before 𝑡(𝑖): 
?̂?(𝑡) = ∏ (1 −
𝑑𝑖
𝑛𝑖
)
𝑖:𝑡(𝑖)<𝑡
 
(3) 
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With this formula, survival step functions can be drawn with the survival probability as 
dependency of the time (Figure 14b). To survive a specific timespan, 𝑡0 → 𝑡(𝑖) is the product 
of all survival probability intervals up until 𝑡(𝑖).  
In order to compare two survival curves, several tests have been developed. The most 
commonly used test is the nonparametric log rank test (or Mantel-Cox test)
252
. It tells whether 
two survival curves significantly differ between each other, which indicates that a particular 
grouping variable might be prognostically relevant
253
. 
a b 
 
 
Figure 14 – Survival Analysis 
(a) Exemplary Time-to-Event illustration. The study starts at a defined time point and monitors the occurrence 
of a specific event. If the outcome of the event is unknown, either because the study ends or a subjects exits 
the study early, the event is censored. 
(b) Exemplary Kaplan-Meier estimator. Group A has a significant better survival than Group B. At the end of 
the study, the probability that an event occurs for Group A is approximately 80 %, whereas for Group B, it is 
around 40 %. Dotted line indicates median survival of Group B meaning that after around 2200 days, the 
probability that an event occurs until the next time interval is 50 %. Censored events are represented by a 
vertical line. 
 The Cox proportional hazards model 1.6.1
A Cox proportional hazard model (Cox regression, Cox PH model) can be calculated to obtain 
an estimation of factors influencing survival
254
. Factors can be, for example the administration 
of a drug, the gender or the age of a participant. They are termed explanatory variables, risk 
factors or covariates and have a specific weight on the hazard rate that is assumed to be 
independent from each other
255
. The proportional hazard assumption of this model states that 
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each unit difference in any of the covariates scales the hazard proportionally at any given 
time. 
Let 𝑋𝑖 = {𝑥𝑖1, 𝑥𝑖2, … , 𝑥𝑖𝑝} be a vector of the realized values of the covariates 𝑝 for the subjects 
𝑖 and let 𝛽 be the corresponding coefficients of the covariates 𝑝. ℎ0(𝑡) represents the baseline 
hazard when all covariates are 𝑋𝑖 = 0. According to the Cox proportional hazard model, the 
hazard rate can be calculated as followed: 
ℎ(𝑡|𝑋𝑖) = ℎ0(𝑡)𝑒𝑥𝑝(𝛽1𝑋𝑖1 + 𝛽2𝑋𝑖2 + ⋯ + 𝛽𝑝𝑋𝑖𝑝) 
ℎ(𝑡|𝑋𝑖) = ℎ0(𝑡)𝑒𝑥𝑝(𝑋𝑖 ∙ 𝛽) 
(4) 
The baseline hazard is often complicated to evaluate as covariates, such as blood pressure, 
cannot be set to 0 in physiological settings. Therefore, the Cox proportional hazard model 
uses a semi-parametric approach to avoid estimation of the baseline hazard. By declaring the 
hazards for two subjects proportionally, a ratio of hazards can be formulated: 
𝐻𝑅 =
ℎ(𝑡|𝑋1)
ℎ(𝑡|𝑋2)
=
ℎ0(𝑡)𝑒𝑥𝑝(𝑋1 ∙ 𝛽)
ℎ0(𝑡)𝑒𝑥𝑝(𝑋2 ∙ 𝛽)
= 𝑒𝑥𝑝(𝛽 ∙ (𝑋1 − 𝑋2)) 
(5) 
From this semi-parametric approach, we can estimate the 𝛽 of a specific covariate 𝑘, by 
holding all other covariates constant and increasing 𝑘 by only one unit: 
𝐻𝑅 =
ℎ(𝑡|(𝑥1, ⋯ , 𝑥𝑘 + 1, ⋯ , 𝑥𝑝)1)
ℎ(𝑡|(𝑥1, ⋯ , 𝑥𝑘, ⋯ , 𝑥𝑝)2)
= 𝑒𝑥𝑝(𝛽𝑘) 
(6) 
With all other covariates remain unchanged and only the covariate 𝑥𝑘 is increased by one unit, 
𝛽𝑘 corresponds to the log hazard ratio. In practical use in a medical setting and patient 
survival as outcome, this formulation describes the changed risk of a patient to die when a 
covariate increases by one unit. For assuming that the covariate 𝑥 is smoking, then 
𝑥𝑆𝑚𝑜𝑘𝑖𝑛𝑔 = 1 represents that a patient smokes and 𝑥𝑆𝑚𝑜𝑘𝑖𝑛𝑔 = 0 that a patient is a non-
smoker. If the patient now is a smoker, the risk to die changes by 𝑒𝑥𝑝(𝛽𝑆𝑚𝑜𝑘𝑖𝑛𝑔) in 
comparison to the non-smoker. If the hazard ratio is above one, the risk to die for a patient 
with the covariate 𝑥 is increased, if it is below one, the risk is reduced. Hence, the hazard ratio 
always compares two groups of subjects that differ in covariates. 
There are various methods to estimate and validate multiple 𝛽 coefficients of a Cox PH 
model
256-258
. In short, the methods try to fit the observed data to an ideal set of coefficients by 
maximizing the partial likelihood. To assess the validity of the regression and its parameters, 
tests like the Wald’s test, the Likelihood ratio test and the Score (log rank) test are commonly 
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used
259
. In order to estimate, how good the calculated model predicts the data, the 
concordance index (C-index, “Harrel’s C”) can be calculated260,261. 
 Parameter Shrinkage – The Lasso Regression 1.6.2
By profiling all expressed genes of a patient cohort, the resulting data is high-dimensional 
(number of patients multiplied by the number of genes). In most settings, the number of 
patients n is much smaller than the number of genes p that are profiled (𝑛 ≪ 𝑝). Estimating a 
Cox regression model that includes all possible gene combinations would not only over 
parameterize the model and difficult to interpret, but also be a computational challenge
262
. 
With every additional covariate included, the possible number of parameter combinations in 
the regression model growths exponentially. This effect has been termed “the curse of 
dimensionality”. Even if all covariates were estimated, only a small number of gene 
combinations would most likely have a major influence on the outcome.  
A reduced number of predictors for assessing the model can lower the prediction error. Next 
to preselection of a set of genes by an educated guess (for example additional experiments 
that indicate the importance of a specific set of genes), stepwise regression and penalized 
regression methods have been developed to shrink the number of predictors
262
. All these 
methods profit from the bias-variance tradeoff:  
Models with a high variance tend to over-fit the noisy training data. Models with a high bias 
oversimplify the training data and thus the model (Figure 15). 
 
Figure 15 – Bias-Variance Tradeoff 
Many algorithms profit from the bias-variance tradeoff. Models with high variance have a high sensitivity to 
the noisy training data, but they tend to over-fit the data. Models with high bias are under-fitting, as they 
oversimplify the underlying data and cannot predict the true data structure. Models with low variance are less 
complex and models with low bias are more complex. The bias-variance tradeoff finds an optimal balance 
between over- and under-fitting and minimizes the error of the model
263
. 
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The penalized regression models introduce a factor that penalizes less realistic coefficients to 
get a simpler model. A so called regularization parameter λ helps to control the bias-variance 
tradeoff. When the parameter λ has been chosen too small, the training data will be over-fit 
and a λ that is too large is often oversimplifying the model by introducing a high bias.  
The least absolute shrinkage and selection operator (LASSO) regression method is one 
penalized regression method that shrinks the values of the coefficients and at the same time 
selects the numbers of predictors
264. In the context of Cox’s proportional hazards models, the 
method has been adapted to fit censored survival data (Regularized Cox Regression)
265
. 
Thereby, many of the covariates are due to the nature of the used penalty term L-1 norm 
minimized exactly to zero. The LASSO regression therefore allows a shrinkage of covariates 
in an unbiased manner
266
. The regularization parameter λ controls for the number of non-zero 
covariates in the model and can be selected by cross-validation. 
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2 Aim of the Dissertation 
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma 
and the one with the worst prognosis
20
. With complex clinical presentation, diagnosis often 
occurs by accident and at late stages, when the tumor has already developed metastases
14
. 
Even with progress in novel checkpoint inhibitor therapies, prognosis of patients with 
advanced ccRCCs is poor with a median overall survival of 15 months
191
.  
After surgical resection of both metastatic and non-metastatic patients, it is essential to assess 
the risk of relapse in order to ensure adequate follow-up
16
. In the clinical routine, the patients’ 
risk is most widely assessed by using the AJCC TNM classification or the SSIGN Score
133,142
. 
Molecular markers and complex signatures failed to improve the prognostic value of these 
classifications so far
267
.  
Therefore, the objective of this study is to identify a robust and simple gene signature 
allowing for a more precise prediction of patients’ risk. 
On the molecular level, ccRCCs show significant inter- and intra-tumor heterogeneity
73
. 
Therefore, the use of a prognostic signature that assesses the risk of ccRCC patients was 
analyzed with regards to tumor heterogeneity. 
The identified signature comprises genes, which might play a role in mediating tumor 
aggressiveness and metastasis. Making use of in vitro and in vivo experiments, we aim to 
elucidate their role in cancer progression to identify possible targets for the treatment of clear 
cell renal cell carcinoma. 
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3 Results 
3.1 KIKA ccRCC models are immunophenotypically 
heterogeneous 
In a first step, we characterized six of the KIKA cell culture ccRCC models (see section 
1.5.4) by SNP array to evaluate CNAs (Supplemental Figure 1) and by screening 242 cell 
surface markers by flow cytometer analysis. Selected results are shown in Figure 16. We 
identified surface markers, which are expressed in all cell lines but show high intratumor 
heterogeneity (Figure 16a) and markers expressed in all cell lines that show low intratumor 
heterogeneity (Figure 16b). Moreover, we found markers that are heterogeneously expressed 
between the cell lines (Figure 16c) and markers that are not expressed on the KIKA cell 
culture ccRCC models (Figure 16d). The complete list of cell surface markers is found in 
Supplemental Figure 2. 
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Figure 16 – Excerpt of 242 analyzed cell surface markers of six different KIKA ccRCC cell 
culture models 
Cell surface markers measured by flow cytometry were sorted according to the number of cell lines 
expressing a surface marker (5 % above respective isotype) and according to the standardized robust 
coefficient of variation (CV). Shown are the top surface markers with (a) high intratumor heterogeneity, 
(b) low intratumor heterogeneity or (c) intertumor heterogeneity. (d) shows exemplary markers that are not 
expressed on the KIKA cell lines (no mean fluorescent signal above isotype). Supplemental Figure 2 lists all 
cell surface markers of the immunophenotypisation. 
Exemplary, we validated one of the surface markers, ICAM1/CD54, in the KIKA cell lines by 
flow cytometry and in vivo by immunohistochemistry on four KIKA cell line derived tumors 
(Figure 17). We find ICAM1 expressed in all tested cell lines in cell culture, with high 
expression in KIKA24 cells and a heterogeneous expression in KIKA27, KIKA38 and 
KIKA75 cells. Xenotransplanted KIKA cells form tumors that show intratumor heterogeneous 
staining for ICAM1. In KIKA75, and KIKA38 derived tumors, a majority of tumor cells 
membranes stain positively for ICAM1. In KIKA27 and especially KIKA24 derived tumors, 
only a fraction of tumor cells stain positively for ICAM1, suggesting a high intratumor 
heterogeneity of ICAM1 expression. Supplemental Figure 3 shows the gating scheme for 
CD54 FACS staining. 
 
No expression High expression No variance High variance 
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a 
 
b 
 
Figure 17 – ICAM1/CD54 is expressed in vitro and in vivo KIKA ccRCC models 
(a) CD54 expression in flow cytometry. CD54 is expressed in all cell lines with varying intensity. Light blue 
indicates isotype staining. 
(b) Expression of CD54 in xenograft tumors. Staining for CD54 reveals heterogeneous distribution with some 
cells of high CD54 expression on the surface and others with no CD54 expression. 
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3.2 KIKA cell lines are resistant to mTOR and tyrosine kinase 
inhibitors 
KIKA cell lines were tested for their drug resistance against the two most commonly used 
small molecule inhibitors (see section 1.4.2) targeting the mTOR (everolimus) and receptor 
tyrosine kinases (sunitinib). Additionally, we tested the EGF receptor inhibitor erlotinib. The 
titration with sunitinib, everolimus and erlotinib revealed high resistance of all tested cell 
lines against all tested drugs (Figure 18). 
a 
0.001 0.01 0.1 1 10 100
0
50
100
150
Everolimus [µM]
R
e
la
ti
v
e
 C
e
ll
 V
ia
b
il
it
y
 [
%
]
 
b 
0.001 0.01 0.1 1 10 100
0
50
100
150
Sunitinib [µM]
R
e
la
ti
v
e
 C
e
ll
 V
ia
b
il
it
y
 [
%
]
 
c 
0.001 0.01 0.1 1 10 100
0
50
100
150
Erlotinib [µM]
R
e
la
ti
v
e
 C
e
ll
 V
ia
b
il
it
y
 [
%
]
KIKA27
KIKA75
KIKA38
 
Figure 18 – KIKA cell lines are resistant to mTOR and tyrosine kinase inhibition 
KIKA cell lines were treated 48 h (KIKA27) or 72h (KIKA38 & KIKA75) with increasing concentrations of (a) 
the mTOR inhibitor Everolimus, (b) the receptor tyrosine kinase inhibitor Sunitinib or the EGF receptor 
inhibitor Erlotinib. Cell growth was measured by CellTiter Blue metabolism and measured by fluorescence in a 
plate reader. Error bars depict mean ± s.e.m. 
3.3 Xenograft ccRCC models are heterogeneous in survival and 
metastasis formation 
By injecting six different primary patient xenograft models orthotopically into NSG mice, we 
observed different survival proportions (Figure 19a) and capacities to form lung metastases 
(Figure 19b), indicating an intertumor heterogeneity. Especially the KIKA75 model, with a 
median survival of 38.5 days, develops highly likely lung metastasis. Therefore, we decided 
to use this model to identify genes that have an impact on the metastatic progression. We 
further examined genomic architecture of this cell line by chromosome painting and whole 
exome sequencing, which revealed a highly instable genome with many rearrangements 
(Supplemental Figure 4). 
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Figure 19 – Intertumor-heterogeneity in tumor development, aggressiveness and potential 
to form lung metastases in primary patient derived xenograft models   
(a) Survival estimates of the different primary patient derived ccRCC xenografts. 100000 KIKA cells of the 
different tumor models were injected into the renal capsule of NSG mice. When the tumor size reached its 
stopping criteria, mice were euthanized. KIKA75 has the fastest tumor progression (median 
survival = 38.5 days).  
(b) Overview of ccRCC models, with clinical parameters of the primary patient. Formation of lung metastases 
was assessed by eye. KIKA75 has the highest capacity to form metastases in NOD scid-gamma (NSG) mice 
(85.7 %). 
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3.4 Generation of an in vivo selection model to identify mediators 
of tumor aggressiveness  
In five rounds and in three biological replicates of an in vivo selection, we transplanted the 
metastases of orthotopically transplanted KIKA75 cells into the renal capsules of NSG mice 
(Figure 20). Primarily, we wanted to select for cells with a higher capacity to metastasize, but 
we are well aware that at the same time cells enriched, selected or adapted for a more 
aggressive phenotype (Figure 21). Survival of mice in the last passage was reduced by 22 %, 
primary tumor size was 50 % increased and more and bigger lung metastases were 
observable. 
 
Figure 20 – Schematic overview of the in vivo selection model. 
The primary ccRCC cell line KIKA75 was transplanted orthotopically into the kidney capsule of NSG mice. 
When the mice had to be euthanized according to the previously defined stopping criteria, the lungs of one of 
the mice per biological replicate were digested and reinjected into the renal capsule of mice of the next round. 
In one round of the first biological replicate, no metastases developed and cells of the digested primary tumor 
were orthotopically transplanted into the next round of mice. After the last round, cell lines were established 
from the first three biological replicates from the lung metastases of three or four mice per replicate group. At 
every step of the first three replicates of the selection process tumor material was collected and expression 
profiled. For the last replicate gene expression data was generated from only the passage 0 and passage 4 
samples. 
KIKA75 
(parental cell line) 
Passage 0 
Passage 1 
Passage 2 
Passage 3 
Passage 4 
Orthotopic transplant of  
primary ccRCC cell line 
Transplant of lung 
metastasis to kidney capsule 
Orthotopic transplant of 
kidney tumor 
Passage 2.2 
Establishment of lung 
metastasis derived cell line 
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Figure 21 – The in vivo selection model selected for more aggressive and metastatic cells 
(a) Mice from the first passage had to be euthanized after 35.0 ± 1.4 days and mice from the last passage
after 27.2 ± 1.3 days (P = 0.0007) when any of the stop criteria defined by the GV-SOLAS was reached. Error
bars represent mean ± s.e.m. (b) Primary tumor size at time of euthanization of the first passage was
0.8 ± 0.4 cm (n = 12) and primary tumors size from the last passage was 1.2 ± 0.8 cm (n = 22; p = 0.044). (c)
Scoring the lung metastases by eye and histology revealed an increase from 1.3 ± 0.3 (n = 12) in passage 0
to 2.2 ± 0.2 (n = 22; P value = 0.0218) in passage 4. P value was calculated using a two-sided Student’s t-
test. Error bars depict mean ± 1.5*IQR.
 Passage 4 derived lung metastasis cell lines exhibit an increased 3.4.1
carrying capacity 
To explain the in vivo differences in tumor formation between the originating KIKA75 cell 
line derived tumors and the tumors of the last passage of the in vivo selection, the growth of 
cells isolated from the lungs of the last passage and from the originating cell line was 
measured. Subsequently, growth rate and carrying capacity were estimated by logistic 
regression (7), fitting the results of metabolic turnover as an estimator for cell number (Figure 
22). 
Logistic regression formula to calculate growth rates 
𝑁𝑡 =
𝐾
1 + (
𝐾 − 𝑁0
𝑁0
) 𝑒−𝑟𝑡
(7) 
𝑁𝑡: Population size at time 𝑡
𝐾: Maximum possible population size, or carrying capacity 
𝑟: Growth rate 
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a b c 
Figure 22 – Cell lines derived from lung metastases of passage 4 had no significant 
difference in growth rate but maximum possible population size 
(a) Growth curves estimated from the originating cell lines and passage 4 lung metastases derived cell
lines. Cell growth of three biological replicates of each condition with 6 technical replicates each was 
measured by CellTiter Blue metabolism. Growth curves were fitted using the growthcurver package in R.  
(b) The growth rate of cells before and after the selection revealed no significant difference in tumor cell
growth rate (passage 0: r = 0.028 ± 0.009 h
-1
, n = 12; passage 4: r = 0.022 ± 0.007 h
-1
, n = 20; P = 0.089).
(c) The maximum possible population size of the passage 4 derived cells is about 1.6 times larger than of
the originating cell line (P = 0.015, two sided Student’s t-test). Error bars depict mean ± 1.5*IQR.
3.5 Expression and genomic analyses of the in vivo selection 
To elucidate the differences in growth potential and metastases formation, we analyzed 
samples of the in vivo selection with the help of gene expression profiles, DNA methylation 
analyses and exome sequencing. 
 Exome Sequencing reveals that the in vivo selection did not select for 3.5.1
subclones 
By comparing the sequenced exome of the primary tumors derived from the originating cell 
line and the primary tumors of the last passage, changes in clonal distribution can be 
characterized. For this analysis, Gregor Warsow identified all functional somatic single 
nucleotide variants (SNVs) and copy number variations (CNVs) of the bulk kidney tumor 
samples. Mouse cell contamination was reduced by alignment to a mouse-human hybrid 
genome. Between 84.9 % and 93.5 % of the reads were human origin. Using the heuristic 
Marcov Chain Monte Carlo method
268,269
, the mutations were allocated to individual mutation
clusters, which are distributed along the branches of a phylogenetic tree. The tree describes 
the relatedness between the subclones. Each subclone carries a set of mutations which is 
collected when traveling from the root of the phylogenetic tree to the subclones respective 
leaf. The aim of the Marcov Chain Monte Carlo method is to achieve a global optimum 
distributing mutations along the tree. Subsequently, to each tumor sample the proportions of 
the different subclones were assigned. However, with this method not all subclones 
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necessarily possess all mutations, which are found along the path from root to leaf. Five 
different subclones with a characteristic mutational pattern were identified (Figure 23). 
Although clone 3 and 4 show subtle variance, the general picture indicates stable clonal 
heterogeneity. Therefore, the changes in aggressiveness between the passages may not be 
explained by clonal outgrowth but by differential expression and epigenetic regulations.  
Figure 23 – No predominant subclone emerges during the in vivo selection 
Using a heuristic Marcov Chain Monte Carlo method, mutations called by exome sequencing were 
distributed along the branches of a phylogenetic tree. Each subclone is characterized by a set of mutations 
(Mut). Clone 3 and 4 show subtle variance but the general picture indicates stable clonal heterogeneity. 
Posterior probability 32.3 %. Data analyzed by Gregor Warsow. 
# 
# 
# 
# 
# 
# 
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 Primary Kidney Samples were used for Gene Expression Analyses 3.5.2
We analyzed the gene expression profile of the kidney tumors, the lungs containing the 
metastases of each step, as well as the isolated cell lines derived from the lung metastases of 
the last passage and the originating cell lines by gene expression microarray analysis. 
Following the limma pipeline
270,271
, arrays were corrected for background, normalized and 
log2-transformed. To increase the sensitivity of microarrays and to reduce the multiple testing 
problem, probes of the microarrays were filtered for duplicates and variance (interquartile 
range of variance < 0.5). Quality control was performed and thereby one outlier was identified 
and removed (Supplemental Figure 5). Gene annotation was subsequently updated to the 
recent ensemble version (Ensembl Release 94, October 2018). 
We decided not to compare the isolated cell lines to the originating cell lines alone, as 
potential gene expression effects induced by the microenvironment of the tumors might be 
affected by the isolation, digestion and culturing procedure conducted to obtain tumor derived 
cell lines.  
Data of the bulk lung with the metastases were analyzed with the caveat of false positive 
results which might have risen from the sampling process in which small metastases from the 
lungs could have resulted in a contamination with normal mouse lung tissue. This mouse 
tissue could be false positively recognized by the human microarray and is less pronounced in 
the bigger primary tumors, where only little adjacent normal tissue was sampled (Figure 24). 
By comparing the expression profile of bulk kidney and lung tumors of the first biological 
replicate to gene expression data of isolated cell lines generated from the lung metastases of 
the last passage, we could show that expression data from the bulk tumor correlates better to 
the cell lines (r
2
 = 0.78 ± 0.01) than the lung metastases to the cell lines (r
2
 = 0.69 ± 0.06; 
p = 0.05). 
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Figure 24 – Linear relationship 
between gene expression profiles of 
primary kidney tumors and their 
corresponding lung metastases to 
the established cell culture lines 
derived from passage 4. 
Raw gene expression values of (a) primary 
kidney tumor or (b) the corresponding lung 
metastases versus the corresponding, 
established and cultured cell lines derived 
from lung metastases of passage 4. The line 
denotes the linear relationship between the 
two groups. 
(c) Boxplot of the r
2
 values shows a 
significant difference between the two 
comparisons. Error bars depict mean ± 
1.5*IQR. 
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 Principle component analysis of the gene expression profiles clusters 3.5.3
samples according to tissue type 
The degree of differences within the cell lines derived from the lung metastases, the lung 
metastases themselves and the primary tumors can also be observed by performing a principle 
component analysis (Figure 25a). The samples cluster according to their tissue of origin in 
the first two principle components (cell line, kidney tumor, lung metastases) and biological 
replicates. Nevertheless, only 34.9 % of the observed variance can be explained by the first 
two principal components. For that reason, the samples had to be subsetted, in order to 
observe significant results in a differential gene expression analysis. By annotating the bead 
chips, we were able to exclude a batch arising from the usage of different microarrays 
(Figure 25b). 
a b
Figure 25 – Principal Component Analysis separates samples into clusters of tissue origin 
and show no batch effect 
The top 500 variant standardized gene expression data of all used Illumina HT12-v4 expression arrays were 
analyzed in a principal component analysis and samples labeled according to (a) tissue origin and (b) 
microarray bead chips. Samples cluster in the first two principal components foremost according to tissue 
origin and show no extensive batch effect. 
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 Principal component analysis of each biological replicate clusters 3.5.4
samples according to the in vivo passage 
By subsetting the primary tumor derived gene expression profiles biological replicates and in 
vivo passages cluster together in a principal component analysis, indicating a common 
trajectory of variance explained by the principal components (Figure 26).  
a b
c  Replicate 1 d  Replicate 2 e  Replicate 3 f  Replicate 4 
Figure 26 – The principal component analysis visualizes a common trajectory of variance 
between the passages of the in vivo selection 
(a) Principal Component Analysis of gene expression profiles of the top 500 variant genes between the
kidney samples. The first principal component describes most of the variance between the samples (41.2 %) 
and samples cluster by their passage of the in vivo selection. The primary tumor material that was not 
passaged yet clusters to the left and primary tumor material from the last passage clusters to the right. The 
second principle component explains variance derived from the different biological replicates (17.4 %). 
(b) Principal Component Analysis of gene expression profiles of the top 500 variant genes between the
analyzed cell lines. The first principal component explains 54 % of the variance between the samples and
mostly describes the difference between the originating cell line and cell lines derived from the lung
metastases of the last passage of replicate 3, 1 and 2. Differences between the originating cell line and
passage 4 are mostly explained by the second principal component (20.5 % variance explained).
(c-f) Subset of each biological replicate of the different passages and kidney tumors. Variance between the
first and the last passage can be explained by the first principal component.
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 DNA Methylation analysis recapitulates the variance of the gene 3.5.5
expression profiles 
To elucidate whether the samples not only vary in gene expression profiles but also on a 
genomic level, DNA methylation profiles of the first and the last passage of genomic DNA of 
the bulk kidney tumors were analyzed using an Illumina Infinium MethylationEpic BeadChip. 
Primary kidney tumors derived directly from orthotropic transplanted originating cell lines 
show a homogenous DNA methylation profile (Figure 27a). Variances in DNA methylation 
between the samples of passage 4 is more pronounced (Figure 27b). Nevertheless, no general 
trend and differences in global methylation on CpG Island (CGI) relation is observable. The 
hierarchical clustering of the most variant methylated CGIs by manhatten distance metric 
groups biological replicates together (Figure 27c). Replicates are also grouped together in a 
principal component analysis of the variant methylated probes and the primary tumors of the 
first passage cluster apart from tumors of the last passage (Figure 27d). 
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Figure 27 – DNA Methylation Analysis 
(a) DNA methylation variance of genomic DNA of bulk kidney tumors is low, (b) whereas the DNA
methylation in the kidney tumors of the last passage shows higher variance. 
(c) Visualisation of the top 1000 variable loci in a heatmap; dissimilarity metric is manhattan distance and
agglomeration strategy by average linking. Samples are colored based on the in vivo passage and sites are
colored based on CGI relation.
(d) Principal component analysis of the first two principal components. Each biological replicate and each in
vivo passage clusters together as a distinct group.
Plots were generated using the RnBeads package.
Color Key and 
Histogram 
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 Differential expressed genes are associated with cell migration, 3.5.6
extracellular binding and extracellular matrix 
To obtain a list of significantly differentially expressed genes, linear models were fitted by 
generalized least squares probe-wise following the limma differential gene expression 
pipeline, biological replicates group-mean parametrized and gene-wise ranked using the 
empirical Bayes method
270,271
.
In order to identify genes that mediate the increased aggressiveness and metastatic outgrowth, 
we compared the differentially expressed genes between both the bulk tumors of passage 0 
and passage 4 and between the originating cell line and passage 4 lung metastases derived cell 
lines. With the knowledge that the human specific bead array might false positively identify 
genes of the mouse microenvironment, as stated in section 3.5.2, we decided to solely rely on 
differential expressed genes of the primary tumors that are also significantly differentially 
expressed in the cell culture setting (adj. P value < 0.05). To reduce the possibility of false 
negative exclusion of primary tumor specific genes we did not apply any fold-change cutoff 
on the cultured cells. 
Of the 3356 significantly differentially expressed genes in the cell culture setting, 183 genes 
were at least two-fold differentially expressed between primary tumors of passage 4 versus 
passage 0 (Figure 28). 140 genes were only differentially expressed in vivo and might 
therefore tumor microenvironment associated (Supplemental Figure 6). 
The 183 differentially expressed genes are highlighted in a volcano plot in Figure 28b and the 
16 genes that are at least 8-fold differentially expressed are additionally labeled. The top 
upregulated genes are Annexin A10 (ANXA10), Tetraspanin 8 (TSPAN8), Biglycan (BGN), C-
X-C Motif Chemokine Ligand 5 (CXCL5) and Interleukin 13 Receptor Subunit Alpha 2 
(IL13RA2). The top down-regulated genes are Somatomedin B And Thrombospondin Type 1 
Domain Containing (SBSPON), Secreted Phosphoprotein 1 (SPP1), Plasminogen Activator, 
Urokinase (PLAU), SLIT And NTRK Like Family Member 4 (SLITRK4) and Collagen Type 
VIII Alpha 1 Chain (COL8A1). The biological replicates, except of one sample, cluster 
together when the differentially expressed genes are plotted in a heat map (Figure 28c). 
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Figure 28 – Differential Gene Expression analysis 
(a) VENN Diagram of all differentially expressed genes with an adjusted P value < 0.05 (BH corrected) 
between the originating and passage 4 derived cell lines, and at least two-fold differentially expressed genes 
of the bulk kidney tumors of passage 4 and passage 0.  
(b) Volcano plot of all differentially expressed genes of the bulk tumor, which are also differentially expressed 
in the cell culture setting. Highlighted in red are all 183 genes that are at least two-fold differentially 
expressed. Annotated are all genes that are at least 8-fold differentially expressed. 
(c) Heat map of the 183 differentially expressed genes. Biological replicates cluster, except of one sample, 
together (Manhattan distance, ward.D linkage). 
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 The in vivo selection selected for extracellular associated genes 3.5.7
The cellular component of the genes is enriched for either extracellular or extracellular 
associated genes (Figure 29a). In addition, the molecular function of these genes is associated 
with extracellular binding and communication (Figure 29b) and their biological function with 
circulation, cell migration, structure regulation and response to stimuli (Figure 29c). 
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Figure 29 – PANTHER overrepresentation test for the gene ontology of the differentially 
expressed genes  
(a) The differentially expressed genes are enriched in the GO cellular component for either extracellular or
extracellular associated genes. (b) The GO molecular functions are enriched for genes that have a role in
extracellular binding and communication. (c) The most enriched GO biological processes are associated with
circulation, cell migration, structure regulation and response to stimuli.
Terms of the same adjacent biological items are colored identically.
PANTHER Overrepresentation Test (Released 2018-11-13). GO Ontology database released 2018-12-01.
Fisher’s exact test, Bonferroni correction for multiple testing.
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3.6 Selection of clinical relevant genes from the in vivo selection 
The genes we identified with our in vivo selection experiment correlate with extracellular 
communication and migration, indicating that they might play a role in metastatic outgrowth. 
Therefore, the question arose whether these genes might be clinically relevant and would 
correlate with metastatic outgrowth and tumor aggressiveness. 
We made use of the publically available TCGA-KIRC patient dataset. Next to RNASeq gene 
expression data, methylation, mutation profiles, survival data and clinical characteristics have 
been collated. Median follow-up was 39 months (Supplemental Figure 7). 
In order to identify clinical relevant processes essential for primary tumor outgrow, a 
hallmark of stage III tumors, we correlated the differentially expressed genes of the in vivo 
selection to processes that happen between stage I and stage III of ccRCCs. Stage III tumors 
have by definition not metastasized to distant organs yet but invaded local tissues. 
 Identification of clinical covariates that are predictive for cancer 3.6.1
specific survival 
It is important to include clinical characteristics that are prognostic for cancer specific 
survival into a gene signature model, as they might correlate with the expression of various 
genes. Therefore, univariate analysis (univariate Cox regression) was performed on all 
patients of stage I to III with all clinical variables of the dataset that were annotated in at least 
90 % of the patients and had > 3 patients per group (see Supplemental Figure 7). The hazard 
function h(t,x) and from this function derived hazard ratios (HR) for the univariate analysis 
are defined in equation (8) and (9). To identify the optimal cut point for stratifying patients 
into risk groups for age and tumor size the maximally selected rank statistics for the outcome 
of cancer specific survival probability was calculated. Thereby, the optimal cutoff for the age 
was identified at 51 years ≡ -0.791 standardized age and tumor size at 7.7 cm. 
Univariate Cox PH model 
ℎ(𝑡| 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒) = ℎ0(𝑡) × e
𝛽×𝑐ℎ𝑎𝑟𝑎𝑠𝑡𝑒𝑟𝑖𝑠𝑡𝑖𝑐 (8) 
Hazard Ratio (HR) 
𝐻𝑅𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒
𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
=
ℎ(𝑡|𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒)
ℎ(𝑡|𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒)
(9) 
ℎ0(𝑡): Baseline hazard 
β: Corresponding coefficient of the covariate 
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Of the 17 tested biomarkers for the univariate regression, eight were significantly associated 
with cancer specific survival of stage I to III patients (P ≤ 0.05) (Figure 30). Stratification of 
patients according to the TNM staging system, tumor grade and the SSIGN Score show a 
significant survival benefit. Interestingly, primary tumors located in the right kidney show 
favorable survival (HR = 0.38; P = 0.003) and patient age at diagnosis had no significant 
association with cancer specific survival (HR = 1.3; P = 0.078). 
 
Figure 30 – Forest plot: Univariate Cox Regression for Cancer Specific Survival (Stage I-III) 
Univariate regression was calculated for the TCGA-KIRC dataset separately for each comparison group using 
8. The impact size of each covariate is estimated by their associated beta coefficients and hazard ratios. Age 
as a continuous variable was standardized to exclude outlier effects. Grade 1 and 2 patients were combined 
as reference group for patient grade. Clinical parameters were analyzed when data was present for > 90 % of 
the patients. Groups with < 3 patients per group were excluded. nonsyn = nonsynonymous * P < 0.05, ** 
P < 0.01, *** P < 0.001. Error bars represent the 95 %-CI. 
Hazard Ratio 
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Nevertheless, standardized patient age correlates with overall survival of patients (HR = 1.41; 
P < 0.001) and especially with survival of a non-cancer caused death (HR = 2.10; P < 0.001) 
(Figure 31a-c). While stratification into two age groups could significantly separate patients 
“overall survival” (Figure 31d; log rank P = 0.00047) and “not cancer specific survival” 
probability (death not by cancer; Figure 31e; log rank P = 0.0035), the estimators were not 
significantly different for “cancer specific survival” (CSS) (Figure 31f). 
a b c 
3
d e f 
Figure 31 – Age is not a significant predictor for cancer specific survival 
(a) The log hazard rate of cancer specific survival for all tumor stages shows no significant association with
the standardized age of patients at diagnosis. (b) Age correlates significantly with overall survival
(HR = 1.41 ± 0.08) and especially with (c) death not related to cancer (HR = 2.10 ± 0.15).
Kaplan-Meier Estimator of (d) cancer specific survival, (e) overall survival and (f) not cancer specific survival
for patients stratified by age 51. This stratification cannot separate cancer specific survival probability into
significant different estimators.
The optimal cut point for stratification by age was calculated using the maximally selected rank statistics.
Filled areas represent the 95 %-confidence intervals. P value calculated by log rank test.
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All clinical and histopathological characteristics for tumor stage, histopathological primary 
tumor size (T-stage), the presence of regional (N-stage) and distant metastases (M-stage), 
tumor grade, tumor size, presence of metastases and the SSIGN Score could significantly 
predict patients’ cancer specific survival of all tumor stages (Figure 32). 
a b c d
e f g h
Figure 32 – Kaplan-Meier estimators for clinical/pathologic characteristics and cancer 
specific survival 
ccRCC patients can be stratified significantly into significantly distinct risk groups by (a) tumor stage, 
(b) primary tumor size, the presence of (c) regional and (d) distant metastases, by (e) tumor grade, (f) tumor
size, (g) presence of necrosis and (h) by the SSIGN-Score. P values calculated by log rank test.
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 Lasso Regression variable shrinkage 3.6.2
To obtain a model able to identify groups of patients with low survival probability, especially 
in early stage cancers which reflect the model of the in vivo selection, least absolute shrinkage 
and selection operator (LASSO) regression in the context of Cox’s proportional hazards 
model (Cox regression) was performed on a total of 444 stage I-III patients (early stages) of 
the ccRCC TCGA Dataset (Figure 33). Two left-censored patients and three patients 
discrepant for stage annotation were excluded from the analysis.  
Figure 33 – Schema describing the method used to obtain the ccRCC early score 
RNASeq Gene expression data of 178 of the 183 highly differentially expressed genes 
identified in the in vivo selection was annotated in the TCGA dataset. Three of the genes 
could not be verified by qRT-PCR (Supplemental Figure 8). Standardized gene expression 
data together with clinical parameters that had a P value below the threshold of 0.2 in the 
univariate Cox regression (see Figure 30) were used as covariates to estimate a Cox 
proportional hazard model
272
. The Mayo SSIGN score, tumor laterality, tumor size in cm and
necrosis status were predictive in univariate analysis for patients’ survival. These variables 
were not included as covariates into the regression, as these clinical characteristics were 
missing from the Sato et al. test dataset (see Supplemental Figure 7 & Figure 48). 
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Hazard rates of the tumor stages (Figure 34a) and primary tumor classification (Figure 34b) 
are not distributed linearly in both cancer specific survival and overall survival, whereas 
tumor grade stratifies patients approximately linearly (Figure 34c). This can also be noted in 
the Kaplan-Meier estimators of these clinical characteristics. Stage II and III alone for 
example cannot separate the survival curves significantly (Figure 32a; p = 0.255) and 
estimators of primary tumor size pT2 and pT3 alone are marginally significantly different 
(Figure 32b; p = 0.043). 
The clinical characteristics stage, pT stage and grade do not correlate linearly with the relative 
hazard. Therefore, instead of replacing these ordinal clinical characteristics with an ascending 
numeric sequence as covariate in the regression, a binary covariate model has been chosen: 
Each level of the clinical characteristics was given its own variable separately. 
a               Grade 
 
b                    pT 
 
c                Stage 
 
Figure 34 – Correlation of stage, grade and primary tumor size with the relative log hazard 
of overall and cancer specific survival 
(a) Tumor grade correlates approximately linearly with the relative log hazard in both overall and cancer 
specific survival. The coefficient of determination R
2
 of the linear correlation of (b) primary tumor T-stage (c) 
and tumor stage was less pronounced. 
Linear regressions for each group are drawn. Error bars depict HR ± standard error. 
Nodal status in 268 and distant metastases status of 29 patients were not assigned in the 
clinical annotation of the dataset. Hence, only the AJCC staging system was included, as it is 
based on the TNM staging system and clinical information of regional and distant metastases 
are included in the annotation. 
In summary, the clinical parameters stage and grade, together with the standardized gene 
expression data of 175 genes were assessed as covariates for the regression model. As 
negative controls we included additionally standardized age and gender. 
When calculating a model with many regression coefficients, the L-1 norm penalized 
estimation by the LASSO regression method can be used to perform variable shrinkage and 
selection
264
. Some regression coefficients for genes and clinical parameters (covariates of the 
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regression) are thereby due to the nature of the used L-1 norm minimized exactly to zero. 
Thus, the LASSO regression allows a gene selection in an unbiased manner to score patients 
by gene expression values and predict patient survival
266
. The number of variables in the
model is controlled by the amount of regularization using a tuning parameter λ. The optimal 
λ-value for each regression was calculated by 10-fold cross-validation. 
To avoid the risk of overfitting the model to the dataset, a bootstrapped approach was 
developed (see Figure 33). 70 % of the patients of the TCGA-KIRC dataset were selected 
randomly as a training dataset on which the LASSO-Regression is applied by using the coxnet 
function of the glmnet package in R
265,273
. This was repeated for 10000 iterations on the
DKFZ ODCF PBS computer cluster. Subsequently, only factors with non-zero regression 
coefficients in more than 50 % of the LASSO-models were selected to calculate the beta 
values of the Stage I-III model (Figure 35)
274
.
Figure 35 – Percentage of non-zero β-coefficients of all covariates of the LASSO regression 
The genes CXCL5, SLC2A9, ONECUT2, PTPN3, TSPAN8, PRDX2 and IL13RA2 of the in vivo selection and 
the clinical covariate “stage I” are the only covariates that were selected by the LASSO regression into more 
than 50 % of the models. 
We termed the model of the weighted sum of expression and patient stage I “ccRCC early 
Score”: 
ccRCC early Score = 0.084  x  IL13RA2  -  0.342  x  SLC2A9  -  0.132  x  PTPN13  + 
  0.327  x  CXCL5  +  0.010  x  PRDX2  +  0.115  x  TSPAN8  + 
    0.172  x  ONECUT2  -  1.398  x  stage 1 
(10)
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As the list of differentially expressed genes used by the LASSO regression was initially 
derived from microarray data with the chance of false positive results, we validated the 
expression of the seven selected genes by quantitative real-time PCR (qRT-PCR) using 
human specific TaqMan probes (Figure 36).  
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Figure 36 – Validation of ccRCC early score genes by quantitative TaqMan real-time PCR 
The expression of ccRCC early score genes is consistent between microarray and qRT-PCR.  
Microarray: Boxplot, error bars depict median ± 1.5*IQR 
qRT-PCR: Barplot, P values calculated using an unpaired, two-sided Student’s t-test. Error bars depict 
mean ± s.e.m. 
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To validate whether the ccRCC early Score can recapitulate the in vivo experiment, the score 
was calculated on the standardized gene expression microarray data of the in vivo selection 
(Figure 37). We saw a high correlation between the ccRCC early score and the passage 
number of the in vivo expression data. This reveals us that the ccRCC early score derived 
from the differentially expressed genes of our experimental setup can predict the in vivo 
passage. The ccRCC early score was obtained with the help of the RNAseq expression data of 
the TCGA-KIRC dataset and gene expression data of the in vivo selection experiment was 
assessed by a microarray. This gives us a hint that the ccRCC early score may be applicable 
across platforms. 
 
Figure 37 – Calculation of ccRCC early scores from gene expression data of primary 
tumors of the in vivo selection model 
To validate the in vivo selection, ccRCC early scores were calculated from the microarray gene expression 
data (KIKA75 was derived from a stage III tumor). Kidney xenograft tumors of the originating tumor have a 
ccRCC early Score of -1.55 ± 0.49 and kidney xenografts of the last passage have a ccRCC early Score of 
0.71 ± 0.25. Between the score and the passages is a linear relationship with an adjusted R
2
 of 0.794. 
The black line represents the linear fit between the different passages and grey areas the 95 % confidence 
intervals of the regression. P value calculated using a two-sided Student’s t-test between adjacent passages. 
Error bars depict mean ± 1.5*IQR. 
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To assess the ability of each of the ccRCC early Score genes to predict the clinical outcome of 
patients’ survival, the univariate hazard ratios of stage I to stage III patients of each gene 
alone were plotted against the log fold-changes of the same genes in the differential 
expression between the last passage and the originating xenografts of the in vivo selection 
(Figure 38). All genes with a log fold-change > 1 have an increased risk of cancer specific 
death and all genes with a log fold-change < 1 have an improved survival probability. 
Therefore, the in vivo selection model selected for genes that correlate to the survival 
probability of ccRCC patients. 
Figure 38 – Univariate hazard ratio vs. log2 fold change of the in vivo selection 
Scatter plot of the differential expressed genes between parental tumors and passage 4 as well as the 
corresponding univariate hazard ratios of all genes annotated in the TCGA-KIRC dataset of patients of stage 
I-III patients. Labeled are the genes that were selected by the LASSO regression.
Genes with a significant univariate hazard ratio which are significantly differentially expressed between
passage 4 and passage 0 (FDR < 0.05) and which are additionally significantly differentially expressed
between passage 4 lung metastases derived cell lines and the originating cell line are labeled according to
their adjusted P value of the differential expression. Otherwise they are labeled light grey.
70 Results 
 The ccRCC early score is the a significant predictor of stage I-III patient 3.6.3
survival in a multivariate analysis 
To assess the efficiency of the variable shrinkage of the LASSO regression, a multivariate 
analysis (Cox multiple regression) was performed using the ccRCC early score and all clinical 
variables that were used as covariates for the regression (Equation 11). The results are 
presented as a Forest plot in (Figure 39). 
Figure 39 – Forest Plot of the multivariate analysis of clinical phenotypes and the ccRCC 
Score of stage I-III patients of the TCGA-KIRC dataset  
Clinical parameters used in the LASSO regression were included in the multivariate analysis (Cox multiple 
regression as in (11). Only the ccRCC early score shows a significant P value. 84 patients of stage IV or 
those with missing information in any of the covariates where excluded from the analysis. * P < 0.05, ** 
P < 0.01, *** P < 0.001. Error bars represent the 95 %-CI. 
Cox multiple PH model 
  ℎ(𝑡, 𝑥) = ℎ0(𝑡) × exp (𝛽1 × 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑎𝑡𝑡𝑟𝑖𝑏𝑢𝑡𝑒 1 + 𝛽2 × 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑎𝑡𝑡𝑟𝑖𝑏𝑢𝑡𝑒 2 + ⋯ +
𝛽𝑛 × 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑎𝑡𝑡𝑟𝑖𝑏𝑢𝑡𝑒 𝑛)
(11)
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 Obtaining a general applicable ccRCC score 3.6.4
When patients of all stages in the ccRCC dataset were scored and tested in a multivariate 
analysis, only stage IV stays together with the ccRCC early score as significant predictor for 
patients’ survival (Figure 40).  
Figure 40 – Forest plot of the multivariate analysis of clinical parameters and the ccRCC 
Score in all patients of the TCGA-KIRC dataset 
Only the ccRCC Score and the clinical parameter “Stage IV” showed significant P values. 3 patients with 
missing information in any of the covariates where excluded from the analysis. * P < 0.05, ** P < 0.01, *** 
P < 0.001. Error bars represent the 95 %-CI. 
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To enhance the predictive power of the ccRCC early score for all patients over all stages, a 
multiple Cox regression was performed by including the ccRCC early score together with 
stage IV annotation (Figure 41 and Equation 12). 
 
Figure 41 – Schema describing the method to obtain a generally applicable ccRCC score 
 
Obtaining the generally applicable ccRCC Score model 
𝑐𝑐𝑅𝐶𝐶 𝑆𝑐𝑜𝑟𝑒 = β1 × ccRCC early Score + β2 × stage IV 
                =  1.085 × ccRCC early Score + 1.621 × stage IV 
           =  1.085 × (0.084 × IL13RA2 - 0.342 × SLC2A9 - 0.132 × 𝑃𝑇𝑃𝑁13 + 0.327 
× 𝐶𝑋𝐶𝐿5- 0.010 × PRDX2 + 0.115 × TSPAN8 + 0.172 × ONECUT2 - 1.398
× stage I) +1.621 × stage IV 
                = 0.091 × IL13RA2 - 0.371 × SLC2A9 - 0.143 × PTPN13 + 0.355 × CXCL5 - 0.011
× PRDX2 + 0.125 × TSPAN8 + 0.187 × ONECUT2 - 1.516 × stage I + 1.621
× stage IV 
 
(12) 
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3.7 The ccRCC Score robustly predicts cancer specific survival of 
ccRCC patients 
With the help of the new ccRCC Score we calculated an individual ccRCC score for every 
patient in the TCGA-KIRC dataset. To assess the effect of the continuous predictor on 
survival, we plotted the Cox proportional log hazard smoothed by the ccRCC Scores of the 
patients
275
 (Figure 42).
a     Cancer Specific Survival b     Disease Free Survival c      Overall Survival 
Figure 42 – Cox proportional log hazard smoothed by ccRCC Scores of the patients. 
The log hazard ratio of (a) cancer specific survival, (b) disease free survival and (c) overall survival with the 
ccRCC Score of a patient show highly significant (p < 0.001) linear relationships. 
The higher the ccRCC Score of a patient, the higher is the individual hazard risk for both 
cancer specific survival (CSS) and disease free survival (DFS).  
For example, the estimated hazard of a patient with a ccRCC Score of 2 has a log hazard rate 
of 2.82, another patient with a ccRCC Score of -2 has a log hazard rate of -1.91.  The 
estimated hazard for the patient with the ccRCC Score of 2 is: 
𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 ℎ𝑎𝑧𝑎𝑟𝑑 =
𝑒2.82
𝑒−1.91
 ≈ 113.30 
Therefore the patient with a ccRCC Score of 2 has an about 113 times increased cancer 
mortality risk in comparison to the patient with a ccRCC Score of -2. 
The observation of a correlation between ccRCC Score and log hazard ratio holds also true 
when patient survival was analyzed for each stage separately (Figure 43a-d). 
The ccRCC Score was trained on patients of tumor stage I-III of the TCGA-KIRC dataset. 
Hence, the ccRCC Score could also predict survival in stage IV patients, which is an 
additional validation of the score and its method (Figure 43d). 
74 Results 
The ccRCC Score in stage I ranges from approximately -3 to 1, in stage II from -1 to 2, stage 
III from -1 to 3 and in stage IV from 0 to 4. Therefore, the question arose whether the 
distribution of ccRCC Scores according to stage was significantly different (Figure 43e). 
Testing correlation between stage and score using Kendall’s rank correlation method shows a 
significant correlation of R
2  
= 0.71 (P < 0.0001). Testing for differences between the mean
showed significant differences between all of the stages, except between stage II and stage III 
patients. 
a      Stage I b      Stage II c       Stage III d      Stage IV 
e 
Figure 43 – Cox proportional log hazard smoothed by ccRCC Scores of patients stratified 
according to tumor stage. 
(a-d) Patients with low tumor stage have generally lower ccRCC Scores and patients with high tumor stages 
have higher ccRCC Scores.  
(e) ccRCC Score correlates with tumor stage (Kendall R
2
 = 0.71, P < 0.0001). Mean ccRCC Score of Stage I
patients (-1.580 ± 0.663) is significantly different from Stage II (-0.104 ± 0.737), Stage III (0.218 ± 0.857) and
Stage IV (1.900 ± 0.781), whereas the ccRCC Score of patients with stage III and stage IV tumors does not
significantly differ. Horizontal lines in the violet plot indicate 0.25, 0.50 and 0.75 quantiles of the samples.
P values are calculated using the two-samples Wilcoxon test.
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Since ccRCC Score and tumor stage correlate with each other, we were wondering whether 
the score remained a significant predictor for patients’ cancer specific survival in a 
multivariate analysis with all patients and with all complete annotated clinical covariates. 
Only necrosis status proved to be another significant and thus independent predictor of cancer 
specific survival. (Figure 44). That means when comparing to non-necrotic patients, patients 
with a histopathologic presence of necrotic areas in ccRCC specimens have an increased risk 
of a cancer specific death by 3.59 and with every rise of this ccRCC Score by 1 a 2.34 times 
increased risk of cancer specific death. 
Figure 44 – Forest Plot of the multivariate analysis of clinical phenotypes and the ccRCC 
Score in the TCGA-KIRC dataset 
All clinical parameters with > 90 % complete data were included in the multivariate analysis (Cox multiple 
regression as in 11). Only the ccRCC Score and the clinical parameter “Necrosis Status” showed significant 
P values. 11 patients with missing information in any of the covariates where excluded from the analysis. 
* P < 0.05, ** p < 0.01, *** p < 0.001. Error bars represent the 95 %-CI.
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Survival estimators are generally displayed by the method of Kaplan-Meier, which was 
achieved by dividing the patients into either two or three groups (Figure 45). Two groups 
were defined by separating patients by the median ccRCC Score. For three patient groups the 
lower and upper quantile of the ccRCC Score were classified as low risk and high risk, 
whereas the 50 % of patients in between were classified as intermediate risk group. 
The stratification of patients into both, two risk and three risk groups, significantly separates 
cancer specific survival probabilities. The high risk group of the binary stratification has only 
73 months median CSS probability, whereas at the end of the observation period after more 
than 12 years the survival probability of the low risk patients was still 90.9 % (Figure 45a). 
By stratifying patients into three risk groups, patients of the high risk group have a median 
survival of 34 months and intermediate risk patients have still an 86.2 % cancer specific 
survival probability after 12 years follow up. In the low risk patient group only one patient 
dies during the observation period and the cancer specific survival probability is still 94.4 % 
(Figure 45b). 
a b 
Figure 45 – The ccRCC Score efficiently stratifies patients into risk groups 
(a) Kaplan-Meier estimator for cancer specific survival (CSS) of the TCGA-KIRC dataset for patients
classified by median ccRCC Score (-0.751). Patients in the high risk group (n=266) have a median CSS of 
2225 days (~73 month), whereas patients in the low risk group (n=266) have a CSS probability of 90.9 % 
after 12 years of survival. (b) For an ordinal ccRCC Score stratification, patients were grouped into three 
groups. The high risk group (n=133; ccRCC Score > 0.449) has a median survival of 1033 days (~34 month), 
the intermediate (n=266) and low risk group (n=133; ccRCC Score < -1.700) have at the end of the follow up 
86.2 % and 94.4 % CSS probability respectively. Dotted lines indicate median survival. Stratifications 
separate CSS probabilities significantly different (log rank test). 
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In a next step, patients were stratified according to both tumor stage and the ccRCC Score-
derived three risk group classification. The ccRCC Scores used to allocate all patients of the 
dataset into risk groups in Figure 45 were also applied to allocate patients into risk groups 
that were stratified according to tumor stage (Figure 46a-d). For each tumor stage the 
assigned risk groups can estimate cancer specific survival probabilities. Nevertheless, the 
number of patients per risk group is dependent on tumor stage (Figure 46e). In stage I only 
two patients were classified as high risk and 133 patients as low risk. In contrast, in stage II 
no patient was classified as low risk, while 11 of the 57 stage II patients in the dataset were at 
high risk with a median survival of 2254 days (73 months). No patient of stage III and IV was 
classified as low risk. The high risk group of stage III patients has a median survival of 1229 
days and of stage IV patients only 721 days. Still, the intermediate risk group showed 
significantly improved cancer specific survival probability.  
By grouping patients with specific ranges of ccRCC scores, the 5-year cancer specific 
survival rates can be calculated (Figure 46f). Patients with low ccRCC Scores have a very 
good prognosis whereas high scores indicate worse 5-year cancer specific survivals. 
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a Stage I b   Stage II c Stage III d   Stage IV
e f 
Figure 46 – Cancer specific survival probability of ccRCC patients stratified according to 
ccRCC Score and patient stage. 
(a-d) Kaplan-Meier estimators for cancer specific survival with stratification of patients according to tumor 
stage and three risk groups using the same stratification boundaries for the ccRCC Score as applied for all 
patients Dotted lines indicate median survival. (e) Balloon-Plot displaying the number of patients per tumor 
stage and ccRCC risk group. (f) 5-year cancer specific survival of patients in ccRCC Score ranges. Patients 
were grouped according to a ccRCC Score range of -3 to 2.5 in 0.5 intervals. 5-year cancer specific survival 
rates with their respective 95 %-CI were calculated for each group. 
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3.8 The ccRCC Score has been validated in an independent 
patient cohort 
The ccRCC score was validated using the independent RNA Sequencing dataset published by 
Sato et al.
31
. Median follow-up of these 100 patients containing validation cohort was 50 
months (Supplemental Figure 7). RNASeq data was TNM normalized, voom transformed 
and standardized according to the TCGA-KIRC dataset to allow comparison and the ccRCC 
Score for each patient calculated (Supplemental Figure 9).  
Also in the validation dataset the log hazard ratio significantly correlates with the ccRCC 
Score (Figure 47). The 95 % confidence interval is larger than the interval of the TCGA-
KIRC dataset due to lower patient number. 
 
Figure 47 – Validation of the ccRCC Score 
in the independent ccRCC patient cohort 
of Sato et al. 
Cox proportional log hazard smoothed by ccRCC 
Scores shows a significant correlation with a 
hazard ratio of 2.2471 ± 0.1406 (P < 0.001) 
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In the Sato et al. cohort, the ccRCC Score is the only significant prognostic factor in a 
multivariate analysis with annotated clinical covariates (Figure 48).  
Figure 48 – Forest Plot of the multivariate analysis of clinical phenotypes and the ccRCC 
Score in the Sato et al. ccRCC dataset 
For the multivariate analysis (Cox multiple regression as in equation 11) all clinical parameters with > 90 % 
complete data were included. Only the ccRCC Score exhibits significant P values of the regression. There 
was no patient with missing information in any of the covariates that had to be excluded from the analysis. 
* P < 0.05, ** P < 0.01, *** P < 0.001. Error bars represent the 95 %-CI.
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Subsequently, patients were divided into risk groups using the same ccRCC Scores that 
allocated patients into risk groups of the TCGA-KIRC dataset. In the validation dataset of 
Sato et al., the ccRCC Score is highly predictive for patient survival in both binary and 
ordinal stratifications (log rank P < 0.0001). Median survival of the high risk group (n = 28) is 
44 months regardless the stage in the binary model. The survival probability for patients in the 
low risk group (n = 72) that have survived for 145 months of follow-up is still 84.1 % (Figure 
49a). 
In an ordinal stratification approach, high risk patients (n = 18) have a median survival of 
only 33 months, whereas the intermediate risk group (n = 41) has a survival probability of 
64.7 % at the end of the follow-up period. The low risk group (n = 41) has a survival 
probability of 92.2 % (Figure 49b). 
a b 
Figure 49 – Kaplan-Meier estimators for overall survival probability of ccRCC of the Sato et 
al. cohort stratified according to the ccRCC Score. 
(a) The same ccRCC Score (-0.759) as in the TCGA-KIRC dataset was applied to divide patients into high
risk (n = 28) and low risk (n = 72) groups. Median survival of the high risk group was 44 months and the low
risk group had an overall survival of 84.1 % after the follow up period. (b) Stratification into three risk groups
according the TCGA-KIRC cohort with ccRCC Scores of -1.700 and 0.449 resulted in 18 patients in the high
risk group with a median survival of 33 months and 41 patients with intermediate risk and 64.7 % survival
probability at the end of the observation period. The 41 low risk patients had 92.2 % survival probability after
145 months. Dotted lines indicate median survival. Stratifications separate patient survival probabilities
significantly different (log rank test).
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3.9 The ccRCC Score has superior predictive power 
To assess the power of the ccRCC Score to predict cancer specific survival (CSS), it was 
compared in the two independent cohorts to the predictive power of other published 
signatures for the ccRCC that are based on gene expression data.  
In 2014, a systematic approach by Gulati et al.
267
 identified six prognostic signatures that are
based on gene expression analysis. They evaluated the signatures by comparing their 
prognostic power to predict CSS of the TCGA-KIRC dataset. At the timepoint of the study, 
only data from 350 patients of the dataset were published. A multiregion biopsy data set of 10 
ccRCCs was additionally analyzed to assess intratumor heterogeneity. However, a true 
validation on an independent large patient cohort was not performed. 
Expression data of 21 of the 23 genes of the Cluster A vs. C and 41 of the 48 genes of the 
Cluster B vs. A/C gene signature of Beleut et al.
276
, 144 of the 157 genes of the gene signature
of Boström et al.
277
, 34 of the 34 genes of the ClearCode34 gene signature from Brooks et
al.
278
, which was derived from the ccA/ccB signature from Brannon et al.
279
, 28 of the 35
genes of the gene signature of Kosari et al.
280
, 40 of 44 genes of the gene signature of Lane et
al.
281
 and 224 of the 259 genes of the gene signature of Zhao et al.
282
 were annotated in the
TCGA KIRC and Sato RNA-seq data sets.  
Interestingly, in none of the tested gene signatures any gene of the ccRCC Score is included. 
At the time of this thesis, the TCGA KIRC dataset comprises of 532 patients. These patients 
and the validation cohort of 100 patients of the Sato et al. dataset were assigned to their 
respective subgroups by unsupervised NMF consensus clustering as proposed by Gulati et 
al.
267
 (Supplemental Figure 14 & Supplemental Figure 15). Exemplary the clustering of
patients is presented for the ClearCode34 signature in both datasets in Figure 50.  
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Figure 50 – NMF Consensus Clustering for TCGA-KIRC and Sato et al. patients according to 
the ClearCode34 signature 
Ordered consensus NMF clustering maps for k = 2 for (a) TCGA-KIRC and (b) Sato et al. patients. 
Cophenetic correlation plots generated for the (c) TCGA-KIRC and (d) Sato et al. datasets were used to 
identify the best cluster representation by NMF Consensus clustering. In both datasets, two clusters 
represent the best separation of patients according to the gene expression data of the tested genes, as 
published for the ClearCode34 signature. 
All NMF consensus plots and reports were generated using the cloud.genepattern.org plattform by the Broad 
Institute
283
.
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To evaluate whether the ccRCC score correlates with any of the other signatures or with 
ordinal and continuous clinical parameters, Kendall rank correlation coefficients were 
calculated (tau test)
284
 (Figure 51 & Figure 52).
TCGA-KIRC 
Figure 51 – Kendall rank correlation coefficients for clinical variables, ccRCC Score and 
published signatures in the TCGA-KIRC ccRCC dataset. 
With the help of the tau test, statistical dependencies of ordered covariates such as tumor stage and grade 
could be estimated. Two and three risk groups of the ccRCC Score and the linear ccRCC Score were 
compared to both clinical variables and other published gene expression signatures for ccRCC. Tumor stage 
shows a high correlation and Fuhrman grade a low correlation with the score in the TCGA-KIRC patient 
datasets. Other signatures correlated only with low correlation to the ccRCC Score, whereas for example 
Kosari’s and Zhao’s correlate highly with a correlation coefficient of 0.74. 
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Sato et al. 
 
Figure 52 – Kendall rank correlation coefficients for clinical variables, ccRCC Score and 
published signatures in the Sato et al. ccRCC dataset. 
As in Figure 51, tumor stage shows a high correlation and Fuhrman grade a low correlation with the ccRCC 
score in both patient datasets. The other published gene signatures correlate only with low correlation to the 
ccRCC Score, whereas for example Kosari’s and Zhao’s correlate highly with a correlation coefficient of 0.78. 
In general, the published signatures correlate much stronger with each other in the Sato et al. dataset. 
As expected, the ccRCC Score correlates with tumor stage in both datasets, as this clinical 
attribute was included as covariate in the model. Fuhrman grade has a slight correlation of 
0.38 in the TCGA-KIRC dataset (Figure 51) but only a correlation of 0.17 in the Sato et al. 
dataset (Figure 52). Tumor laterality, gender, history of neoadjuvant treatment and VHL 
mutations do not correlate with the ccRCC Score. To the other signatures only minor 
correlations of 0.22 to 0.43 in TCGA-KIRC and 0.19 to 0.43, depending on risk stratification, 
are recognizable. The other published signatures however correlate highly with each other, for 
example the signature of Zhao and Kosari with a correlation of 0.74 and 0.79. Interestingly, 
the annotation of new metastases in the Sato et al. dataset shows quite some association to the 
ccRCC Score. 
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Kaplan-Meier estimators of the published signatures depict that all analyzed signatures can 
significantly discriminate cancer specific survival in the TCGA-KIRC patient cohort, with 
P < 0.001 (log rank), confirming their results in the most recent TCGA-KIRC cohort 
(Figure 54). 
Patients in Beleut’s cluster A had significantly better prognosis than cluster B and C, whereas 
between cluster B and C no significant survival differences could be identified. TGF-β score 
high classified patients of the Boström signature show worse survival. The ccB cluster of the 
ClearCode34 signature (the simplified ccA/ccB signature) has lower survival probabilities. 
CSS of the aggressive subgroup, defined by Kosari, was worse than the non-aggressive 
subgroup. CSS of the aggressive subgroup, defined by Lane, was worse than the indolent 
subgroup of patients. Patients with a high TGFβ score had worse survival than patients with a 
low score. Patients in Zhao’s poor prognosis cluster 2 had worse CSS than cluster 1, 
supporting the results of Gulati et al.
267
.
Testing the signatures in the dataset of Sato et al. shows that the six published signatures can 
also significantly stratify ccRCC patients into prognostic groups (Figure 54).  
The predicted hazard ratios of the more aggressive subgroup in comparison to the benign 
group of the various gene signatures are summarized for both the TCGA-KIRC dataset as 
well as the Sato et al. patient cohort in (Table 7). For completeness, I additionally stated the 
hazard ratios for these datasets that were calculated by Gulati et al. on a previous version of 
the TCGA-KIRC dataset with only 350 patients
267
. Unfortunately, the authors of this study
did not publish their patient classifications for comparison. 
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Figure 53 – Published gene expression signatures show different power in predicting 
ccRCC cancer specific survival in the TCGA-KIRC cohort 
Kaplan-Meier estimators of cancer specific survival for ccRCC patient groups of the TCGA-KIRC dataset 
identified by published gene expression signatures. All signatures stratify patients into significantly different 
groups with increased and decreased survival probabilities (logrank test). 
Dotted lines indicate median survival time. 
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Figure 54 – Published gene expression signatures show different power in predicting 
ccRCC overall survival in the Sato et al. cohort 
Kaplan-Meier estimators of overall survival for ccRCC patient groups of the Sato et al. dataset identified by 
published gene expression signatures. All signatures stratify patients into significantly different groups with 
increased and decreased survival probabilities (logrank test). 
Dotted lines indicate median survival time. 
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Table 7 – Univariate hazard ratios of ccRCC patients classified by published signatures and the 
ccRCC Score 
Study 
HR 
[TCGA-KIRC] 
(95 % CI) 
No. Of cases 
(n = 532) (%) 
P value      
(log rank 
test) 
HR 
[TCGA - Gulati et 
al.] (95 % CI) 
No. Of cases 
(n = 350 (%) 
P value 
HR 
[Sato et al.] 
(95 % CI) 
No. Of cases 
(n = 100) (%) 
P value       
(log rank 
test) 
       
   
Beleut signature 
      
   
Cluster A 1.00 (Ref) 194 (36) 
 
1.00 (Ref) 127 (36) 
 
1.00 (Ref) 48 (48)  
Cluster B 
2.87 
(1.67-4.94) 
186 (35) 
 
2.27 
(1.31-3.96) 
175 (50) 
 
3.71 
(1.27-10.90) 
32 (32)  
Cluster C 
3.23 
(1.84-5.65) 
152 (29) < 0.001 
2.30 
(1.13-4.66) 
48 (14) 0.005 
5.92 
(1.93-18.23) 
20 (20) 0.003 
       
   
Boström 
signature:       
   
TGF-b signature 
low 
1.00 (Ref) 316 (59) 
 
1.00 (Ref) 175 (50) 
 
1.00 (Ref) 53 (53)  
TGF-b signature 
high 
3.97 
(2.61-6.03) 
216 (41) < 0.001 1.98 (1.23-3.16) 175 (50) 0.003 
3.22 
(1.32-7.86) 
47 (47) 0.007 
       
   
ClearCode34 
signature:       
   
ccA 1.00 (Ref) 323 (61) 
 
1.00 (Ref) 240 (69) 
 
1.00 (Ref) 66 (66)  
ccB 
3.3 
(2.2-5.0) 
209 (39) < 0.001 
4.90 
(3.09-7.76) 
110 (31) < 0.001 
4.30 
(1.85-10.02) 
34 (34) < 0.001 
       
   
Kosari signature: 
      
   
Nonaggressive 
subgroup 
1.00 (Ref) 334 (63) 
 
1.00 (Ref) 242 (69) 
 
1.00 (Ref) 63 (63)  
Aggressive 
subgroup 
3.66 
(2.43-5.51) 
198 (37) < 0.001 
2.85 
(1.84-4.43) 
108 (31) < 0.001 
4.80 
(1.97-11.70) 
37 (37) < 0.001 
       
   
Lane signature: 
      
   
Indolent 1.00 (Ref) 288 (54) 
 
1.00 (Ref) 219 (63) 
 
1.00 (Ref) 66 (66)  
Aggressive 
subgroup 
4.96 
(3.12-7.88) 
244 (46) < 0.001 
4.21 
(2.62-6.77) 
131 (37) < 0.001 
4.25 
(1.80-10.03) 
34 (34) < 0.001 
          
Zhao signature: 
      
   
Cluster 1 (good) 1.00 (Ref) 297 (56) 
 
1.00 (Ref) 269 (77) 
 
1.00 (Ref) 59 (59)  
Cluster 2 (poor) 
3.61 
(2.35-5.54) 
235 (44) < 0.001 
5.26 
(3.37-8.22) 
81 (23) < 0.001 3.21 (1.36-7.59) 41 (41) 0.005 
       
   
ccRCC Score (3 
groups):       
   
low risk 1.00 (Ref) 133 (25) 
    
1.00 (Ref) 41 (41)  
intermediate risk 
8.98 
(1.20-67.30) 
266 (50) 
    
6.06 
(1.34-27.33) 
41 (41)  
High risk 
113.97 
(15.87-818.60) 
133 (25) < 0.001 
   
18.21 
(3.96-83.75) 
18 (18) < 0.001 
       
   
ccRCC Score (2 
groups):       
   
low risk 1.00 (Ref) 266 (50) 
    
1.00 (Ref) 72 (72)  
high risk 
16.51 
(7.66-35.56) 
266 (50) < 0.001 
   
6.55 
(2.77-15.53) 
28 (28) < 0.001 
       
   
ccRCC Score 
(linear): 
2.72 
(2.35-3.15) 
532 (100) < 0.001 
   
2.25 
(1.71-2.96) 
100 (100) < 0.001 
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The C index, also called concordance index or “Harrel’s C”, is used to validate the predictive 
ability of censored data such as in a Cox Regression model
260
. It was calculated for both 
published signatures and the ccRCC Score (Figure 55a, b). In both datasets, the ccRCC Score 
had the highest C index. In contrast to the continuous ccRCC Score which goes along with a 
high predictive power (Harrel’s C Index of 0.88), stratification of patients lowers the 
predictive power (Harrel’s C Index of ≤ 0.84). It is notable that none of the published 
signatures could reach the predictive power of the classical clinical annotation stage. 
a TCGA-KIRC b Sato et al. 
  
Figure 55 – Comparative analysis of the predictive power of clinical phenotypes, published 
gene signatures and the ccRCC Score 
The Harrel’s C Index was calculated in order to compare the fits of the gene signatures Cox regression 
models. In both datasets, the ccRCC Score had superior survival predictive power. All published signatures 
based on gene expression data have worse predictive power than most of the clinical characteristics such as 
tumor grade or SSIGN Score. Error bars depict C-Index ± standard error. 
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Another common metric to compare survival predictions is the likelihood ratio test
285
. When 
comparing the scores, the continuous ccRCC Score has superior predictive power above the 
other variables (Figure 56). 
a TCGA-KIRC b Sato et al. 
  
Figure 56 – Likelihood ratios of clinical phenotypes, published gene signatures and the 
ccRCC Score to predict patients survival 
The Likelihood ratio was calculated in order to compare the predictive power of the different gene signatures 
and clinical parameters. In both datasets, the ccRCC Score had superior survival predictive power. 
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3.10 The Heidelberg ccRCC mini cohort 
We collected follow up data of those patients, which were used to establish ccRCC tumor 
models (Supplemental Figure 10). Microarray gene expression profiling was performed by 
Teresa Rigo-Watermeier
1
 and the data imported and normalized as described before
(see section 3.5.2). Subsequently, gene expression data of the ccRCC score genes was 
standardized using the scaling factors used for the TCGA-KIRC data standardization 
(see Supplemental Figure 9). 
Our follow up was incomplete to estimate cancer specific survival, yet sufficient to estimate 
progression free survival. We calculated the ccRCC score for each patient, classified them 
according to their score into “low”, “intermediate” and “high” risk groups (Supplemental 
Figure 11) and calculated Kaplan-Meier estimators (Figure 57a). No patient was classified as 
low risk, four patients were of intermediate and nine patients of high risk. In addition, in this 
small cohort, the ccRCC score significantly separated patients’ progression free survival into 
two distinct groups. 
One could argue that the survival difference of the small cohort was due to the presence of 
metastasis at the time point of tumor resection. However, when calculating Kaplan-Meier 
estimators for either metastatic or non-metastatic patients, the separation did not show a 
significant difference between the two groups (Figure 57b). Two early relapsing patients with 
non-metastatic tumors were classified by the ccRCC score as high risk patients. Therefore, the 
score had improved the risk classification of our patient cohort. 
a b 
Figure 57 – Progression free survival of the Heidelberg ccRCC mini cohort 
(a) Stratification of patients of the Heidelberg ccRCC cohort into three risk groups according the TCGA-KIRC
cohort with ccRCC Scores of -1.700 and 0.449 resulted in 9 patients with high risk and 4 patients with
intermediate risk. Stratifications separate progression free survival probabilities significantly different (logrank
test). (b) Stratification of the patients according to their metastasis status did not significantly separate
progression free survival probabilities.
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3.11 Distinct subclonal regions have higher ccRCC scores 
Gerlinger et al. described the vast intratumor heterogeneity of ccRCC by multiregion 
sequencing (see section 1.2.2)
72,73
. In their studies of 2012 and 2014, most regions of ten
analyzed patients were additionally profiled for gene expression using microarrays. This 
allowed us to calculate the ccRCC score for most of the identified subclones. We stratified the 
different regions of the tumors into the 3-tiered ccRCC Score risk categories, presented in 
section 3.7. Gulati et al. applied this approach exemplarily for the ccAccB signature
267
. We
likewise visually delineated the subclonal regions with identical ccRCC Score categories on 
the phylogenetic trees describing tumor development (Figure 58). In eight of ten patients, all 
regions of a tumor were classified into a single risk category. Two patients (EV001 and 
EV006) had tumor regions of both intermediate and high risk (Supplemental Figure 12). 
94 Results 
Figure 58 –  Intratumor heterogeneity of ccRCC risk scores categories 
Regions within ccRCC tumors were colored according to their ccRCC Score into intermediate risk 
(yellow; ccRCC Score < 0.449) or high risk (red; ccRCC Score > 0.449) categories. Metastatic patients had 
stage IV tumors and non-metastatic patients had stage II tumors. GL = Germline. R = primary tumor region, 
M = metastatic region, VT = venous thrombus. Clones without gene expression data described by original 
publication were left out. 
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Subsequently, the phylogenetic trees were recolored according to the ccRCC Score to 
illustrate changes of the ccRCC Score along tumor evolution (Figure 59). 
Figure 59 – Intratumor heterogeneity of ccRCC Scores 
The phylogenetic trees that describe the tumor evolution of each patient were recolored according to their 
ccRCC Scores. Metastatic patients had stage IV tumors and non-metastatic patients had stage II tumors. 
GL = Germline. R = primary tumor region, M = metastatic region, VT = venous thrombus. Subclones without 
gene expression data described by original publication were left out. 
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This analysis revealed a vast intratumor heterogeneity of the ccRCC scores. As expected, the 
non-metastatic patients showed lower maximal subclonal ccRCC scores (RMH008 = -0.43, 
RK26 = -0.26) accompanied by a lower range of differences in scores between the subclones 
(RMH008 = 0.43, RK26 = 0.92) (Table 8). Metastatic patients had higher maximum ccRCC 
scores (up to 3.64 in patient EV002) as well as larger differences between the subclonal 
ccRCC scores (up to 2.38 in EV001 and 2.12 in EV005). This means that the predicted 5-year 
survival rate varies substantially when comparing the subclonal regions of a single tumor. For 
example, if only region R4a of the patient EV001 would have been sampled for gene 
expression analysis, a 5-year survival probability of 82.3 % would have been estimated by 
calculating the ccRCC score. However, the phylogenetic more distant subclone R3 has a 
predicted 5-year survival probability of only 12.2 %. 
Table 8 – Overview of the multiregion analysis of ten ccRCC patients 
Patient ccRCC Score range Max. ccRCC Score 
difference 
Predicted 5-year survival 
(min > max ccRCC score 
in percent) 
EV001 0.01  2.389 2.379 82.3  12.2 
EV002 2.012  3.642 1.630 23.6  0.1 
EV003 1.763  3.441 1.678 32.4  0.2 
EV005 0.943  3.061 2.118 60.9  1.6 
EV006 0.066  1.368 1.302 81.4  46.9 
EV007 1.288  2.919 1.631 49.6  2.8 
RK26 -1.184  -0.264 0.920 94.3  86.2 
RMH002 1.299  2.146 0.847 49.3  19.2 
RMH004 1.204  3.135 1.931 52.5  1.2 
RMH008 -0.856  -0.426 0.430 92.1  88.1 
 
We wondered whether the ccRCC Score showed a linear relationship to the number of non-
synonymous mutations. Therefore, the two parameters were plotted against each other and the 
corresponding linear models were calculated (Figure 60). We found that for six patients an 
increasing mutation number corresponded to an increasing ccRCC score. One patient 
(EV002) showed no such correlation and three patients had a negative correlation (RMH002, 
EV006 & RK26). 
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Figure 60 – Relationship between the number of non-synonymous mutations (evolutionary 
distance) originating from the germline and the ccRCC Score 
For 5 patients, a positive linear relationship between the number of non-synonymous mutations and the 
ccRCC Score was identified, whereas for 2 patients the relationship was negative. 
To identify a possible correlation between ccRCC Score and mutational load, we plotted the 
number of non-synonymous mutations of the bulk tumors of patients of the TCGA dataset 
against their ccRCC Score (Figure 61). We could not identify a significant correlation 
between the number of mutations and the ccRCC Score. 
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Figure 61 – Dotplot of non-synonymous mutations of the TCGA patient cohort and their 
corresponding ccRCC Score, subsetted according to patient stage 
The number of non-synonymous mutations does not correlate with the ccRCC Score. The number of non-
synonymous mutations was assessed by summing up all annotated mutations of cBioportal for each patient. 
3.12 The ccRCC-Score gives added value above the classical TNM-
stage classification 
To estimate the value the ccRCC-Score adds to patients’ risk stratification over stage 
classification, we tested whether patients within a specific stage classification could be 
identified. For this purpose, we applied an individual risk stratification cutpoint for patients 
within a tumor stage according to maximally selected rank statistics
286
 and draw Kaplan-
Meier estimators (Figure 62). Hereby, we could define patients with very good prognosis, 
especially for those of stage I to stage III. 10-year survival probability of the low risk group 
was between 94.8 % (stage III) and 100 % (Stage II). This shows the benefits of ccRCC Score 
risk stratifications within a stage group over the classical clinical stage classification. 
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a Stage I b Stage II 
  
c Stage III d Stage IV 
  
Figure 62 – Risk Stratification by the ccRCC Score gives added value to the stage 
classification of patients by identifying patients with good prognosis within a stage group 
Overlay of survival curves estimating survival for patients either according to the stage alone (grey) and for 
patients within a stage group stratified by the ccRCC Score (High risk: Red curve; Low Risk: Dark green 
curve). Patients were stratified using following ccRCC scores calculated by maximally selected rank statistics. 
Stage I: -1.376, Stage II: -0.237, Stage III: 0.104, Stage IV: 1.367 
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3.13 Identification of potential drug targets for stage I patients 
We were interested in identifying potential drug targets by making use of the ccRCC Score 
derived risk stratification within the group of stage I patients (Figure 62a). Therefore, we 
analyzed RNASeq gene expression data of high risk and low risk patients and calculated 
differentially expressed genes between the groups (Figure 63). We identified 547 genes that 
were at least two-fold upregulated and had an adjusted P value below 0.05. 
 
Figure 63 – Volcano plot of 
differentially expressed genes 
between high risk and low risk 
stage I patients 
All genes that are at least 8-fold 
differentially expressed are labeled 
and highlighted in red.  
We made use of the DGIdb drug interaction database to identify druggable targets in the high 
risk stage I patient cohort
287
. We entered all genes that were at least two-fold differentially 
expressed and made use of the following preset filters: “FDA approved”, “antineoplastic” and 
“immunotherapies”. Additionally we searched only for the following interaction types 
“inhibitor”, “antagonist”, “antibody”, “blocker”, “channel blocker”, “cleavage”, “desensitize 
the target”, “gating inhibitor”, “incorporation into and destabilization”, “inhibitor, 
competitive”, “inhibitory allosteric modulator”, “inhibitory immune response”, “inverse 
agonist”, “negative modulator”, “neutralizer”, “partial antagonist”, “reducer”, “suppressor” 
and “vaccine”. 
The drug interaction database recognized 546 of the 547 genes and identified nine potential 
drugs for six potential druggable targets, which could be tested in high risk stage I patients 
(Table 9). 
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Table 9 – DGIdb Drug Interaction Database results for high risk stage I patients sorted by 
differentially expression 
Gene Drug Interaction types log FC adj.P.Val 
GPR87 CYCLOPHOSPHAMIDE antagonist 1.9119 6.6E-10 
ERBB4 IBRUTINIB inhibitor 1.4718 1.6E-04 
B4GALNT1 DINUTUXIMAB antibody 1.3220 7.7E-05 
IL6 SILTUXIMAB antagonist|antibody|inhibitor 1.2444 2.6E-04 
TUBB3 TRASTUZUMAB 
EMTANSINE 
inhibitor 
1.2209 1.6E-10 
TUBB3 PACLITAXEL inhibitor 1.2209 1.6E-10 
TUBB3 CABAZITAXEL inhibitor 1.2209 1.6E-10 
TUBB3 BRENTUXIMAB 
VEDOTIN 
inhibitor 
1.2209 1.6E-10 
KCNH2 AMSACRINE inhibitor 1.1036 2.9E-05 
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3.14 TSPAN8 expression increases throughout the in vivo 
selection 
Among the ccRCC signature genes, Tetraspanin-8 (TSPAN8) was one of the most 
differentially expressed genes of the in vivo selection (18.37-fold, adj. P Value < 0.001). We 
validated these results using Taqman qRT-PCR (Figure 64) and observed a strong induction 
of this gene along the passages (67.83 ± 7.062-fold). 
 
Figure 64 – Relative mRNA expression of TSPAN8 in different passages of the in vivo 
selection 
Expression of TSPAN8 RNA levels in the primary tumors of the different passages was assessed by 
Taqman-PCR and normalized to TSPAN8 expression of the basal KIKA75 cell line. Normal kidney expression 
of TSPAN8 was included for comparison. TSPAN8 is significantly and increasingly upregulated along the 
passages of the in vivo selection. 2-4 biological replicates in 3 technical replicates were analyzed for each 
passage and replicate. P value was calculated using a two-sided Student’s t-test. Error bars depict 
mean ± s.e.m. 
In addition to transcriptional levels, TSPAN8 protein levels were validated 
immunohistochemically using an antibody generated by Ailane et al.
288
. In passage 0, only 
few cell clusters positive for TSPAN8 staining were detected (Figure 65). The normal 
proximal tubule cells of the kidney showed weak TSPAN8 expression at their luminal 
boarder. 
In most tumor regions of the last in vivo passage, the cellular membrane of tumor and 
metastases cells were strongly enriched for TSPAN8. Other tumor regions showed less 
TSPAN8 enrichment. Still we could not identify any specific co-localization of TSPAN8 
expressing cells with vessels, extracellular matrix, tumor boarder or necrotic tumor regions. 
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Figure 65 – Immunohistochemistry of TSPAN8 of primary tumor and corresponding 
metastases of the first and the last passage of the in vivo selection 
Paraffin embedded tumor material was stained for TSPAN8 (TS29.2). In the primary tumor and the lung 
metastases of the first passage only little and dispersed staining for TSPAN8 is detectable. The apical 
boarder of the proximal kidney epithelium stained weakly positive for TSPAN8. 
The cell membrane of passage 4 tumor and metastases cells show high TSPAN8 expression in most regions, 
whereas in other regions no or only little TSPAN8 staining is detected. Staining of TSPAN8 did not co-locate 
with tumor boarder, vessels, extracellular matrix or necrotic tumor regions. 
Enlarged are regions with heterogeneous TSPAN8 expression. Staining was performed by Ornella Kossi. 
The established cell lines from the lung metastases of the last passage (see section 3.4.1) 
continued to express TSPAN8 in their first passages, whereas higher passaged cells showed 
declining expression of TSPAN8 (Figure 66). This indicates that the expression of TSPAN8 
was either induced by the tumor microenvironment or repressed caused by unknown cell 
culture conditions. 
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Figure 66 – TSPAN8 expression in passage 
4 lung metastases derived cell lines in 
comparison to the basal cell line 
The expression of TSPAN8 in comparison to the 
basal cell line KIKA75 is high in the first passages 
after generating the cell lines from passage 4 lung 
metastases. However, the higher the passages of 
the cell lines, the lower the expression of TSPAN8, 
eventually returning to the basal cell level after 
seven in vitro passages. 
Three cell lines per in vivo selection replicate were 
generated and three replicates each for each in 
vitro passage were analyzed. P value was 
calculated using a two-sided Student’s t-test. Error 
bars depict mean ± s.e.m. 
3.15 TSPAN8 is heterogeneously expressed between ccRCC 
patients 
We tested TSPAN8 expression in our primary patient derived ccRCC cell lines and compared 
it to the expression of TSPAN8 in normal kidney tissue (Figure 67a). The cell lines KIKA12, 
KIKA27 and KIKA75 had only little TSPAN8 mRNA expression (0.012, 0.013 and 0.089-
fold respectively), whereas the cell lines KIKA24 and KIKA38 had levels close to the normal 
kidney control (0.721 and 0.479-fold). We tested the expression of TSPAN8 by flow 
cytometry and found similar results on protein level (Figure 67b). To test whether this inter 
patient heterogeneity was observable in a larger patient set, we analyzed TSPAN8 expression 
level of the TCGA KIRC dataset and compared it to annotated normal kidney samples 
(Figure 67c). Interestingly, TSPAN8 mRNA expression in the tumor material was 
significantly lower compared to normal kidney tissue (log2 normalized RSEM counts: 
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Tumor = 3.48 ± 2.91; Normal = 9.84 ± 1.29). Additionally, the intertumor heterogeneity of 
TSPAN8 expression was much higher in tumor than normal tissue. 
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Figure 67 – Relative Expression of TSPAN8 in the different primary patient derived cell lines 
in comparison to normal kidney expression 
(a) The cell lines KIKA12, KIKA27 and KIKA75 express TSPAN8 mRNA only slightly in comparison to normal 
kidney, whereas KIKA24 and KIKA38 express levels of TSPAN8 comparable to normal kidney tissue 
(qRT-PCR). Error bars depict mean ± 95 %-CI. 
(b) Protein levels of TSPAN8 correspond to the mRNA level results. In KIKA12, KIKA27 and KIKA75, only a 
subset of cells stained positive for TSPAN8. The line indicates the isotype control. Error bars depict 
mean ± 1.5*IQR. 
(c) RNASeq expression of TSPAN8 in the TCGA KIRC patient dataset. TSPAN8 is significantly lower 
expressed in bulk tumor tissue in comparison to normal kidney tissue. Nevertheless, a vast intertumor 
heterogeneity in the expression of TSPAN8 is discernible. P value was calculated using a two-sided Student’s 
t-test.  
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3.16 Expression levels of TSPAN8 predict patient survival of late 
ccRCC tumor stages 
We were wondering whether the different expression levels of TSPAN8 also have an influence 
on patients’ cancer specific survival probability. Therefore, we stratified patients according to 
maximally selected rank statistics
286
 into TSPAN8 high and low expressing tumors and 
calculated their survival probabilities (Figure 68).  
Although showing a trend, TSPAN8 could not significantly separate patients’ cancer specific 
survival in the TCGA-KIRC dataset, according to the classical levels of significance. 
However, in the Sato et al. validation cohort, TSPAN8 expression profiles significantly 
separated patients’ overall survival. 
a
 
b
 
Figure 68 – Kaplan Meier estimators of patients’ survival, stratified by the expression of 
TSPAN8  
While stratification of TSPAN8 expression profiles of the tumors does not separate patient survival 
probabilities in the (a) TCGA-KIRC dataset, survival of the (b) Sato et al. cohort could be significantly 
separated (log rank test). 
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Hence, we were asking whether TSPAN8 only influences the survival probability of patients 
at a specific tumor stage. To answer this question, patients were additionally stratified 
according to tumor stage (Figure 69). Patients were grouped into either stage I & II or stage 
III & IV patients, as the Sato et al. dataset consists only of 13 stage III and 12 stage IV 
patients (see Supplemental Figure 7). 
Patients of the early stages I and II showed no difference in survival in both datasets. 
However, TCGA-KIRC dataset of 206 patients of advanced stage III and IV showed 
significantly different survival probabilities. The cancer specific survival of patients harboring 
TSPAN8 low expressing tumors was enhanced. In the Sato et al. stage III & IV dataset, 
including only 25 patients, survival of patients was not significantly different according to the 
classic significance level (p = 0.073), although the same trend as for the TCGA-KIRC dataset 
was discernable. 
 TCGA-KIRC  Sato et al. 
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Figure 69 – Survival stratified according to TSPAN8 expression and tumor stage 
Patients of both the TCGA KIRC and Sato et al. datasets were stratified according to TSPAN8 expression 
and tumor stage. Patients of stage I and II, and patients of stage III and IV were combined, respectively. The 
TCGA-KIRC dataset patients of Stage III/IV show significantly different survival probabilities when stratified 
for TSPAN8 expression profiles, revealing enhanced survival in TSPAN8 low patients. For patients of the 
Sato et al. cohort, survival probabilities are not significantly different, yet the same trend for enhanced overall 
survival of patients with TSPAN8 low expressing tumors can be seen. 
For each group, the optimal TSPAN8 expression cutoff to divide patients was calculated separately by 
maximally selected rank statistics with a minimal proportion of 20 % per group. P values calculated by log 
rank test. 
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This difference in survival probabilities according to TSPAN8 expression motivated us to 
check for the distribution of TSPAN8 expression according to tumor stage (Figure 70). 
However, no correlation of TSPAN8 expression and tumor stage was found. 
 
Figure 70 – Violin plots of 
TSPAN8 expression and ccRCC 
tumor stages 
Standardized TSPAN8 expression 
levels of TCGA-KIRC patients were 
plotted against their respective tumor 
stage. There is no discernible 
difference between TSPAN8 and 
tumor stage. P value was calculated 
using a two-sided Student’s t-test. 
3.17 Generation of TSPAN8 knockdown and overexpression KIKA 
models 
The tetraspanin transmembrane protein family is known to alter cellular signaling 
properties
289,290
. Therefore, we hypothesized that TSPAN8 contributes to tumor growth, 
metastasis and thus to the malignancy of this disease, which had been previously shown in 
other cancer entities
291,292
. 
As depicted earlier (Figure 67b), two of our KIKA cell line models show high TSPAN8 
expression levels (KIKA24 and KIKA38), whereas in the KIKA27 and KIKA75 cell lines, 
only a minority of the cells express TSPAN8. We transduced the cell lines to stably express a 
luciferase transgene (Renilla-luciferin 2-monooxygenase), which allowed us to monitor their 
growth in vivo after xenotransplantation. 
Cell lines were transduced with lentiviral vectors expressing inducible short hairpin RNAs 
(shRNAs) to silence TSPAN8 expression via RNA interference (RNAi)
293
. We aimed for a 
transduction efficiency of approximately 30 % to ensure a single vector integration per cell. 
Subsequently, transduced cells were selected with puromycin, as the cells proved to be highly 
susceptible for cell sorting. Thereby, three different cell lines were established for each KIKA 
model: Two different shRNAs (shTSPAN8(1) and shTSPAN8(2)) and, as a control, a non-
silencing shRNA was used that shows minimal homology to the human genome. Efficiency of 
the knockdown was evaluated by qRT-PCR (Figure 71a) and FACS (Figure 72).  
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We saw a significant knockdown of TSPAN8 on mRNA levels in all generated cell lines. The 
knockdown efficiency varied between the cell lines and shRNAs. The first shRNA led to a 
decreased TSPAN8 mRNA levels of 50, 13, 21 and 35 percent in KIKA24, KIKA27, KIKA38 
and KIKA75, respectively in comparison to the not induced cell lines. The second shRNA 
was slightly more efficient and led to decreased mRNA levels of 17, 13, 10 and 35 percent. 
To validate the knockdown on protein level, the generated cell lines were stained with a 
TSPAN8 specific antibody
288
 and analyzed on a flow cytometer (Figure 72 & Supplemental 
Figure 13). Thereby, we could show that the levels of TSPAN8 were also reduced on protein 
level. Nevertheless, the cell lines expressing high basal TSPAN8 levels showed a reduction in 
TSPAN8 staining intensity, yet still detectable above isotype staining. Interestingly, the 
knockdown of TSPAN8 with the first shRNA in the KIKA24 cell line lead only to an mRNA 
reduction of 50 %, but showed a strong reduction on protein level. 
Next, we established inducible TSPAN8 overexpressing cell lines. Especially the cell lines 
with low basal TSPAN8 expression showed a strong leakiness of the vector on mRNA level 
(Figure 71b), which could not be seen on protein levels (Figure 72). After induction with 
doxycycline, TSPAN8 showed a strong induction on both mRNA and protein levels in all used 
cell lines. 
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Figure 71 – qRT-PCR of TSPAN8 knockdown and overexpression in different KIKA models 
(a) TSPAN8 mRNA levels are significantly reduced after doxycycline induction in both tested shRNA vectors 
in all tested KIKA models. (b) Overexpression of TSPAN8 shows leakiness in the cell lines with low TSPAN8 
levels. The levels of TSPAN8 are significantly enriched after inducing the overexpression with doxycycline. 
P value was calculated using a two-sided Student’s t-test. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not 
significant, ox = overexpression. Error bars depict mean ± s.e.m. 
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Figure 72 – Protein levels of TSPAN8 in TSPAN8 knockdown and overexpressing KIKA 
models measured by flow cytometry 
Overexpression of TSPAN8 is highly efficient in both of the TSPAN8 low expressing cell lines and is 
discernible in the KIKA24 cell line. TSPAN8 knockdown shows a strong reduction of TSPAN8 in KIKA24, 
KIKA38 and KIKA75. ox = overexpression 
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3.18 The knockdown of TSPAN8 delays tumor growth 
We pretreated NSG mice with doxycycline for seven days, orthotopically injected the 
generated TSPAN8 knockdown KIKA cell lines and finally measured tumor growth over time 
as shown in Figure 73. 
 
 
Figure 73 – Schema of in vivo TSPAN8 knockdown experiments 
Mice of the knockdown group were pretreated with doxycycline for 7 days before orthotopic injection of 
doxycycline pretreated KIKA cells carrying a luciferase transgene and either a shRNA targeting TSPAN8 or a 
non-targeting scramble shRNA. Tumor growth was monitored with IVIS 200 imager system at least once a 
week. 
In all tested models, doxycycline alone had no significant effect on tumor growth  
(Figure 74a, Figure 75a, Figure 76a, Figure 77a). The effect of TSPAN8 knockdown varied 
between the tumor models and the used shRNAs. In the KIKA24 model, the shTSPAN8(1) 
showed only a 50 % reduction of TSPAN8 on mRNA level but was highly efficient in the 
reduction of TSPAN8 on protein level (Figure 71a, Figure 72). The induction of this shRNA 
in the in vivo tumor growth experiment showed a significant reduction of tumor growth 
(Figure 74b). shTSPAN8(2) showed no effect on tumor growth (Figure 74c). 
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Figure 74 – Orthotopic tumor growth of KIKA24 in dependence of TSPAN8 
(a) Doxycycline treatment has no effect on tumor growth. (b) Knockdown of TSPAN8 with shTSPAN8(1) 
significantly affects tumor growth (c) Induction of shTSPAN8(2) has no effect on tumor growth. 
Tumor signal was normalized to day 0 and followed up for 49 days. P value was calculated for the last three 
time points using a two-sided Student’s t-test. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not significant. 
Error bars depict mean ± s.e.m. 
KIKA27 is the cell line with the lowest basal TSPAN8 levels in our study (Figure 67a,b). 
Knockdown of TSPAN8 in this line reduced the mRNA levels even further. As protein levels 
in vitro were already low, knockdown efficiency on protein level could not be determined. 
Strikingly, in vivo, knockdown of TSPAN8 with both shRNAs had a strong effect on tumor 
growth as it stopped tumor growth in shTSPAN8(1) cell line derived tumors (Figure 75b) and 
delayed tumor growth substantially in shTSPAN8(2) tumors (Figure 75c). 
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Figure 75 – Orthotopic tumor growth of KIKA27 in dependence of TSPAN8 
(a) Doxycycline treatment has no effect on tumor growth. (b,c) Knockdown of TSPAN8 with both shRNAs 
affects tumor growth significantly. 
Tumor signal was normalized to day 0 and followed for 94 days. P value was calculated for the last three 
time points using a two-sided Student’s t-test. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not significant. 
Error bars depict mean ± s.e.m. 
KIKA38 show high basal TSPAN8 levels (Figure 67a,b) and knockdown was highly efficient 
on mRNA levels (TSPAN8 levels of 21 % and 10 %, Figure 71a). Nevertheless, with reduced 
TSPAN8 protein levels, the majority of cells still stained positively for TSPAN8 (Figure 72). 
The reduction of TSPAN8 levels in the KIKA38 derived tumors by doxycycline induction in 
vivo had no significant influence on tumor growth (Figure 76b,c). 
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Figure 76 – Orthotopic tumor growth of KIKA38 in dependence of TSPAN8 
(a) Doxycycline treatment has no effect on tumor growth. (b,c) Knockdown of TSPAN8 with both shRNAs 
has no effect on tumor growth. 
Tumor signal was normalized to day 0 and followed for 63 days. P value was calculated for the last three 
time points using a two-sided Student’s t-test. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not significant. 
Error bars depict mean ± s.e.m. 
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The KIKA75 line contains of cells with heterogeneous TSPAN8 expression. Whereas the 
majority of cells show no TSPAN8 signal, 5-30 % of the cells have varying levels of TSPAN8 
(Figure 67b, Figure 72). Knockdown of TSPAN8 on mRNA levels to 35 % of the normal 
level led to a reduction on protein level, yet incomplete (Figure 71a, Figure 72). The 
knockdown delayed cell line derived tumor growth with both shRNAs (Figure 77b,c). 
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Figure 77 – Orthotopic tumor growth of KIKA75 in dependence of TSPAN8 
(a) Doxycycline treatment has no effect on tumor growth. (b) Knockdown of TSPAN8 with shTSPAN8(1) 
significantly delays tumor growth. (c) Induction of shTSPAN8(2) has a strong effect on tumor growth. 
Tumor signal was normalized to day 0 and followed for 35 days. P value was calculated for the last three 
time points using a two-sided Student’s t-test. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not significant. 
Error bars depict mean ± s.e.m. 
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3.19 Overexpression of TSPAN8 has no effect on tumor growth 
We wondered whether high levels of TSPAN8 alone are sufficient enough to promote tumor 
growth. Therefore, we tested in vivo tumor formation of the KIKA models with low TSPAN8 
levels with an inducible TSPAN8 overexpression vector and the TSPAN8 high KIKA38 
model in comparison. 
Overexpression of TSPAN8 had no significant effect on tumor growth in KIKA27 and 
KIKA38 derived tumors and surprisingly reduced tumor growth of KIKA75 derived tumors 
(Figure 78). Thus, the in vivo TSPAN8 overexpression did not show the opposite effect of the 
TSPAN8 knockdown models. 
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Figure 78 – Orthotopic tumor growth of KIKA models with TSPAN8 overexpression 
(a,b) TSPAN8 overexpression shows no significant effect on tumor growth in KIKA27 and KIKA38 derived 
tumors. (c) The overexpression of TSPAN8 in KIKA75 derived tumors slows down tumor growth significantly 
at day 33. P value was calculated for the last three time points using a two-sided Student’s t-test. * p < 0.05, 
** p < 0.01, *** p < 0.001, ns = not significant, ox = overexpression. Error bars depict mean ± s.e.m. 
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3.20 Knockdown of TSPAN8 stops tumor growth on already 
established tumors 
As shown earlier, knockdown of TSPAN8 in TSPAN8 low tumor models inhibited tumor 
formation (see Figure 75 and Figure 77). Next, we wondered whether knockdown of 
TSPAN8 may also have an effect on already established tumors (Figure 79). For this purpose, 
we let KIKA27 derived tumors grow for 56 days, randomized the mice according to tumor 
size and induced the TSPAN8 knockdown in one of the groups (Figure 80). 
 
Figure 79 – Schema of in vivo TSPAN8 knockdown on established tumors 
NSG mice were orthotopically injected with KIKA cells carrying a luciferase transgene and one of two 
different shRNA targeting TSPAN8. Tumor growth was monitored with IVIS 200 imager system at least once 
a week. After 56 or 90 days, mice were randomized into two groups of similar tumor size. We subsequently 
induced the knockdown in one of the groups by giving doxycycline containing drinking water until the end of 
the experiment and measured tumor growth over time.  
Both shTSPAN8 KIKA27 derived tumors showed normal tumor development after orthotopic 
cell injection. A strong decrease in tumor signal right after injection was observed, which 
recovered over time and reached approximate starting values after 56 days of tumor growth 
(Figure 80a+c). When TSPAN8 knockdown was induced in one of the randomized groups, 
tumor growth was halted (Figure 80b) or delayed (Figure 80d), whereas the non-induced 
group showed exponential tumor growth. This result indicates that TSPAN8 plays a general 
role in tumor growth of our ccRCC models. 
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Figure 80 – Knockdown of TSPAN8 delays tumor growth of established KIKA27 tumors 
After 56 days of tumor growth, we randomized mice of either shTSPAN8(1) or shTSPAN8(2) into two groups 
of equal tumor size (a,c). One of each groups was given doxycycline containing drinking water and tumor 
growth was followed over time. Tumors with the TSPAN8 knockdown (b) halt in growth or (d) show delayed 
growth. 
* p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. Error bars depict mean ± s.e.m. 
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3.21 TSPAN8 overexpression has no influence on gene expression 
in vitro 
We wondered whether TSPAN8 plays a potential role in tumor progression. Therefore, we 
tested if differential expression of TSPAN8 in the KIKA cell lines had an influence on cellular 
expression profiles in vitro. 
For this purpose, RNA of overexpressed TSPAN8 in the KIKA27 and KIKA75 cell lines that 
have low basal TSPAN8 expression levels were analyzed by comparative gene expression 
profiling. The microarray analysis shows increased TSPAN8 signal intensity (Figure 81a,b), 
which has already been validated by qRT-PCR and FACS (see section 3.17). 
From this gene expression profiling data we performed differential expression analysis by 
treatment-contrast parametrization (Figure 81c,d). Only a few genes were differentially 
expressed, among them TSPAN8. In the KIKA27 cell line, the differential expression 
significance level of TSPAN8 did not reach an adjusted P value below 0.05 (adj. P 
value = 0.0578), possibly due to only two analyzed samples per group. This indicates that 
overexpression of TSPAN8 does not greatly change cellular gene expression patterns. Among 
the upregulated genes in the KIKA27 cell line was IL13RA2, one gene of the ccRCC 
signature. 
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Figure 81 – Overexpression of TSPAN8 has only a minor impact on gene expression 
Microarray analysis shows that in both, (a) KIKA27 and (b) KIKA75 cell lines, mean TSPAN8 signal intensity 
is raised above background when the TSPAN8 overexpression cell lines are induced with doxycycline 
(compare section 3.17). Dotted line indicates background signal intensity. Error bars depict mean ± 1.5*IQR. 
Volcano Plot of differentially expressed genes of the TSPAN8 overexpressing cell lines (c) KIKA27 or 
(d) KIKA75. Genes with an adj. P value > 0.1 and logFC > 1.5 are annotated. Dotted line indicates an 
adjusted P value = 0.1 
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3.22 TSPAN8 knockdown has no influence on gene expression in 
vitro 
Gene expression profiling was performed from RNA of KIKA38 TSPAN8 knockdown cells, 
which showed high endogenous TSPAN8 expression. As already validated by qRT-PCR and 
FACS analysis (see section 3.17), TSPAN8 signal intensity was also reduced also in the 
microarray analysis (Figure 82a). 
We performed differential expression analysis of the paired samples (Figure 82b). Only a few 
genes were significantly differentially regulated, among them TSPAN8 (logFC = -2.90).  
a 
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Figure 82 – Knockdown of TSPAN8 in the KIKA38 cell line has a minor impact on gene 
expression 
(a) In both TSPAN8 knockdown cell lines, mean TSPAN8 signal intensity of the microarrays is reduced after 
doxycycline induction (compare section 3.17). Dotted line indicates background signal intensity. 
(b) Volcano Plot of differentially expressed genes of the KIKA38 TSPAN8 knockdown cell line. Labeled are 
genes with a logFC > 1.5 and an adj. P value > 0.05. Dotted line indicates an adjusted P value = 0.05, genes 
with a smaller P value are colored according to their significance level. Error bars depict mean ± 1.5*IQR. 
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3.23 Changes in TSPAN8 level have no influence on growth rates 
in vitro 
We wondered whether the inhibition of tumor growth after TSPAN8 knockdown was a cell 
intrinsic effect. Therefore, cell growth of KIKA27 and KIKA75 cell lines was analyzed, 
which showed strongest tumor growth inhibition in vitro. After pretreating the cells with 
doxycycline for three days, cell growth was followed for 12 days without replacing the media 
and analyzed by CellTiter Blue consumption as a measurement for cell viability. Growth 
curves were fitted by logistic regression and mean growth rates were estimated for TSPAN8 
knockdown as well as TSPAN8 overexpression cell lines. 
The results indicate that there is no significant difference in cellular growth rates between the 
induced knockdown of TSPAN8 in both KIKA27 (Figure 83a) and KIKA75 cell lines 
(Figure 83b). Similarly, overexpression of TSPAN8 had no significant effect on cell growth. 
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Figure 83 – Growth rates of KIKA27 cell lines estimated by logistic regression 
shTSPAN8 cell lines were seeded in four ((a) KIKA27) or three ((b) KIKA75) and TSPAN8 overexpression 
cell lines in two biological replicates. For each replicate, 500 cells per time point were seeded in three 
technical replicates and cell growth was assessed by CellTiter Blue consumption as a measurement for cell 
viability. The growth rate was estimated by logistic regression of the growth curves. No significant difference 
in growth rates between the different experimental conditions was observed. P value was calculated using a 
two-sided Student’s t-test. Error bars depict mean ± 1.5*IQR. 
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3.24 TSPAN8 expression is not dependent on TP53  
Agaësse et al. demonstrated that p53 regulates the expression of TSPAN8 to prevent tumor 
invasiveness in melanoma
294
. To test this hypothesis in renal cancer, we analyzed TSPAN8 
expression according to the mutational status of p53 (Figure 84a). Of the 532 patients of the 
TCGA KIRC cohort, eight patients had a truncating p53 mutation (1.5 %) and seven patients a 
p53 missense mutation (1.3 %). We could not observe a significant correlation of mutational 
status of TP53 and TSPAN8 expression levels. Additionally, TSPAN8 mRNA levels in the 
TCGA-KIRC patient cohort did not correlate with either TP53 mRNA (Figure 84b) or 
protein expression levels (Figure 84c). 
a 
 
b 
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Figure 84 – p53 mutation or expression status does not correlate with TSPAN8 gene or 
protein expression 
(a) Mutational status of p53 in patients of the TCGA-KIRC cohort was plotted against standardized TSPAN8 
expression levels. P value was calculated using a two-sided Student’s t-test. 
(b) Scatter plot of standardized TP53 mRNA expression levels with standardized TSPAN8 expression levels. 
No correlation is observable. 
(c) Scatter plot of z-scored TP53 protein expression levels with standardized TSPAN8 expression levels. No 
correlation is observable. 
The linear model, R-squared values and F-statistics were calculated using the stats R-package. 
  
Results  125 
 
3.25 FOXA2 target genes are enriched in the in vivo selection 
It has been shown that FOXA2 drives tumor progression in ovarian and uterine 
carcinomas
295,296
 and that high FOXA2 expression in ccRCC has dismal patient outcomes
297
. 
We found an enrichment for FOXA2 (also called HNF3B) target genes in the list of 
differentially regulated genes of the in vivo selection, indicating that increased aggressiveness 
of the selected tumors might be regulated by FOXA2 (Figure 85). 
a
 
b
 
Figure 85 – Gene Set Enrichment Analysis of FOXA2 target genes 
(a) Enrichment for genes containing the FOXA2 consensus sequence in their promotor 
(b) Enrichment for genes harboring the transcription factor binding site around 4kb of their transcription start 
sites (v7.4 TRANSFAC). 
3.26 Knockdown of FOXA2 delays tumor growth by regulating 
TSPAN8 expression 
FOXA2 was, relatively to normal kidney, highly upregulated in the KIKA models as shown in 
Figure 86a. Moreover, FOXA2 expression was found to be expressed in the TCGA-KIRC 
patient cohort (Figure 86b). However, no difference in FOXA2 expression between tumor 
and normal tissue is discernible. Nevertheless, stage I patients have significantly lower 
FOXA2 expression levels, than late stage patients. This is also reflected in the cancer specific 
survival probabilities showing that patients with low FOXA2 expression levels have 
significantly better survival probabilities than patients with high FOXA2 levels (Figure 86c). 
 
NES = 1.4215 
p.adj = 0.0171 
NES = 1.3928 
p.adj = 0.0634 
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Figure 86 – FOXA2 is highly expressed in KIKA cell lines and aggressive ccRCCs 
(a) FOXA2 expression levels of KIKA models were determined by qRT-PCR and normalized to normal 
kidney. Error bars depict mean ± 95 %-CI. 
(b) RNASeq log2 RSEM expression values of FOXA2 in the TCGA KIRC patient dataset over the stages. 
FOXA2 expression shows no difference between bulk tumor tissue and normal kidney tissue, but FOXA2 is 
significantly higher expressed between stage I and the other stages. P value was calculated using a 
two-sided Student’s t-test. Error bars depict mean ± 1.5*IQR. 
(c) Kaplan Meier estimators of patients’ survival, stratified by the expression of FOXA2. Stratification of 
patients according to FOXA2 expression levels separates patient survival probabilities significantly (log rank 
test). 
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We established FOXA2 knockdown in the KIKA27 cell line by transducing two shRNAs 
simultaneously. Thereby, we achieved a knockdown efficiency of 77 % (Figure 86a). In a 
next step, a FOXA2 overexpressing cell line was generated. Even though FOXA2 has 
relatively high basal expression levels, the vector showed strong leakiness (Figure 87b). By 
inducing the vector, we observed a relatively to the not induced cell line 105-fold 
overexpression of FOXA2. However, the cells started to detach from the surface and became 
apoptotic (data not shown). Surprisingly, TSPAN8 expression was dependent on FOXA2 
expression: Knockdown of FOXA2 led to a reduction of TSPAN8 levels (60.3 %) and 
overexpression to an increase of TSPAN8 levels (6.6-fold). The increased basal levels of 
FOXA2 due to leakiness of the vector had no influence on TSPAN8 levels. 
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Figure 87 – Expression levels of FOXA2 in the KIKA27 cell line correlate with TSPAN8 
expression levels 
(a) Knockdown with a combination of two shRNAs and (b) overexpression efficiency of FOXA2 was estimated 
by qRT-PCR. Expression levels of TSPAN8 significantly change upon FOXA2 (c) knockdown and (d) 
overexpression. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. Error bars depict mean ± 95 %-CI 
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The question arose whether FOXA2 regulates the expression of TSPAN8 directly. We 
analyzed the chromosomal region of TSPAN8 and corresponding Chip-Seq data, which the 
ENCODE project has collected for the HepG2 cell line and liver tissue (Figure 88a). Indeed, 
FOXA2 binds the transcription start site of TSPAN8 in these tissues. With the help of the 
Methylation Plotter
298
, the beta values of the CpGs covered by the Epic methylation array 
were plotted for the genomic TSPAN8 region
299,300
. Interestingly, these FOXA2 binding sites 
were also differentially methylated between the first and the last passage of the in vivo 
selection (Figure 88b).  
a 
 
b 
Figure 88 – The genomic Region of TSPAN8 is differentially methylated 
(a) FOXA2 Chip-Seq binding sites in HepG2 and liver for the chromosomal region of TSPAN8 
(Chr12:71498410-71610830). We accessed the Encode Chip-Seq datasets (ENCFF379JAQ, 
ENCFF857BOL, ENCFF965MSA, ENCFF294WXK) via the UCSC Genome Browser 
(https://www.encodeproject.org/) 
(b) The β-Values of the CpGs for the chromosomal region of TSPAN8 covered by the epic methylation array 
were plotted by the Methylation Plotter. Methylation means for each group and for each CpGs of the genomic 
TSPAN8 region (Chromosome 12q21.1) are shown in a methylation profile plot. Significant differentially 
methylated positions (calculated with the Kruskal-Wallis test) are indicated by asterisks. 
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To investigate the effect of FOXA2 knockdown in vivo, we xenotransplanted the FOXA2 
knockdown KIKA27 cell line and followed tumor growth. Doxycycline induced FOXA2 
knockdown in KIKA27 derived tumors delayed tumor growth significantly in comparison to 
normal FOXA2 levels (Figure 89). 
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Figure 89 – In vivo KIKA27 derived tumor growth 
with FOXA2 knockdown 
Knockdown of FOXA2 significantly delays tumor growth. * 
p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. 
Error bars depict mean ± s.e.m. 
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4 Discussion 
4.1 The ccRCC Score signature 
We developed a LASSO regression based ccRCC signature that surpasses the survival 
predictions of all other published gene expression based signatures for ccRCC (Figure 55 & 
Figure 56) and is capable of identifying high risk patients in early stage tumors (Figure 62).  
The advantage of our signature over other published signatures is the inclusion of clinical 
parameters into the regression (Equation (12)). The clinical stage or the SSIGN-score alone 
showed better prediction power than all signatures published that are based on gene 
expression data (Figure 55 & Figure 56). Including clinical variables such as stage into a 
regression model improves the predictive power. Unfortunately, we could not reproduce the 
signatures presented by Wang et al.
301
 and Buttner et al.
302,303
. Neither did their studies report 
the classification of each patient in the TCGA-KIRC cohort, nor could we reproduce the 
classification according to their publications. Therefore, we were unable to assess the power 
of our ccRCC score in comparison to their patient classification method. 
We hypothesize that our in vivo model selects for genes that promote a more aggressive 
phenotype with enhanced capacity to metastasize (Figure 20). As we were especially 
interested in clinical relevant processes, mediating tumor outgrow, we correlated differentially 
expressed genes of this selection with processes that occur between stage I and stage III of 
ccRCCs. 
We included all clinical covariates into the LASSO regression that were annotated in both the 
TCGA-KIRC training and the Sato. et al. test cohort, and which had at least a univariate 
P value for the hazard ratio below the threshold of 0.2 (Figure 30). As tumor stage did not 
correlate linearly with the cancer specific relative hazard, we estimated its hazard using binary 
predictors (Figure 34c). The in the TCGA-KIRC and Sato et al. dataset reported four-tiered 
tumor grade is outdated, therefore, we used the WHO-ISUP grading system, which combines 
the old grade I and II patients into a single group
304
. Interestingly, age is not a significant 
predictor for cancer specific survival, but for non-cancer related survival (Figure 31a,c). This 
is contrary to the fact that ccRCC is an age related disease (Figure 2a). Nonetheless, most 
studies only present overall survival, not taking into account that age itself is a life limiting 
factor. Moreover, we found that laterality of the tumor is predictive for patients’ survival 
(Figure 30). Chandrasekar et al. analyzed a large patient cohort of more than 50,000 RCC 
patients
13
 and could not observe a significant correlation of tumor laterality and hazard ratio, 
yet he saw a low but significant correlation with age. This argues that our dataset was not 
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large enough to estimate linear predictors with minimal influence on the cancer specific 
survival. However, variables with little influence on the survival were not selected by the 
parameter shrinkage of the LASSO regression. 
The final ccRCC model that had been selected by the LASSO regression on stage I to stage III 
patients (Figure 33) was extended to stage IV patients (Figure 41). It comprises of seven 
genes and the clinical covariates stage I and stage IV as binary classifiers. CXCL5, IL13RA2, 
ONECUT2 and TSPAN8 have a positive weight in the ccRCC Score, whereas expression of 
PRDX2, PTPN13, SLC2A9 reduce the score. In the following, the genes their role in cancer 
progression will be shortly introduced. 
The C-X-C Motif Chemokine Ligand 5 (CXCL5) is a chemokine that mediates chemotaxis of 
neutrophils
305
. Several roles of neutrophils in tumor development have been proposed, among 
them the production of matrix metalloproteases enabling tumor cell migration and 
invasion
306,307
. Recently, the role of neutrophils in the progression of cancer has been reported 
to lie additionally in the escort of circulating tumor cells facilitating thereby metastasis
308
. 
Interleukin 13 receptor alpha 2 (IL13RA2) has been associated with acquired sunitinib 
resistance in ccRCC by inhibiting apoptosis
309
. IL13RA2 binds IL-13 with very high affinity 
but has no signaling domain
310
. Thereby, it was suggested that it might act as a decoy 
receptor
311
. It has been reported that NKT cells act with the help of IL-13 as tumor 
suppressors by inducing cell differentiation
312
.  
Studies reporting about the role of the transcription factor One cut homeobox 2 (ONECUT2) 
in cancer progression are limited, but it has been shown to drive neuroendocrine tumors
313-315
. 
In those tumors, it induces the expression of a survival program and supports metastases
316,317
. 
Tetraspanin-8 (TSPAN8) is a member of the transmembrane 4 superfamily and has been 
associated with tumor progression and metastasis
292,318-321
. TSPAN8 will be further discussed 
in section 4.2. 
The tumor repressor Peroxiredoxin 2 (PRDX2) reduces the reactive oxygen species (ROS) 
alkyl hydroperoxides and hydrogen peroxide
322
. High PRDX2-levels protect the cell from 
high ROS levels and from ROS-induced mutations like DNA double strand breaks, which 
impair the genomic stability
323,324
.  
The Protein Tyrosine Phosphatase, Non-Receptor Type 13 (PTPN13) dephosphorylates Fas 
receptor, IκB, PTEN, Ephrin B and has been shown to regulate Rho signaling pathways325-327. 
Thereby, it can act as a tumor suppressor by inactivating the Src tyrosine kinase
328
. 
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Additionally, it has been shown to promote apoptosis via insulin receptor substrate 1 
dephosphorylation and thereby inactivating insulin-like growth factor signaling via the Akt 
pathway
329
. 
The Solute Carrier Family 2 Member 9 (SLC2A9) is a glucose/fructose/uric acid transporter, 
which is physiological expressed in the proximal tubules of the kidney
330-332
. Functioning as 
an antioxidant, uric acid can reduce oxidative stress when its intracellular levels are elevated 
upon SLC2A9 expression
333
. Therefore, SLC2A9 has been identified as a tumor suppressor in 
hepatocellular and prostate carcinoma
334,335
.  
The described functions of CXCL5, IL13RA2, ONECUT2, TSPAN8 as pro-tumorigenic genes 
and PRDX2, PTPN13, SLC2A9 as tumor suppressors can be correlated to the survival of 
ccRCC patients. On the one hand, the LASSO regression on stage I-III selected for pro-
tumorigenic genes with a high hazard ratio. These genes got upregulated during the in vivo 
selection (Figure 38). On the other hand, it selected for genes with a hazard ratio below one, 
which got downregulated in the in vivo selection. Hence, using the LASSO regression 
approach, clinically relevant genes were selected that might be new and interesting clear cell 
renal cell carcinoma targets. 
Tumor necrosis is a covariate of the SSIGN Score (see section 1.3.1.3) and was the only 
significant clinical parameter in a multivariate analysis with the ccRCC score (Figure 44). 
Unfortunately, the patients of the Sato et al. cohort had no tumor necrosis annotation. 
Including this variable into the final ccRCC score model might even improve the predictive 
power.  
We calculated the ccRCC Scores for all patients of the TCGA-KIRC and thereby estimated 
cancer specific survival (Figure 42a). As expected from a training data set, the log hazard rate 
strongly correlated with the ccRCC Score. Additionally, not only cancer specific survival but 
also disease free and overall survival could be estimated from the ccRCC Score  
(Figure 42b,c). We validated the training cohort with an independent ccRCC RNASeq 
cohort, published by Sato and colleagues in 2013
31
. We observed the same linear correlation 
between ccRCC Score and survival (Figure 47), with the ccRCC Score as the only significant 
predictor for patients’ survival in a multivariate analysis (Figure 48). 
For everyday clinical situations, it is easier to classify patients into risk categories. Therefore, 
patients of the TCGA-KIRC cohort were stratified either by the median into two risk groups 
(ccRCC Score = -0.751) or by the lower (ccRCC Score = -1.700) and upper quartile (ccRCC 
Score = 0.449), resulting in three risk groups (Figure 45). We used the same ccRCC Scores in 
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order to classify patients into risk groups, independent of the cohort and source. Stratification 
into risk groups distributed patients of both the TCGA-KIRC and the Sato et al. dataset into 
very distinct groups (Figure 45 & Figure 49). This was also true for the estimation of 
progression free survival of the mini cohort from Heidelberg including 13 patients of which 
the gene expression profile was analyzed (Figure 57). 
Stratification of patients into risk groups reduces the predictive power of the analysis
336
. We 
obtain higher C-indices and likelihood ratios when applying the continuous ccRCC Score than 
the three-tier or even two-tier risk stratification (Figure 56). A categorization into smaller 
intervals allowed us for more precise estimations of the 5-year survival (Figure 46f). 
Intratumor heterogeneity is a clinical challenge in ccRCC. Gerlinger and his team were the 
first to show that within a single ccRCC tumor of a patient, multiple distinct different 
subclones coexist
72,73
. By sequencing, they were able to generate phylogenetic trees that 
represent the tumor evolution with driver mutations in the trunk of the tree and subclonal 
genomic events distinguishing the branches of the tree. The group classified 63 different 
regions of the ten patients with the help of the ccA/ccB signature
267,279
. Gulati et al. observed 
extensive intratumor heterogeneity when applying the ccA/ccB risk categorization. Only two 
tumors (EV005 and RMH008) had homogeneous risk scores for all tumor regions. In 
comparison, tumor regional risk classification by the ccRCC Score classified all but two 
patients (EV001 and EV006) into a homogeneous risk group (Figure 58). This is an 
advantage over the ccAccB signature as a single biopsy might already help to stratify patients 
into risk categories.  
Nevertheless, when analyzing the subclonal regions with a continuous ccRCC Score, vast 
intratumor heterogeneous differences are observable (Figure 59), with differences in ccRCC 
Scores of up to 2.379 (EV001).  Estimation of predicted 5-year survival probabilities for each 
region using the ccRCC Score (see above) revealed vast differences. The most benign tumor 
region R4a of patient EV001 has a good prognosis of 82.3 % 5-year survival probability. The 
region R3 however, which is appeared later in tumor evolution, indicates only a potential 5-
year survival probability of 12.2 %. This demonstrates that risk stratification overly simplifies 
the complex intratumor heterogeneous structure of the tumor and a continuous risk predictor 
might map the system better. Therefore, in order to provide a well-founded approximation of 
patient risk using the ccRCC score, several tumor regions must be analyzed.  
We were interested in identifying a relationship between evolutionary distance and tumor 
aggressiveness. Therefore, we plotted the number of non-synonymous mutations as a 
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measurement of evolution against the ccRCC Score (Figure 60). In six patients, increased 
mutational burden was associated with an increased ccRCC Score. One patient had no such 
correlation and three patients were invers correlated, among them the non-metastatic stage II 
patients. 
Since the relationship between evolutionary distance of a tumor region with its aggressiveness 
could not be answered conclusively by the ten patients of the multiregional analysis, we 
plotted the number of non-synonymous mutations against the ccRCC Score of patients of the 
TCGA-KIRC cohort (Figure 61). We could not identify any correlation between ccRCC 
Score as measurement of tumor aggressiveness and evolutionary distance. 
As stated before, we show that the ccRCC Score has superior predictive power over all 
ccRCC signatures that are based on gene expression data (Figure 55 & Figure 56). 
Nevertheless, as the risk classification by stage or SSIGN score is already good in predicting 
cancer specific survival we wondered, whether the ccRCC Score could give additional 
information over these classical clinical parameters. Hence, we calculated optimal cutoffs for 
the ccRCC Score within each stage category and stratified patients into high and low risk 
groups (Figure 62). Surprisingly, low risk patients within stage I to III had very good cancer 
specific survival probabilities between 94.8 and 100 %. The identification of a subpopulation 
of patients with such a good prognosis would help to determine the optimal need for follow-
up after nephrectomy. So far, in Germany, clinical follow up is performed according to the 
stage and grade of the tumor, dividing patients into three risk groups
16
. The main difference 
between the risk groups is the recommended frequency of computerized tomography (CT) or 
magnetic resonance imaging (MRI) scans. Those examinations are not only expensive, but in 
the case of CT scans the radiation is also burdening the patient. A reduced amount of 
examinations would be beneficial for low risk patients, especially patients with stage III 
tumors, as they would have been grouped into the high risk group with up to eight scans 
within two years after nephrectomy. For low risk patients, the guidelines recommend only 
three to four scans in the same period. Patients of the high risk group within a stage category 
defined by the ccRCC Score could be the potential target group and benefit from an adjuvant 
therapy. 
Patients of the low risk score groups of stage I to III show very good prognosis. We were 
wondering whether we might identify differentially expressed genes in the high risk group of 
patients that might be druggable. Hence, we made use of the DGIdb drug interaction database 
to search for already approved drugs that interact with genes upregulated in the high risk 
group of stage I patients (Figure 63). Thereby, we identified six upregulated genes that 
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interact with nine different drugs (Table 9), among them is the receptor tyrosine kinase Erb-
B2 Receptor Tyrosine Kinase 4 (ERBB4 or HER4). Many patients benefit from targeting 
RTKs by multi-tyrosine kinase inhibitors such as sunitinib and sorafenib. Therefore, it could 
be of interest to investigate signaling through ERBB4 in ccRCC and whether ccRCC patients 
would benefit from targeting ERBB4 as well. Another possible target might be Beta-1,4-N-
Acetyl-Galactosaminyltransferase 1 (B4GALNT1) catalyzing the biosynthesis of the 
disialoganglioside GD2, which was found to be a potential target to treat in neuroblastoma 
with the monoclonal antibody dinutuximab
337
. Hence, identifying upregulated genes in high 
risk stage I ccRCC patients as potential druggable targets represent another application by 
which patient stratification via the ccRCC Score could help to improve the understanding and 
therapy of ccRCC. 
4.2 TSPAN8 is an attractive surface marker to target ccRCC 
Tetraspanin 8 (TSPAN8; also TM4SF3 or CO-029) is encoded by the TSPAN8 gene and 
belongs to the transmembrane 4 superfamily (tetraspanin family)
292
. With short intracellular 
N- and C-termini, tetraspanins span the membrane four times (Figure 90). Of importance is 
the second extracellular loop, which is larger than the others. This loop consists of a constant 
region and of a variable region which bind other tetraspanins and other transmembrane 
proteins respectively, to form tetraspanin-enriched membrane microdomains (TEMs)
338,339
. 
TEMs are stabilized by cholesterol and gangliosides but differ structurally from lipid rafts
340
. 
TEMs are highly enriched for integrins (mostly α3β1, α4β1 and α6β1)341, G-protein-coupled 
receptors
342
, growth factor receptors
343
, peptidases, immunoglobulin superfamily 
members
344,345
 and other transmembrane proteins like EPCAM and CD44
340
. Thereby, TEMs 
can act as platforms for a variety of signaling pathways. The tetraspanin scaffold determines 
the function of the microdomaine based on the combination of binding partners rather than by 
tetraspanins directly
346
.  
In these TEMs, tetraspanins regulate cell adhesion, spreading, migration and via exosomes 
cell-cell communication. Exosomes are small vesicles (30-120nm) that are released from cells 
and fuse or bind selectively with target cells
347,348
. Inside the lipid bilayer of the exosomes 
enzymes, mRNA and microRNA can be transferred to the target cells and modulate their 
function
292,349,350
. Exosomes are highly enriched for tetraspanins but whether they have an 
influence on the exosome composition is unknown
351,352
. 
Expression of the tetraspanins CD82 and CD9 has been associated with tumor suppression
353
, 
whereas CD151 and TSPAN8 seem to support tumor progression and metastasis
292,318-321
. 
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TSPAN8 is significantly upregulated in many cancers, such as gastrointestinal
354-357
, 
liver
358,359
, ovary
360
, pancreatic
361
, prostate
362
, esophagus cancer
363
, glioma
364
 and 
melanoma
365,366
. As it is the case for most tetraspanins, the pro-invasive and pro-metastatic 
role of TSPAN8 is mainly regulated via scaffolding of binding partners such as E-cadherin
356
, 
claudin 7, EPCAM, α6β4 integrin, CD44v6 and EWIF345,355,359. It has been reported that 
TSPAN8 might modulate the tumor microenvironment with the help of exosomes, which 
might promote angiogenesis of endothelial cells in cooperation with CD151
321,354,367,368
. In 
addition, exosomes have been linked to matrix remodeling by activating matrix 
metalloproteases
367,369
, which support tumor growth and invasion.  
. 
 
Figure 90 – Structure of Tetraspanins 
Tetraspanins have short cytosolic C- and N-termini 
and cross the membrane four times with 
hydrophobic transmembrane domains. They are 
connected by loops of which the large extracellular 
loop is of importance, as it binds other tetraspanins 
with its constant region (labeled with A, B and E) to 
form a so called tetraspanin-web. With its variable 
region, tetraspanins bind other partners. Together 
they form tetraspanin-enriched microdomains 
(TEMs), which may act as signaling hubs. 
With kind permission of Springer Nature, License 
Number 4518130548095 
A proteomic analysis in colorectal cancer cell lines suggested that TSPAN8 together with the 
tetraspanin CD9 facilitates clustering of epidermal growth factor receptors (EGFRs) and 
CD44
370
. We find CD44 as one of the most abundant expressed surface molecules on the 
surface of all KIKA cell lines (Figure 16b). The hyaluronic acid binding surface molecule 
CD44 has been shown to activate EGFRs and thereby promotes cell survival and remodeling 
of the tumor microenvironment
371
. In ccRCC, the expression of CD44 has been correlated 
with highly aggressive tumor progression
372
. We observed EGFR expression on all KIKA cell 
lines, but with less pronounced intensity (Supplemental Figure 2). In renal carcinoma cell 
line experiments, the activation of EGFR signaling has been proposed as a potential resistance 
mechanism for Sunitinib treatments
373
. Nevertheless, treatment with the EGFR inhibitor 
Erlotinib alone did not show any effect on cell viability in our patient derived ccRCC cell 
lines (Figure 18c). 
TSPAN8 is the most differentially regulated gene in the in vivo selection of the seven 
hallmark genes of the identified ccRCC signature (Figure 28 & Figure 38). Looking at 
138  Discussion 
TSPAN8 expression it became increasingly upregulated along the passages (Figure 64). With 
the help of IHC, we observed intratumor heterogeneity of TSPAN8 positive cells 
(Figure 65). In the primary tumors, which derived from xenotransplantation of the originating 
KIKA75 cell line only few TSPAN8 positive cells were found, mostly clustering together. 
The tumors of the last in vivo selection stained highly positive for membranous TSPAN8. But 
still, we could observe areas with TSPAN8 positive cells and areas with no or only weak 
TSPAN8 expression. We did not observe any relationship of TSPAN8 positive cells to tumor 
boarder, vessels or extracellular matrix. 
Also within our different KIKA cell lines, TSPAN8 was heterogeneously expressed 
(Figure 67a,b). This heterogeneous expression of TSPAN8 was also observable in the 
TCGA-KIRC patient cohort (Figure 67c).  
Stratification of patients by the expression of TSPAN8 shows a significant overall survival 
benefit for patients with low TSPAN8 expression in the Sato et al. patient cohort. Although, 
this survival benefit is not significant for cancer specific survival in the TCGA-KIRC patient 
cohort, the trend is pointing towards the same direction (Figure 68). In early stage patients of 
both ccRCC cohorts, TSPAN8 expression levels have no prognostic value for patients’ 
survival (Figure 69). In patients of the TCGA-KIRC cohort with stage III and IV, however, 
high TSPAN8 expression correlates with worse prognosis. For the Sato et al. cohort which 
includes only 25 stage III and IV patients, stratification into risk groups using TSPAN8 
expression shows the same trend for patient prognosis, but is not significant. (Figure 69).  
To investigate the role of TSPAN8 in the disease progression of ccRCC, we used two cell 
lines with high basal TSPAN8 expression (KIKA24 & KIKA38), a cell line with low 
(KIKA75) and a cell line with no basal TSPAN8 expression (KIKA27) on protein level 
(Figure 67b). For each of them, we generated two TSPAN8 knockdown and one TSPAN8 
overexpression cell line (Figure 71 & Figure 72). Although the knockdown efficiency of the 
two shRNAs was relatively high on RNA level, on protein level, the knockdown in the cell 
lines with high basal TSPAN8 expression only reduced the amount of absolute protein 
abundancy on the cell surface. The vector used for the overexpression of TSPAN8 was leaky 
and therefore, we observed upregulated basal TSPAN8 levels in the not induced cell lines. 
We subsequently transplanted these KIKA cell lines orthotopially into NSG mice (Figure 73). 
We saw no doxycycline induced effect on tumor growth when using a non-targeting shRNA 
control (Figure 74a, Figure 75a, Figure 76a, and Figure 77a). Also, an overexpression of 
TSPAN8 did not influence tumor aggressiveness or tumor growth (Figure 78). However, a 
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reduction of TSPAN8 stopped tumor growth of both the shTSPAN8(1) KIKA27 cell line 
(Figure 75b) and the shTSPAN8(2) KIKA75 cell line (Figure 77c). The shTSPAN8(2) 
KIKA27 (Figure 75c) cell line, the shTSPAN8(1) KIKA24 cell line (Figure 74b) and the 
shTSPAN8(1) KIKA75 cell line (Figure 77b) showed delayed tumor growth. Knockdown of 
TSPAN8 had no effect on the shTSPAN8(2) KIKA24 (Figure 74c) and on both of the 
shTSPAN8 KIKA38 cell lines (Figure 76b,c). By inducing TSPAN8 knockdown on already 
established KIKA27 tumors (Figure 79), we could stop (Figure 80b) or delay (Figure 80d) 
tumor growth. 
Our study is the first to show the effect of TSPAN8 in vivo on primary patient xenografts. The 
data so far suggest that low amounts of TSPAN8 on the surface of tumor cells may be 
sufficient to mediate tumor aggressiveness in vivo, but a loss of protein stops or delays tumor 
growth.  
In mouse xenograft models with commercial cell lines, TSPAN8 has already been identified 
as an attractive target molecule to target colorectal and ovarian cancer
288,360,374
. For this, 
monoclonal antibodies have been developed and especially the Ts29.2 mAB generated in the 
lab of Claude Boucheix proved highly effective
288
. They could show that intraperitoneal 
treatment of subcutaneous transplanted colorectal cancer cell lines with the antibody alone 
delayed primary tumor growth significantly, if treated early. These results recapitulate the 
effect of TSPAN8 knockdown that we observed for ccRCC patient xenografts. In contrast to 
previously published data, Ailane et al. did not observe differences of cell proliferation in 
vitro and could not observe differences in vessel formation. Aurélie Maisonial-Besset and her 
team coupled the same antibody with a radioactive 
111
In or 
177
Lu and treated nude mice 
xenografted with colorectal cancer cell lines. This treatment resulted in inhibited tumor 
growth using 100-fold reduced amounts of antibodies in comparison to treatment with an 
uncoupled antibody
375
. Another antibody targeting TSPAN8 has been developed by Park et 
al.
360
. Epithelial ovarian cancer (EOC) cell lines were intraperitoneally injected into BALB/c-
nude mice and simultaneously treated intravenously with their antibody, which resulted in a 
reduced number of metastases. Consistent with the study by Ailane et al., in vitro treatment of 
cell lines with the antibody by Park et al. did not influence cellular viability in vitro nor 
endothelial cell activation in vivo. However, they observed that treatment of tumor cells lead 
to an increased internalization of TSPAN8. 
In accordance with the published data for the in vitro function of TSPAN8 (Figure 83), we 
observed no effect on cell proliferation
288,360,363,365
. This is also supported by the fact that we 
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could not observe any differentially expressed genes between overexpression or knockdown 
of TSPAN8 in vitro (Figure 81 & Figure 82). 
Surprisingly, normal bulk kidney samples showed higher TSPAN8 expression than ccRCC 
tumor tissue (Figure 67c & Figure 69). In normal kidney tissue, TSPAN8 is mainly 
expressed in the endothelium of the vasculature and in the apical membrane of cells of the 
proximal tubules of the kidney, the proposed ccRCC cell of origin
376,377
 (see section 1.2.1). 
Therefore, high basal TSPAN8 expression in normal tissue may be an obstacle for a 
therapeutic use of mABs targeting TSPAN8. When treating mice with radiolabeled 
α-TSPAN8 antibodies, Bonnet et al. saw off-target binding to spleen, liver, lung, heart and 
kidney tissue, which show basal TSPAN8 expression in normal tissue
374
. Additionally, the 
use of radioactive labeled antibodies may lead to excessive blood radiotoxicity, as TSPAN8-
rich exosomes are secreted from tumor tissue into the circulation
351,352
. Interestingly, the 
Tspan8 knockout mouse shows only a weak phenotype with reduced male body weight and 
reduced bone mineral density
378
 
TSPAN8 is a scaffold protein that forms tetraspanin-enriched microdomain clusters with cell-
matrix interaction proteins. Studies suggest that TSPAN8 may influence invasiveness of 
tumor cells into the microenvironment by interacting and crosslinking cell surface 
molecules
363,365
. Especially its role in inhibition of E-cadherin
356
 and in clustering with 
CD44
355
 have been previously reported as essential regulators of tumor invasiveness, EMT 
and metastasis
371,379
. By elucidating the interaction network of TSPAN8, future studies will 
eventually decipher a mechanism, by which TSPAN8 influences tumor aggressiveness. 
TSPAN8 has been identified as an early marker for kidney injury that modulates migration 
and invasiveness of renal tubule cells to repair renal tissue
380
. Acute kidney injury is a 
complex and multifactorial disease, but it is mainly caused by exposure to toxins or ischemic 
stress
381
. The injury leads to an acute reduction and malfunction of the glomerular filtration, 
followed by hypoxia and inflammation of the surrounding tissue. In contrast to the glomerulus 
as the primary filtration unit of the kidney, the renal tubules can regenerate after injury. Upon 
kidney injury, a cellular repair program is activated
382
. From uninjured proximal tubule cells, 
so called scattered tubular cells (STCs) emerge in order to facilitate tubular regeneration
383
. 
These cells express de novo CD44 
384
, CD24 
385
, vimentin and CD133 
386
, which are markers 
of which we also found some upregulated in the KIKA ccRCC cell lines (Figure 16). 
Subsequently, the tubules regenerate and kidney function is slowly reestablished
381
. Patients 
with acute kidney injury may potentially develop a chronic kidney disease and subsequently 
renal cell carcinoma
387,388
. Hirukawa et al. identified TSPAN8 as a marker for acute kidney 
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injury, whereas other tetraspanins like CD151 and CD9 did not change their expression
380
. 
The authors observed that TSPAN8 expression was independent of spatial proximity to the 
injury and suggested a systemic activation, which is in line with our observation when 
characterizing TSPAN8 expression patterns (Figure 65). Moreover, another study by Penas et 
al. found that tetraspanins were involved in regulating wound healing of normal keratinocytes 
in vitro
389
. Uncontrolled wound healing has often been proposed as a mechanism to promote 
cancer progression
390
. Many aspects of wound healings resemble aspects of tumor 
progression. In healthy tissue, the re-epithelialization is self-limiting as soon as the wound is 
closed, whereas tumor cells lose their control over proliferation and migration. The kidney 
injury molecule-1 (KIM-1) is highly upregulated in STCs and during kidney repair processes. 
Ghislaine Scelo and her group investigated into whether blood levels of KIM-1 is a predictive 
marker for kidney cancer
391
. They could show that high plasma levels correlate with the 
incidence of RCC even 5 years before cancer diagnosis. 
In the progression of kidney cancer, TSPAN8 might support invasiveness of tumor cells by 
forming TEM signaling hubs and activate processes that resemble uncontrolled wound 
healing processes. 
4.3 FOXA2 is a potential transcriptional regulator of TSPAN8 
Agaësse et al. have shown that in cutaneous melanoma, the tumor suppressor tumor 
protein 53 (TP53) is a transcriptional repressor of TSPAN8. In contrast to many other tumors, 
TP53 is mutated in only 2.8 % of the ccRCC patients of the ccRCC patients
31,63
 and both gene 
and protein levels did not correlate with TSPAN8 expression (Figure 84). 
We could show that FOXA2 target genes were enriched in the in vivo selection for FOXA2 
target genes (Figure 85), even if the transcription factor itself was not differentially 
expressed. The helix-turn-helix transcription factor FOXA2 or HNF3β is a member of the 
forkhead box protein family
392
. Their activity as transcriptional activators of genes in dense 
chromatin regions has been associated with many processes, such as cellular growth, 
proliferation and differentiation
392-395
. Forkhead box proteins play an essential role in the 
embryonic development and are therefore prone to play a role in cancer development
392,396,397
. 
In the developing embryo for example, FOXA2 is essential to form the notochord that 
regulates the dorsoventral pattern of somites and neural tube
398,399
.  
The role of FOXA2 in cancer development is ambivalent. On the one hand it has been shown 
to act as a tumor and metastasis suppressor in liver
400-403
 and pancreatic cancer
404
. On the 
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other hand, it promotes neuroendocrine tumors of the prostate
405
, drives uterine carcinomas
296
 
and ovarian cancer
295
, where it is required for the maintenance of cancer stem cells
406
. 
Except for the Wilms tumor, which is a kidney tumor distinct from renal cell carcinoma and 
ccRCC, where FOXA2 expression was detected
407
, little is known about its function in the 
carcinogenesis in other subtypes of kidney cancer. As described in section 1.2.1, the HIF-
pathway is essential for ccRCC development. A HIF-FOXA2 axis has been found to promote 
neuroendocrine prostate tumors, it might also play a role in the tumorigenesis of ccRCC
408
. 
CNAs with a gain of FOXA2 have been reported in late grade ccRCC
409
 and Jia et al. 
associated high FOXA2 expression with bad overall survival prognosis when stratifying 
patients by median FOXA2 levels
297
. We analyzed the more appropriate cancer specific 
survival statistics (see section 3.6.1) and could confirm their assumption when applying 
maximally selected rank statistics to find an optimal FOXA2 level to stratify patients  
(Figure 86c). Later stages of ccRCC show significantly higher FOXA2 expression levels 
(Figure 86b). This finding is in line with the high basal expression levels of FOXA2 in the 
KIKA cell lines (Figure 86a), which were derived from late patient stages
1
.  
As overexpression of FOXA2 showed deleterious effects in the cells, KIKA27 FOXA2 
knockdown cell line were orthotopically transplanted into NSG mice and tumor growth 
monitored. Knockdown of FOXA2 led to a significantly delayed tumor growth in mice 
(Figure 89). This result indicates that FOXA2 regulated gene expression has an effect on 
KIKA27 derived tumor progression.  Nevertheless, whether this is a cell line intrinsic effect 
or plays a global role in ccRCC has to be validated in more cell lines in future studies. 
FOXA2 binds the promotor of TSPAN8 in HepG2 and liver hepatocytes
299,300,410
 (Figure 88a) 
and therefore we wondered whether differential FOXA2 levels influence also TSPAN8 levels 
in our ccRCC cell lines. By inducing a FOXA2 knockdown in the TSPAN8 low expressing 
KIKA27 cell line, we observed a reduction of TSPAN8 levels according to FOXA2 levels 
(Figure 87a,c). Overexpression of FOXA2 was leaky resulting in increased FOXA2 basal 
levels without induction of the overexpression construct (Figure 87a). This slight 
overexpression had no effect on TSPAN8 levels, but the extensive overexpression of FOXA2 
also increased TSPAN8 levels significantly (Figure 87c).  
Cytosine methylation to 5-methylcytosine of CpG dinucleotides is a common epigenetic 
process in vertebrates in order to regulate gene expression, with hypomethylated promotors as 
being active and hypermethylated promkotors rendering the gene expression inactive
411-413
. In 
cancer, tumor suppressor genes are commonly hypermethylated, whereas oncogenes tend to 
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be hypomethylated
414
. TSPAN8 has been shown to be epigenetically regulated
415
 and cell lines 
derived from the lung metastases of the last passage of the in vivo selection slowly 
downregulated TSPAN8 in cell culture conditions (see Figure 66), which is in accordance 
with reported demethylation and therefore epigenetic regulation kinetics
416
.  
We did not analyze the differentially methylated regions between the different passages of the 
passage 4 lung metastases derived cell lines, but we could show that the genomic region of 
TSPAN8 was highly methylated in the first passage of the in vivo selection and gets 
demethylated during the selection process (Figure 88b). The epic array covers about 850.000 
CpGs, including ENCODE open chromatin and enhancer regions
417
. Among them are those 
bound by the transcription factor FOXA2. We observed that the promoter regions of TSPAN8 
that have FOXA2 consensus sequences and are bound in hepatic cell lines by FOXA2 were 
hypomethylated in the last passage of the in vivo section. 
In summary, we identified a simple signature that can predict patients’ survival robustly. 
Tetraspanin-8 is among the genes of the signature playing an essential role in tumor 
progression in vivo. Our data indicates that TSPAN8 is regulated by a differentially 
methylated promoter which is bound by the transcription factor FOXA2. Future studies may 
examine the transcriptional regulation and mechanism of TSPAN8 in the progression of clear 
cell renal cell carcinoma. 
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5 Material and Methods 
5.1 Primary Patient Material 
Primary patient clear cell renal cell carcinomas were obtained from PD Dr. Sascha Pahernik 
from the Department of Urology (University Clinic Heidelberg/Nürnberg). The study was 
approved by the ethical committee of the University of Heidelberg (case number 207/2005) 
and conducted in accordance with the Helsinki Declaration. A written informed consent was 
obtained from every patient. Tumor material was classified as clear cell renal cell carcinoma 
by the pathology department and during xenotransplantation morphological properties of the 
parental patient tumors were preserved. Human origin of the xenografts was verified by 
hKi67 staining. All tumors were highly vascularized, pervaded by a branched blood vessel 
network 
5.2 Xenograft mouse model 
Animal experiments were previously approved by the national authorities 
(Regierungspräsidium Karlsruhe; authorization number G-233/11 and G28/17) and studies 
were conducted according to the GV-SOLAS regulations. Mice were housed and bred in the 
DKFZ animal facility under specific pathogen free (SPF) conditions and maintained in 
individually ventilated cages (IVCs). Xenograft mouse experiments were carried out in 
NOD.Cg-Prkdc
scid
 Il2rg
tm1Wjl
 (NSG) mice.  
5.3 Cell Culture of primary cell lines 
Primary patient derived cell lines were cultured in Renal CSC medium at 37°C and 5 % CO2 
(Table 10). The medium was partly replaced twice a week and cells were splitted in a ratio of 
1:2 to 1:8 when cell density exceeded the culture flasks. Passaging was performed by 
dissociating the cells with Accutase (Thermo Scientific) and replating according to Table 11. 
For cryopreservation, cells were aliquoted, re-suspended in CryoStor CS10 (Sigma) and 
stored in liquid nitrogen. 
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Table 10 – Renal CSC Medium 
Compound Amount Company 
Advanced DMEM/F12 500 mL Thermo Scientific 
bFGF 50 ng/mL PeproTech 
BSA 1 % Thermo Scientific 
Epinephrine 1 µM Sigma 
Glucose 0.6 % Sigma 
Glutamine 2 mM Sigma 
H2O 25 mL Thermo Scientific 
hEGF 20 ng/mL PeproTech 
Heparine 2 µg/mL Sigma 
Hepes 5 mM Sigma 
Hydrocortisone 0.2 µg/mL Sigma 
L-glutathione 1 µg/mL Sigma 
Lipid Mix 1 mL Sigma 
LONG R3 IGF-I 10 ng/mL Sigma 
N2 Supplement 5 mL Thermo Scientific 
Trace Elements A 250 µL Mediatech 
Trace Elements B 500 µL Mediatech 
Trace Elements C 500 µL Mediatech 
Triiodothryonine 10 nM Sigma 
β-mercaptoethanol 100 µM Thermo Scientific 
 
Table 11 – Cell lines and their culture conditions 
Cell Line Culture Flask Growth condition 
KIKA12 Corning® Costar® Ultra-Low Attachment Flasks Spheres 
KIKA24 Corning® Costar® Ultra-Low Attachment Flasks Spheres 
KIKA27 Corning® CellBIND® Surface Flasks Adherent 
KIKA38 Corning® Costar® Ultra-Low Attachment Flasks Spheres 
KIKA75 Corning® Costar® Ultra-Low Attachment Flasks Spheres 
 
5.4 In vitro drug treatment 
To obtain the drug response rates of cell lines in vitro, each cell line was seeded in three 
biological and four technical replicates for each drug concentration and control one day prior 
treatment (KIKA75, KIKA38: 7000 cells/well, Corning 96-well clear flat bottom ultra-low 
attachment plates; KIKA27: 7000 cells/well, Corning 96-well clear flat bottom CellBind 
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plates). Drugs and the solvent DMSO as control were titrated in four technical replicates each 
onto the cells. As positive control, staurosporine (Sigma, 1µM) was added to eight technical 
replicates per cell line and replicate. The cells were incubated for 48 hours (KIKA27) or 
72 hours (KIKA38, KIKA75) in the incubator (37°C, 5 % CO2). Subsequently, cell viability 
was measured with the Cell Titer-Blue Cell Viability Assay (Promega). CellTiter-Blue (20µl 
CTB per 200µl medium) was incubated for 4 hours in the incubator (37°C and 5 % CO2) and 
measured with a fluorescent plate reader at 560(20)Ex/590(10)Em. 
5.5 Tumor cell injection into the kidney capsule 
20 minutes before the operation Carprofen s.c. (5mg/kg) was given to the mice. Mice were 
anesthetized by injecting ketamin (90 mg/kg) and xylazinhydrochloride (14.5 mg/kg) 
intraperitoneally and as soon as the pedal withdrawal reflex was absent, the animals were 
placed on heating pads. Eyes were covered with dexpanthenol cream to prevent dehydration. 
The right kidney was exposed with a small incision on the right flank and tumor cells were 
injected together with Matrigel (3 mg/ml, maximum 30 µl) into the kidney capsule. As 
postoperative pain treatment a carprofen-gel (10 mg/kg/day) was placed into the cage. 
5.6 In vivo bioluminescence imaging 
In order to monitor tumor growth, ccRCC primary patient derived KIKA models were 
transduced with a luciferase transgene (Renilla-luciferin 2-monooxygenase) and monitored 
weekly using the IVIS 200 imager system. For imaging, mice were injected intraperitoneally 
with D-Luciferine Firefly Potassium salt (15 mg/mL, 5 µl/g/mouse in PBS) 6 minutes prior 
measuring and anesthetized with isoflurane (4.5 % during initiation, 1-2 % to uphold 
anesthesia). Data was analyzed by the Living Image software. 
5.7 In vivo doxycycline-inducible knockdown 
The knockdown of genes via the pTRIPZ-vector system was induced by applying doxycycline 
to the animals via their drinking water (2 mg/mL) 
5.8 Stopping criteria for animal experiments 
The general condition of the animals is monitored daily. When animals suffer middle 
afflictions (in accordance with Annex VIII der RL 2010/63/EU) they were monitored twice a 
day and as soon as their health condition worsened (body weight loss of > 20 %, anorexia, 
apathy, signs of dehydration, fur anomalies, paralysis, scoliosis, shortness of breath, paleness, 
in accordance with GV-SOLAS) or after an observation period of more than one year, they 
were euthanized by cervical dislocation. 
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Measurement of tumor growth with bioluminescence allows identification of stopping criteria 
before the appearance of e.g. dyspnea. As stopping criteria a 1000-fold increase of the initial 
signaling was defined. 
5.9 Tumor dissociation 
 Kidney tumor 5.9.1
The primary tumor was excised and cut into small pieces and transferred into gentleMACS C-
tubes with CO2 independent medium (Thermo Fischer Scientific) supplemented with the 
human Tumor Dissociation Kit (Miltenyi Biotec). Dissociation of the tumor was performed 
using the “kidney” program of the gentleMACS following an incubation at 37°C using the 
MACSMix tube rotator for 15 minutes. The process was repeated until the tumor was 
completely dissociated, which was visually determined under the microscope. 
 Lung metastases 5.9.2
The lung metastases were excised by removing as much normal lung material as possible and 
transferred into gentleMACS C-tubes together with CO2 independent medium (ThermoFisher 
Scientific) supplemented with 2.5 mg/mL Collagenase D (Sigma), 1 mgP/mL Elastase 
(Worthington) and 100 µg/mL DNase (Sigma). For dissociation, the “lung” program of the 
gentleMACS was used following incubation at 37°C using the MACSMix tube rotator for 
15 minutes. The process was repeated until the tumor was completely dissociated, which was 
visually determined under the microscope. 
 Generation of cell lines 5.9.3
The dissociation suspension was filtered through 100 µm and 70 µm strainers and lysed with 
ACK lysis buffer to remove erythrocytes. Tumor cells were cultured in Renal-CSC medium 
together with 5 μg/ml Fungizone (Thermo Scientific), 50 U/ml Penicillin, 50 µg/ml 
Streptomycin (Sigma) and Y-27632 (Sigma). After 24h, the medium was replaced by Renal-
CSC medium. 
5.10 Measurement of tumor size and metastases scoring 
Tumor size was measured by measuring the diameter of the tumor with a ruler. Metastasis 
scoring was performed as followed: Score 0 = no lung metastases discernible by eye or 
histology of the median cut of the lung. Score 1 = micrometastasis detectable by microscopy 
(< 100 µm). Score 2 = metastases visible by eye or by microscopy (> 100µm). 
Score 3 = Multifocal metastasis >1 mm each. 
Material and Methods  149 
 
5.11 Flow cytometry 
For flow cytometry stainings, dissociated cells were resuspended in PBS (Sigma), 
supplemented with 1 % BSA (Thermo Fischer) and 2mM EDTA (Invitrogen), and incubated 
with antibodies or fluorophore-coupled antibodies (Table 12) for 30 minutes in the dark at 
4°C. After staining, samples were washed twice with the staining buffer. If required, the cells 
were incubated with a secondary antibody for 15 minutes in the dark (Table 13) and 
subsequently washed twice. For analysis, cells were filtered and co-stained with 0.1 µg/mL 
DAPI (Thermo Fisher) and recorderd on the LSRForessa analyzer (BD Biosciences). Final 
analysis was performed using FlowJo v10 (Tree Star; Ashland, OR).  
Table 12 – Primary Antibodies used for FACS 
Name Manufacturer (Cat. No.) Dilution 
APC-Rat IgG1 kappa Isotype (eBRG1) Thermo Fisher (17-4301-82) 1:20 
APC-Mouse IgG2b kappa Isotype (eBMG2b) Thermo Fisher (17-4732-42) 1:20 
APC Mouse Isotype Control BD Biosciences (554681) 1:20 
BB515 Mouse Anti-Human CD54 (ICAM1) BD Biosciences (564685) 1:100 
BB515 Mouse IgG1 kappa Isotype Control BD Biosciences (564416) 1:100 
hTSPAN8 Ts29.2, Boucheix et al.
288
 1µg/1*10
6
 cells 
Additional, the Human Cell Surface Marker Screening Panel (BD Lyoplate) was used 
following the manufacturer's recommendations to immunophenotype the KIKA cell lines. 
25000 cells per antibody were used and counterstained with secondary antibodies (Table 13). 
Cells were co-stained with 0.1 µg/mL DAPI (Thermo Fisher) and recorderd on the Guava 
easyCyte System (Millipore). Final analysis was performed using FlowJo v10 (Tree Star; 
Ashland, OR).  
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Table 13 – Secondary Antibodies used for FACS 
Name Manufacturer (Cat. No.) Dilution 
F(ab’)2 Donkey Anti-Mo IgG APC eBiosciences 1:100 
Goat Anti-Mouse IgG Human ads-PE SouthernBiotech 1:300 
Goat Anti-Rat IgG (H+L) Mouse ads-PE SouthernBiotech 1:300 
 
5.12 Hematoxilin and Eosin (HE) and Immunohistochemistry (IHC) 
staining 
Hematoxilin and Eosin (HE) and immunohistochemistry (IHC) staining was performed by 
Vanessa Vogel and Ornella Kossi (Hi-STEM). Tumor samples were fixed at room 
temperature in 10 % formalin (Sigma) for at least 48h and dehydrated with increasing ethanol 
and xylene (Sigma) concentrations. Tumor samples were embedded in paraffin and cut for 
staining. 
For IHC and HE staining, slides were deparaffinized, rehydrated by xylene and decreasing 
concentrations of ethanol.  
HE staining was done either automatically using a tissue stainer or manually. For both 
methods, following protocol is applied. Slides were incubated in hematoxylin according to 
Mayer (Sigma), washed with water and subsequent staining with Eosine Y (Sigma). Staining 
was fixated by acetic acid followed by increasing concentrations of ethanol. Slides were 
covered with xylene based mounting medium (ThermoFisher) and cover slips. 
For IHC, antigens were unmasked by proteolytic induced epitope retrieval (Proteinase K, 
1.5 mAU/ml, Qiagen) or heat induced using a steam pot with citrate buffer of either pH 6.0 or 
pH 9.0. Primary antibodies were incubated 30 minutes at RT or overnight at 4°C, washed and 
endogenous peroxidase blocked by H2O2. Subsequently, the slides were incubated with the 
HRP dual link rabbit/mouse (Dako) polymer system for 20 minutes, washed and stained with 
the DAB chromogen (Dako kit). The slides were counterstained with hematoxylin (Sigma) 
and washed with water. Slides were covered with aqueous based mounting medium (Sigma) 
and cover slips. 
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Table 14 – Primary Antibodies used for IHC 
Antigen Manufacturer (Cat. No.) Dilution 
ICAM1 Sigma (HPA004877) 1:100 
hKi67 Dako (M7240) 1:1000 
hTSPAN8 Ts29.2, Boucheix et al.
288
 4 µg/mL 
 
5.13 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
RNA was extracted from both tumor tissue and cell lines with the help of the miRNeasy mini 
kit (Qiagen) and subsequently reverse-transcribed with the high capacity cDNA reverse-
transcription kit (Applied Biosystems) according to the manufacturers protocol.  
Triplicates of 10 ng of reverse transcribed RNA were analyzed by quantitative real-time 
polymerase chain reaction (qRT-PCR) using TaqMan probes (Table 15; Thermo Fischer 
Scientific, 6-carbofluorescein (FAM) labeled) and TaqMan™ Fast Advanced Master Mix 
(Thermo Fischer Scientific) in a 10 µl reaction according to the fast protocol using the Viia 
Real-Time PCR System (Applied Biosystems). 
Table 15 – TaqMan probes used for qRT-PCR 
TaqMan Probe Assay ID 
CXCL5 Hs01099660_g1 
GAPDH Hs02786624_g1 
IL13RA2 Hs00152924_m1 
LOC644936 (AC026410.1) Hs04978470_g1 
ONECUT2 Hs00191477_m1 
PPIA Hs04194521_s1 
PRDX2 Hs00853603_s1 
PTMA Hs02339492_g1 
PTPN13 Hs01106214_m1 
SLC2A9 Hs01119178_m1 
TSPAN8 Hs00610327_m1 
ZMIZ1-AS1 Hs05005383_m1 
 
The data was acquired and analyzed using the QuantStudio™ Real-Time PCR Software 
(Applied Biosystems). The ΔΔCT method was applied using GAPDH and PPIA as multiple 
endogenous controls. Normal kidney was used as positive control (Clonetech).  
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5.14 Gibson cloning of FOXA2 and TSPAN8 overexpression 
vectors 
The pTRIPz backbone vector was linearized with the restriction enzymes AgeI and MluI and 
purified by gel extraction (QIAquick Gel Extraction Kit). FOXA2 transcript variant 1 
(NM_021784.4) and TSPAN8 (NM_004616.2) mRNA was synthesized by GeneArt Strings 
(ThermoFisher). Overhangs for the Gibson assembly with AgeI and MluI restriction sites, 
stop codon and pTRIPz homologous regions were added by using following primers (Sigma) 
in a touchdown PCR (Q5 High-Fidelity DNA Polymerase, NEB): 
Table 16 – Primer to anneal overhangs (small characters: homologous regions; capitals: 
overhang) 
Primer Primer Sequence 
FOXA2 Fwd tcgtttagtgaaccgtcagatcgcaaccggtATGCACTCGGCTTCCAGTATG 
FOXA2 Rv gcgccaaaacccggcgcggaggccaacgcgtTTAAGAGGAGTTCATAATGGGCC  
TSPAN8 Fwd tcgtttagtgaaccgtcagatcgcaaccggtATGGCAGGTGTGAGTGCC 
TSPAN8 Rv gcgccaaaacccggcgcggaggccaacgcgttcaTTTGTTCCCGATCTGGCAATAC 
 
a
 
 
b
 
Figure 91 – Vector Maps of the cloned overexpression constructs 
(a) pTRIPz-FOXA2 overexpression vector 
(b) pTRIPz-TSPAN8 overexpression vector 
Amplified DNA fragments were purified by gel extraction and subsequently cloned into the 
pTRIPz-backbone vector with the Gibson assembly master mix (NEB). 
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5.15 Gibson cloning of luciferase expression vector 
The luciferase vector was cloned similarily as the overexpression vectors. The Lego-iCer2 
backbone was linearized by BamH1 and BsrG1 digest and purified by gel extraction 
(QIAquick Gel Extraction Kit). The luc2 gene
418
 was amplified per PCR from an in-house 
Lego-luc2-venus vector construct, the IRES sequence from the Lego-iCer2 vector and the 
zeocin resistance cassette from an in-house miRE_Ren713_stblTomatoEz_Zeo vector. 
Following primers were used to amplify the fragments together with homologous regions for 
the Gibson assembly: 
Table 17 – Primer to anneal overhangs (small characters: homologous regions; capitals: 
overhang) 
Primer Primer Sequence 
Luc2 Fw gtcctccgattgactgagtcgcccgGATCCCAGTGTGGTGGTACGGGAATTCATGGAAGATG
CCAAAAACATTAAGAAGGGC 
Luc2 Rv ttacgtagcggccGCGGCGCGCCGGCCCTCG  
IRES Fw tcgtttagtgaaccgtcagatcgcaaccggtATGGCAGGTGTGAGTGCC 
IRES Rv gccggcgcgccgcGGCCGCTACGTAAATTCC 
ZeoR Fw ataatatggccactcgagATGGCCAAGTTGACCAGTG 
ZeoR Rv gtgctggcggccggccgctttacttgcatgcTCAGTCCTGCTCCTCGGC 
 
Amplified DNA fragments were purified by gel extraction and subsequently cloned into the 
pLego-backbone vector with the Gibson assembly master mix (NEB). 
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Figure 92 – Vector Maps of the cloned 
luciferase vector construct 
 
5.16 Plasmid amplification 
Constructs were transformed into one shot stbl3 chemically competent e.coli (Invitrogen) and 
grown on selective antibiotics agarose plates. Colonies were picked and grown in 3 mL LB-
Cultures containing carbenicillin (37°C, 160 rpm, 8h). Plasmids were isolated using QIAprep 
Spin Miniprep Kit (Qiagen) and DNA sequence analyzed by Sanger sequencing (see section 
5.17). Plasmids were further amplified by growing in 150 mL LB-cultures (37°C, 160 rpm, 
14h) and subsequent isolation using QIAprep Spin Maxiprep Kit (Qiagen). 
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5.17 Sanger Sequencing 
Plasmid DNA was isolated from stbl3 bacteria by the Plasmid Maxi Kit (QIAGEN) and sent 
for Sanger sequencing (SUPREMERUN, GATC, Eurofins) together with applicable primers 
(Table 18). Sequencing results were analyzed with ApE (v2.0.55, M. Wayne Davis, May 4, 
2018). 
Table 18 – Sequencing Primer list 
Name Direction Primer 
pTRIPz shRNA fw GGAAAGAATCAAGGAGG 
pTRIPz EM7 rv GGTCCGAGGTTCTAGACGAG 
pTRIPz UBC rv GGGTTCTAAGGCCGAGTCTT 
Lego fw AAAGAGCTCACAACCCCTCA 
Luc2 fw CGAGGTGCCTAAAGGACTGA 
Luc2 rv TCGATATGTGCGTCGGTAAA 
IRES rv GGAAAGACCCCTAGGAATGC 
ZeoR fw GTGGTCGGAGGTCGTGTC 
ZeoR rv AAGTCGTCCTCCACGAAGTC 
pTRIPz  std fw GCCTCTTCGCTATTACGCCAG 
pTRIPz  std rv TTAGGCACCCCAGGCTTTAC 
pTRIPz  M13-21 fw TGTAAAACGACGGCCAGT 
pTRIPz  M13-R rv CAGGAAACAGCTATGAC 
 
5.18 Lentiviral knockdown and overexpression of target genes 
To generate lentiviral particles, HEK-293T cells (ATCC) were cultured to a confluence of 
60 % in T150 flasks (TPP) in IMDM medium supplemented with 10 % heat-inactivated FCS 
(Thermo Scientific). Cells were pre-treated 1h before transfection with Chloroquine (25 µM). 
With the help of the calcium-phosphate transfection method as described before
248
, the 
packaging plasmid (psPAX2; 37.5 µg), the envelope plasmid (pMD2.G; 5 µg) and the 
lentiviral vector (50 µg, Table 19, section 5.14, 5.15) were transfected into HEK-293T cells. 
24 h post-transfection, medium was replaced with the collection medium (IMDM, 10 % FCS, 
1 mM Sodium Butyrate). After 24 to 36 h later, the supernatant containing the produced virus 
particles was collected, filtered (0.45 µm (Millipore) and ultra-centrifuged (SW32, 21 000 
rpm, 2 h, 4°C; Beckman Coulter). The viral pellet was resuspended in 1/500
th
 of the starting 
supernatant volume PBS and stored at -80°C. 
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The virus titer was determined by transduction of target cells in serial dilutions using 10 
µg/mL polybrene (Sigma) together with 1 µg/mL doxycycline (Sigma) and flow cytometer 
analysis 72 h later. A virus concentration of 30% transduction efficiency was chosen and 
subsequently used for cell transduction. To select for positive transduced cells, puromycin (2 
µg/mL; ThermoFisher) or Zeozine (100 µg/mL; ThermoFisher) was added to the medium and 
replaced together with the medium every other day. Untransduced cells, missing the 
resistance gene on the viral vector, were used as a selection control. Selection was performed 
until no live cells were detected in the selection control anymore. Selection efficiency was 
evaluated by inducing the cells with doxycycline 72 h and subsequent flow cytometry analysis 
of the RFP reporter protein. 
Table 19 – shRNA Vectors 
Vector Short hairpin Sequence (5’-3’) 
pTRIPz shFOXA2 V2THS_86206 AAGAGGAGTTCATAATGGG 
pTRIPz shFOXA2 V3THS_306420 TGAGGTCCATTTTGTGGGG 
pTRIPz shTSPAN8 V2THS_42312 ATAGCTTTGGCATGGTCTC 
pTRIPz shTSPAN8 V3THS_341934 AGATTTGAAAACAGCTCCT 
pTRIPz non-targeting CTTACTCTCGCCCAAGCGAGAG 
 
5.19 Growth Curves 
To obtain the growth rates of cell lines in vitro, each cell line was seeded in six technical 
replicates for each time point (KIKA75, KIKA24, KIKA38: 3000 cells/well, Corning 96-well 
clear flat bottom ultra-low attachment plates; KIKA27: 1000 cells/well, Corning 96-well clear 
flat bottom CellBind plates). Knockdown conditions were pretreated for three days with 1 
µg/ml Doxycycline prior seeding. Cell viability as an indicator for cell number was measured 
with the Cell Titer-Blue Cell Viability Assay (Promega). CellTiter-Blue (20µl CTB per 200µl 
medium) was incubated for 4 h at 37°C and measured with a fluorescent plate reader at 
560(20)Ex/590(10)Em. 
Growth rates were calculated with the help of the growthcurver package
419
 and growth rate 
differences tested for significance using the two-sided Student's t-test. With the help of mean 
regression factors, a combined growth model was calculated for each condition. 
5.20 Statistical Tests 
To compare unpaired normally distributed data, the Student’s t-test was applied. If unpaired 
data was not normally distributed (not significant Shapiro-Wilk normality test) data was 
compared using the unpaired two-samples Wilcoxon test. If not stated otherwise, Pearson 
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correlation was used to test for correlation between unordered numeric covariates. To test for 
correlation between ordered covariates, the non-parametric tau test was calculated to estimate 
the Kendall rank correlation coefficients and subsequently plotted with the help of the stats
420
 
and corrplot package
421
. 
5.21 Statistical Software and Extensions 
For statistical analysis, both GraphPad Prism 7.03 and R (3.5.1)
422
 with Bioconductor
423
 were 
used. Following R extensions were used: readr and readxl to import data into R
424,425
, 
ggplot2
426
, ggrepel
427
 and ggpubr
428
 for graphics, dplyr and reshape2 for data 
transformation
429,430
, doParallel and foreach for task parallelization and parallel computing
431
, 
knitr
432
, BiocStyle
433
 and Rmarkdown
434
 for rendering the R code into a html document.  
5.22 Gene Expression profiling 
Gene expression profiling of Genomic DNA free total RNA was performed at the Genomics 
and Proteomics DKFZ Core Facility (GPCF). RNA, extracted as stated above, with a RIN > 7 
was spotted on Illumina HumanHT12v4 BeadChips and analyzed. Sample probe profiles, 
control probe profiles and probe feature data were exported from the raw bead array scans by 
using the Gene Expression extension of GenomeStudio V2011.1 (Illumina). 
 Import and Quality Control of Expression Profiling 5.22.1
Expression data was further analyzed using R (3.5.1)
422
 and Bioconductor
423
, following the 
limma pipeline
271
. In short: The background was corrected and the samples were quantile 
normalized by using the control probes of the Illumina BeadArray and subsequently log2 
transformed
435
 (Supplemental Figure 5A-D). To reduce the multiple testing problem
436
, 
probe sets within the 0.5 quantile of the interquartile range (IQR) and duplicated entrez probes 
were removed
437
. The quality of this final dataset was analyzed to remove potential outliers
438
. 
Outliers were classified when samples were outliers in at least two of the following metrics: 
Distances between arrays, boxplots (Kolmogorov-Smirnov statistic Ka between each array's 
distribution and the distribution of the pooled data) and MA plots (Hoeffing's D-statistic). One 
sample was classified as outlier in at least two metrics and removed subsequently 
(Supplemental Figure 5E-G). Gene symbol annotation was updated using the BioMart 
database (column Illumina_HumanHT_12_v4)
439
. The final expression set was subsetted for 
differential gene expression analysis and standardized (z-score =  
𝑥−𝜇
𝜎
) for supervised 
clustering and principal component analyses. 
158  Material and Methods 
Background expression threshold was estimated by making use of the negative control probes 
on the arrays
440
. We defined probes to be expressed when their signal intensity was 10% 
above the 95 % percentile of the negative control probes. 
 Hierarchical Clustering 5.22.2
Clustering method used, if not stated otherwise, is Ward's minimum variance method
441,442
 
and the distance measured using the L1 norm (absolute distance, between two vectors, also 
called Manhattan) to calculate the distance matrix. 
 Coefficient of Determination 5.22.3
To compare whole gene expression profiles of bulk lung metastases and kidney tumors with 
the respective cell lines derived from the lung metastases of passage 4, the coefficient of 
determination (R
2
) was calculated by the square of the sample correlation coefficient of the 
linear regression. The mean of the coefficients of determination was calculated for each group 
and compared using Student’s t-test (unpaired, two-sided). 
 Principal Component Analysis 5.22.4
To reduce the multidimensional gene expression profiles, principal component analysis was 
performed on the top 500 variant genes
443,444
. Only samples of interest were included in this 
analysis to maximize the explanations of variance between the samples. 
 Methylation Array 5.22.5
DNA Methylation status of 850 million probes was assessed using the Infinium 
MethylationEPIC BeadChip (Illumina). The Genomics and Proteomics DKFZ Core Facility 
(GPCF) treated the DNA with sodium bisulfite and performed the infinium assay. Raw data 
was imported and analyzed with RnBeads
445
 and minfi
446
. Methylation profiles of seleced 
genomic regions were plotted with the Methylation plotter
298
. 
 Differential Gene Expression Analysis 5.22.6
Differential gene expression analysis of the multifactor designed experiments was performed 
fitting linear models for each probe by the limma package
270,271
. Samples were group-means 
parametrized, contrasted for the comparison of interest and statistical analysis was performed 
by an empirical Bayes method. 
5.23 ccRCC TCGA Dataset 
Level 3 RNA-Seq mRNA expression data of 532 Clear Cell Renal Cell Carcinoma patients 
(TCGA, KIRC), RSEM quantified, was downloaded from cBioportal
447,448
. Counts were 
TMM normalized, preprocessed using the voom method
449
 and standardized (z-score =  
𝑥−𝜇
𝜎
). 
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Additionally, z-scored TP53 protein expression data, measured by reverse-phase protein array, 
was downloaded from cBioportal. 
 SSIGN Score 5.23.1
The composite Mayo SSIGN score was calculated for each patient according to the scoring 
system suggested by Frank et al.
142
. Tumor stage, size, grade and necrosis was obtained from 
the clinical annotation of the dataset. Not available data was interpreted as 0 for the respective 
category. 
 Survival Analysis 5.23.2
Survival probabilities were analyzed by estimate a survival function on patient survival 
data
251. Time point of death because of the cancer (“VITAL_STATUS = “Dead” and 
“TUMOR_STATUS” = “WITH TUMOR”) was recorded as an event and patients alive 
(“VITAL_STATUS” = “Alive”) after the observation period or death of non-cancer reasons 
(“VITAL_STATUS = “Dead” and “TUMOR_STATUS” = “TUMOR FREE”) were censored 
(right-censoring). Patients were assigned to a group, Kaplan Meier estimators calculated
450
 
and plotted with the help of the survminer R package
451
. The log rank test was performed to 
test for significant differences of Kaplan Meier Estimators
452
. Hazard ratios were calculated 
using Cox’s proportional hazard model.  
 Maximally Selected Rank Statistics 5.23.3
With the help of the outcome-oriented survminer
451
 and maxstat package
286
, the cutpoint for 
stratification of low and high risk groups of patients was calculated. 
5.24 LASSO Regression 
LASSO regression in the context of Cox’s proportional hazard model was performed on 
standardized gene expression data using the coxnet function of the glmnet R package
265,273
.  
To avoid overfitting, LASSO regression was performed in 10000 iterations with 70 % 
randomly selected patients of the cohort each. The λ-value with minimal cross-validated error 
in 10-folds for each regression was selected. Only factors with non-zero regression 
coefficients in more than 50 % of the LASSO-models were selected to calculate the beta 
coefficients for the ccRCC score. C-statistics were calculated to evaluate the fit of the 
regression
453,454. Patient’s scores were calculated using the ccRCC score as the weighted sum 
of standardized gene expression. 
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 ODCF PBS Cluster 5.24.1
The iterations were calculated on the PBS cluster of the DKFZ Omics IT and Data 
Management Core Facility (ODCF). Each node of the cluster has up to 64 cores and a clock 
frequency of 2.0 - 2.7 Ghz. One node with 64 assigned cores and a maximum of 120 GB 
RAM was utilized to run the script and create the result file (loaded modules: pandoc/2.2.1 
and R/3.5.0). 
5.25 Validation ccRCC Dataset Sato et al. 
The aligned 100 bp paired-end reads (Illumina HiSeq2000) of the Sato et al.
31
 RNA 
Sequencing were downloaded from the European Genome-phenome Archive (EGA) with the 
accession number EGAS00001000509 (Data Set ID: EGAD00001000597). The expressions 
counts matrix was calculated following the workflow package rnaseqGene from 
Bioconductor
455
: The sorted bam files were imported in R
456
 and paired reads associated to 
the UCSC hg19 gene model
457
 for only those genes that are covered by the TCGA KIRC 
dataset using the GenomicAlignment package
458
. Counts were TMM normalized, preprocessed 
using the voom method
449
 and standardized using the scaling factors used for the TCGA 
Dataset. All patient samples had complete clinical features and were used for the analysis
31
. 
5.26 Multivariate Analysis 
To evaluate whether the ccRCC score is an independent prognostic variable, a proportional 
hazard model was calculated with all additional collected clinical relevant phenotypes that 
were present in > 90 % of the cohort. Model coefficients and statistics are plotted using the 
ggforest function of the survminer package
451
. 
5.27 Consensus NMF clustering 
All prognostic signatures for ccRCC that are based on gene expression data were applied on 
both the TCGA-KIRC Dataset as well as the Sato et al. dataset as proposed by Gulati et al.
267
 
by unsupervised NMF clustering using the Broad Institute’s GenePattern server 
(http://cloud.genepattern.org) with the NMFConsensus Module Version 5 and a cluster 
number from two to 10 in 2000 iterations
283
. 
5.28 C and log rank statistics 
The rank correlation (concordance index) or the log rank statistics for the censored survival 
data was calculated using the survival package
459
. 
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5.29 Intratumor heterogeneity of the ccRCC score – Subclonal 
analysis 
Subclonal microarray expression data GSE31610 and GSE53000 were downloaded from the 
Gene Expression Omnibus (GEO) archive. Clinical data and non-synonymous mutations were 
accessed from the supplemental data of Gerlinger et al.
73
. Expression data was imported in R, 
gene annotation updated using the BioMart database (column affy_hugene_1_0_st_v1)
439
 and 
expression data standardized as described before. The ccRCC Score and a corresponding 
color was calculated for each available subclonal region. Subsequently, the number of non-
synonymous was plotted against the corresponding ccRCC score of each region. When more 
than one branch was present for a region (e.g. R3min and R3dom), both branches were 
colored according to the corresponding expression data (e.g. R3). 
5.30 Gene Set Enrichment Analysis (GSEA) 
GSEA was performed by using differential gene expression data ordered by logFC as pre-
ranked list for the fgsea package
460
. 
5.31 Karyogram and Chromosome Painting 
Cells were incubated 2h with vinblastine sulfate (2 µg/mL). Next, cells were spun down 
(5min, 150 g) and resuspended in a hypotonic solution (0.275 % KCl & 0.5 % NaCitrate). 
After 20 minute incubation at 37°C, cells were spun down (5 min, 150 g) and fixed using 10 
mL of a 3:1 mixture of Methanol and Acetic Acid. Cells were incubated for 10 minutes in the 
fixative, spun down (5 min, 150 g) and resuspended in 2 mL fresh fixative. The cells were 
spread by dropping the fixated cell solution on microscope slides heated above a water bath 
(70°C). Nuclei were either stained with DAPI for a karyogram or chromosomes individually 
stained, performed by Dr. Larisa Savelyeva. 
5.32 SNP Array 
SNPs array hybridization was performed at the Genomics and Proteomics DKFZ Core 
Facility (GPCF). Genomic DNA, extracted as stated above, with a RIN > 7 was spotted on 
Illumina InfiniumOmni2-5-8v1-3 BeadChips and analyzed. Signal and feature data were 
exported from the raw bead array scans by using the Genotyping extension of GenomeStudio 
2.0 (Illumina). 
CNV analysis was performed by the CNV Analysis tool of GenomeStudio 2.0 and CNVs 
plotted by the Circos software
461
. 
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5.33 Graphics Software 
Adobe Illustrator CS6 and BioRender was used to design figures, Adobe Photoshop CS6 to 
resize histological images. 
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Supplemental Figure 1 – Circos plot of the CNA of all KIKA models 
The copy number alterations were identified by the Infinium Omni2.5-8 SNP array. 
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Supplemental Figure 2 – Immunophenotypisation of the KIKA cell lines 
Cell surface markers measured by flow cytometry were sorted according to the number of cell lines expressing a 
surface marker (5% above respective isotype) and according to the standardized robust coefficient of variation 
(CV). 
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Supplemental Figure 3 – Gating Scheme BB515::CD54/ICAM1 
(a) KIKA24, (b) KIKA27, (c) KIKA38, (d) KIKA75 
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Supplemental Figure 4 – Genome of KIKA75 
a) Karyogram and chromosome painting of the KIKA75 cell line, made by Larisa Savelyeva 
b) Copy number alterations of KIKA75 by whole exome sequencing, analyzed by Gregor Warsow 
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Supplemental Figure 5 – Quality control of microarray data 
Boxplot of Log2 probe intensities of the 87 samples analyzed Illumina HT12v4 BeadArrays before (A) and after 
(B) background correction and quantile-normalization. (C) Not normalized and (D) background corrected and 
quantile-normalized ranked log2 means of all probes on all arrays against their standard deviations 
ArrayQualityMetrics quality control: Bar chart and figure legends were adapted from the package output 
(E) Outlier detection for Distances between arrays: Sum of distances to other arrays Sa. Based on the distribution 
of the values across all arrays, a threshold of 59.8 was determined, 3 arrays exceeded the threshold and were 
considered outliers. (F) Outlier detection for Boxplots: Kolmogorov-Smirnov statistic Ka. Based on the distribution 
of the values across all arrays, a threshold of 0.0667 was determined, 5 arrays exceeded the threshold and were 
considered outliers. (G) Outlier detection for MA plots: Da. A threshold of 0.15 was used, None of the arrays 
exceeded the threshold and was considered an outlier. Vertical lines indicate outlier thresholds. (H) Dendrogram 
of the standardized samples (z-scores) with Manhattan distance and Ward’s linkage. Cell line derived cluster 
apart from xenograft derived RNA expression profiles. 
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Supplemental Figure 6 – PANTHER overrepresentation test for the gene ontology of the 
differentially expressed genes, that are not differentially expressed between passage 4 lung 
metastases derived cell lines and the originating cell line 
Terms of the same biological items are colored identically. PANTHER Overrepresentation Test (Released 2018-
11-13), GO Ontology database released 2018-12-01, Fisher’s exact test, Bonferroni correction for multiple testing. 
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Characteristic TCGA KIRC (n = 532) Sato et al. (n = 100) 
Age – yr   
   Mean 60.6 ± 12.1 63.7 ± 11.4 
   Median (range) 61.0 (26-90) 64 (25-91) 
Sex – no. (%)   
  Female 188 (35.3) 23 (23) 
  Male 344 (64.7) 77 (77) 
Race – no. (%)   
  Asian 8 (1.5)  
  Black or African American 55 (10.3)  
  Caucasian 462 (86.8)  
  Not Available 7 (1.3)  
Ethnicity – no. (%)   
  Hispanic or Latino 26 (4.9)  
  Other 354 (66.5)  
  Not Available 152 (28.6)  
TNM Classification – no. (%)   
  Stage I 266 (50.0) 65 (65) 
  Stage II 57 (10.7) 10 (10) 
  Stage III 123 (23.1) 13 (13) 
  Stage IV 83 (15.6) 12 (12) 
  Discrepancy 3 (0.6)  
Fuhrman Grade – no. (%)   
  G1 14 (2.6) 13 (13) 
  G2 228 (42.9) 58 (58) 
  G3 206 (38.7) 22 (22) 
  G4 76 (14.3) 5 (5) 
  GX / Not Available 8 (1.5) 2 (2) 
Laterality – no. (%)   
  Left 251 (47.2)  
  Right 280 (52.6)  
  Bilateral 1 (0.2)  
VHL mutated – no. (%) 225 (42.3) 66 (66) 
History of Neoadjuvant Treatment – no. (%) 17 (3.2) 100 (100) 
White Blood Cell counts – no. (%)   
  Normal 266 (50.0)  
  Elevated 164 (30.8)  
  Low 8 (1.5)  
  Not Available 94 (17.7)  
Hemoglobin level – no. (%)   
  Normal 184 (15.2)  
  Elevated 5 (0.9)  
  Low 262 (49.2)  
  Not Available 81 (34.6)  
Platelet Count – no. (%)   
  Normal 358 (67.3)  
  Elevated 37 (7.0)  
  Low 46 (8.6)  
  Not Available 91 (17.1)  
IDH Level – no. (%)   
  Normal 72 (13.5)  
  Elevated 12 (2.2)  
  Not Available 448 (84.2)  
Median follow-up 1199 days 1536 days 
Total no. of deaths 175 23 
No. of deaths from ccRCC 104  
 
Supplemental Figure 7 – Patient classification of the TCGA KIRC and Sato et al. ccRCC 
cohort 
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Supplemental Figure 8 – Excluded differential expressed genes 
Genes of the in vivo selection that were differentially expressed between the microarrays, but could not be 
validated by quantitative TaqMan real-time PCR. P values calculated using an unpaired, two-sided Student’s 
t-test. Error bars depict mean ± s.e.m. 
 
 
Symbol (Entrez ID) Center Scale 
IL13RA2 (3598) -0.215532994647864 1.94353172038516 
SLC2A9 (56606) 4.0200715670196 1.22002756911761 
PTPN13 (5783) 5.36338272647119 0.854811787225463 
CXCL5 (6374) 0.363609006323805 3.24779314225545 
PRDX2 (7001) 7.29049780755846 0.802574629971008 
TSPAN8 (7103) -0.878408470041345 2.79943988032313 
ONECUT2 (9480) -1.57348772908843 2.19490878291467 
 
Supplemental Figure 9 – Scaling factors from the TCGA-KIRC dataset used to standardize 
microarray data 
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Characteristic Heidelberg (n = 13) 
Age – yr  
   Mean 64.0 ± 11.63 
   Median (range) 64.0 (49-87) 
Sex – no. (%)  
  Female 2 (15,4) 
  Male 11 (84.6) 
TNM Classification – no. (%)  
  Stage I 3 (23.1) 
  Stage II 0 (0) 
  Stage III 3 (23.1) 
  Stage IV 7 (53.8) 
Fuhrman Grade – no. (%)  
  G1 1 (7.7) 
  G2 5 (38.5) 
  G3 5 (38.5) 
  G4 2 (15.4) 
Laterality – no. (%)  
  Left 6 (46.2) 
  Right 5 (38.5) 
  Bilateral 1 (7.7) 
  NA 1 (7.7) 
Median follow-up 431 days 
Total no. of deaths 2 (15.4) 
No. of deaths from ccRCC 1 (7.7) 
 
Supplemental Figure 10 – Patient classification of the Heidelberg ccRCC cohort 
 
Patient PFS event PFS days Stage ccRCC Score ccRCC Score - 3 risk groups 
RCC8 0 1443 III 0.3968 intermediate 
RCC12 1 77 III 1.4033 high 
RCC15 0 5 IV 1.7475 high 
RCC18 0 431 IV 1.8590 high 
RCC20 1 462 IV 1.8051 high 
RCC23 0 1862 I -1.0635 intermediate 
RCC24 1 16 IV 3.7268 high 
RCC27 1 22 IV 2.9468 high 
RCC28 1 530 I -1.0825 intermediate 
RCC38 0 157 IV 3.6582 high 
RCC40 0 1145 I -1.3892 intermediate 
RCC50 1 9 IV 2.9063 high 
RCC75 1 90 III 1.7267 high 
 
Supplemental Figure 11 – Heidelberg Mini Cohort Patient Classification 
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Patient Region Distance Risk Catagory 5-year 
survival 
rate [%] 
Hazard 
Rate 
ccRCC 
Score 
Hex-
Color-
Code 
EV001 M2a 68 High Risk 24.52 2.79 1.985 #B25700 
EV001 M2b 61 Intermediate Risk 78.02 1.17 0.251 #DDB400 
EV001 R1 71 High Risk 32.85 2.74 1.752 #B86400 
EV001 R2 72 High Risk 43.08 2.63 1.473 #BE7100 
EV001 R3 70 High Risk 12.18 2.95 2.389 #A84000 
EV001 R4a 48 Intermediate Risk 82.28 0.77 0.010 #E2C100 
EV001 R5 68 High Risk 28.44 2.76 1.873 #B55C00 
EV001 R8 69 High Risk 17.15 2.86 2.211 #AC4A00 
EV002 R1 41 High Risk 0.06 4.50 3.642 #8B0000 
EV002 R3 53 High Risk 0.31 4.14 3.396 #900C00 
EV002 R4 46 High Risk 23.59 2.79 2.012 #B15400 
EV002 R7 47 High Risk 1.55 3.65 3.071 #971C00 
EV002 R9 52 High Risk 1.56 3.62 3.070 #971C00 
EV003 R1 35 High Risk 29.04 2.76 1.857 #B55C00 
EV003 R2 38 High Risk 31.31 2.75 1.794 #B76100 
EV003 R5 39 High Risk 0.56 3.94 3.290 #931200 
EV003 R6 45 High Risk 0.24 4.14 3.441 #8F0A00 
EV003 R7 36 High Risk 32.43 2.74 1.763 #B76100 
EV005 R1 43 High Risk 18.76 2.85 2.159 #AE4D00 
EV005 R2 46 High Risk 1.62 3.62 3.061 #991E00 
EV005 R3 43 High Risk 2.65 3.46 2.934 #9B2400 
EV005 R4 41 High Risk 40.85 2.67 1.534 #BD6E00 
EV005 R5 42 High Risk 60.92 2.22 0.943 #CB8D00 
EV005 R6dom 45 High Risk 44.25 2.63 1.440 #BF7300 
EV005 R7 48 High Risk 45.22 2.61 1.413 #C07600 
EV006 R1 59 Intermediate Risk 75.84 1.38 0.359 #DAAF00 
EV006 R2 60 Intermediate Risk 74.28 1.52 0.431 #D8AA00 
EV006 R3 58 High Risk 46.85 2.58 1.368 #C27900 
EV006 R4 59 High Risk 66.51 1.97 0.748 #D09700 
EV006 R7 64 Intermediate Risk 74.29 1.52 0.431 #D8AA00 
EV006 R15 60 High Risk 73.67 1.54 0.459 #D7A700 
EV006 N1a 57 Intermediate Risk 81.36 0.88 0.066 #E1BE00 
EV006 N1b 57 High Risk 64.87 2.02 0.807 #CE9500 
EV007 R1 34 High Risk 7.49 3.09 2.597 #A33600 
EV007 R2 36 High Risk 2.79 3.46 2.919 #9B2400 
EV007 R3min 32 High Risk 12.73 2.92 2.368 #A94200 
EV007 R4 33 High Risk 39.15 2.69 1.580 #BC6C00 
EV007 R5 29 High Risk 17.55 2.85 2.198 #AC4A00 
EV007 R6 45 High Risk 12.63 2.92 2.372 #A94200 
EV007 R9dom 32 High Risk 49.65 2.52 1.288 #C37B00 
RMH002 R1 24 High Risk 49.27 2.55 1.299 #C37B00 
RMH002 R2 17 High Risk 19.18 2.85 2.146 #AE4D00 
RMH002 R3 30 High Risk 44.20 2.63 1.442 #BF7300 
RMH002 R6 29 High Risk 22.58 2.81 2.042 #B15400 
RMH004 R2 70 High Risk 1.18 3.65 3.135 #961900 
RMH004 R3 41 High Risk 51.85 2.49 1.224 #C58000 
RMH004 R4 60 High Risk 2.99 3.46 2.900 #9C2600 
RMH004 R8 54 High Risk 7.81 3.09 2.581 #A33600 
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RMH004 VT 42 High Risk 52.54 2.49 1.204 #C58000 
RMH008 R1 37 Intermediate Risk 88.60 0.03 -0.467 #EEDA00 
RMH008 R2 45 Intermediate Risk 88.14 0.10 -0.426 #EDD800 
RMH008 R3 38 Intermediate Risk 90.17 -0.18 -0.624 #F2E200 
RMH008 R4min 41 Intermediate Risk 89.08 -0.03 -0.513 #EFDD00 
RMH008 R6min 40 Intermediate Risk 88.64 0.02 -0.471 #EEDA00 
RMH008 R8 38 Intermediate Risk 92.12 -0.48 -0.856 #F7EF00 
RK26 R1 31 Intermediate Risk 94.26 -0.86 -1.184 #FFFF00 
RK26 R2 34 Intermediate Risk 94.11 -0.82 -1.158 #FFFF00 
RK26 R3 30 Intermediate Risk 93.37 -0.68 -1.035 #FBF700 
RK26 R4 30 Intermediate Risk 93.13 -0.65 -0.999 #FBF700 
RK26 R5dom 13 Intermediate Risk 91.87 -0.43 -0.822 #F6EC00 
RK26 R7 9 Intermediate Risk 87.86 0.12 -0.400 #ECD500 
RK26 R8 18 Intermediate Risk 89.72 -0.12 -0.577 #F0E000 
RK26 R10 17 Intermediate Risk 86.21 0.34 -0.264 #E8CE00 
RK26 R11 19 Intermediate Risk 87.25 0.18 -0.348 #EBD300 
 
Supplemental Figure 12 – Multiregion ccRCC Score analysis 
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Supplemental Figure 13 – Gating Scheme of TS29.2  
(a) KIKA24, (b) KIKA27, (c) KIKA38 and (d) KIKA75 
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Patient 
CSS 
days 
CSS 
event 
ccRCC early score 
ccRCC early Score - 3 risk 
groups 
ccRCC early Score - 2 risk 
groups 
ccRCC Score 
ccRCC Score - 3 risk 
groups 
ccRCC Score - 2 risk 
groups 
Grade Gender 
TCGA-6D-AA2E 362 0 -1.4140 Intermediate Risk Low Risk -1.5342 Intermediate Risk Low Risk G2 FEMALE 
TCGA-A3-3306 1119 0 -2.8345 Low Risk Low Risk -3.0754 Low Risk Low Risk G3 MALE 
TCGA-A3-3307 1435 0 -0.5873 Intermediate Risk High Risk -0.6372 Intermediate Risk High Risk G3 MALE 
TCGA-A3-3308 16 0 0.4782 High Risk High Risk 0.5188 High Risk High Risk G2 FEMALE 
TCGA-A3-3311 1190 0 -1.3597 Intermediate Risk Low Risk -1.4752 Intermediate Risk Low Risk G2 MALE 
TCGA-A3-3313 735 0 -2.3533 Low Risk Low Risk -2.5533 Low Risk Low Risk G3 MALE 
TCGA-A3-3316 1492 0 0.8343 High Risk High Risk 0.9052 High Risk High Risk G3 MALE 
TCGA-A3-3317 1490 0 -0.2335 Intermediate Risk High Risk -0.2533 Intermediate Risk High Risk G2 MALE 
TCGA-A3-3319 1129 0 -1.0845 Intermediate Risk Low Risk -1.1766 Intermediate Risk Low Risk G2 MALE 
TCGA-A3-3320 1507 0 -1.8050 Low Risk Low Risk -1.9584 Low Risk Low Risk G1 FEMALE 
TCGA-A3-3322 1477 0 -1.7014 Low Risk Low Risk -1.8460 Low Risk Low Risk G2 MALE 
TCGA-A3-3323 1105 0 -1.4207 Intermediate Risk Low Risk -1.5415 Intermediate Risk Low Risk G1 MALE 
TCGA-A3-3324 1185 0 -2.1367 Low Risk Low Risk -2.3183 Low Risk Low Risk G3 MALE 
TCGA-A3-3325 1169 0 -1.3895 Intermediate Risk Low Risk -1.5076 Intermediate Risk Low Risk G2 MALE 
TCGA-A3-3326 1136 0 -2.0203 Low Risk Low Risk -2.1920 Low Risk Low Risk G1 MALE 
TCGA-A3-3328 1384 0 -1.2453 Intermediate Risk Low Risk -1.3512 Intermediate Risk Low Risk G2 MALE 
TCGA-A3-3329 1623 0 -1.9442 Low Risk Low Risk -2.1094 Low Risk Low Risk G2 MALE 
TCGA-A3-3331 1484 0 -1.7507 Low Risk Low Risk -1.8994 Low Risk Low Risk G2 FEMALE 
TCGA-A3-3335 1885 0 -0.3869 Intermediate Risk High Risk -0.4197 Intermediate Risk High Risk G4 MALE 
TCGA-A3-3343 944 0 0.0692 High Risk High Risk 0.0751 Intermediate Risk High Risk G3 MALE 
TCGA-A3-3346 137 1 0.6787 High Risk High Risk 0.7364 High Risk High Risk G3 MALE 
TCGA-A3-3347 1609 0 0.5500 High Risk High Risk 0.5968 High Risk High Risk G2 FEMALE 
TCGA-A3-3349 1384 0 -1.5425 Intermediate Risk Low Risk -1.6736 Intermediate Risk Low Risk G2 FEMALE 
TCGA-A3-3351 909 0 0.2123 High Risk High Risk 0.2304 Intermediate Risk High Risk G2 MALE 
TCGA-A3-3352 561 0 -0.0955 Intermediate Risk High Risk -0.1036 Intermediate Risk High Risk G3 MALE 
TCGA-A3-3357 2686 0 -0.6345 Intermediate Risk High Risk -0.6884 Intermediate Risk High Risk G3 MALE 
TCGA-A3-3358 1306 0 -1.5430 Intermediate Risk Low Risk -1.6741 Intermediate Risk Low Risk G2 FEMALE 
TCGA-A3-3359 2502 0 -1.9511 Low Risk Low Risk -2.1169 Low Risk Low Risk G2 FEMALE 
TCGA-A3-3362 1558 0 -1.8580 Low Risk Low Risk -2.0159 Low Risk Low Risk G2 FEMALE 
TCGA-A3-3363 319 0 -0.2076 Intermediate Risk High Risk -0.2252 Intermediate Risk High Risk G2 MALE 
TCGA-A3-3365 872 0 -0.8871 Intermediate Risk Low Risk -0.9625 Intermediate Risk Low Risk G2 MALE 
TCGA-A3-3367 2268 0 -2.0275 Low Risk Low Risk -2.1998 Low Risk Low Risk G3 MALE 
TCGA-A3-3370 2272 0 -2.2710 Low Risk Low Risk -2.4640 Low Risk Low Risk G2 FEMALE 
TCGA-A3-3372 735 0 -0.2470 Intermediate Risk High Risk -0.2680 Intermediate Risk High Risk G2 MALE 
TCGA-A3-3373 1620 0 -1.6052 Low Risk Low Risk -1.7416 Low Risk Low Risk G3 FEMALE 
TCGA-A3-3374 1313 0 -1.2375 Intermediate Risk Low Risk -1.3427 Intermediate Risk Low Risk G2 FEMALE 
TCGA-A3-3376 1695 0 -1.6540 Low Risk Low Risk -1.7945 Low Risk Low Risk G2 MALE 
TCGA-A3-3378 630 0 -1.2560 Intermediate Risk Low Risk -1.3628 Intermediate Risk Low Risk G3 MALE 
TCGA-A3-3380 567 0 -1.7500 Low Risk Low Risk -1.8988 Low Risk Low Risk G2 MALE 
TCGA-A3-3382 574 0 -0.8323 Intermediate Risk Low Risk -0.9031 Intermediate Risk Low Risk G3 MALE 
TCGA-A3-3383 860 0 -1.9153 Low Risk Low Risk -2.0781 Low Risk Low Risk G2 MALE 
TCGA-A3-3385 1991 0 -2.0145 Low Risk Low Risk -2.1857 Low Risk Low Risk G2 FEMALE 
TCGA-A3-3387 617 0 -1.6678 Low Risk Low Risk -1.8096 Low Risk Low Risk G2 MALE 
TCGA-A3-A6NI 1017 0 -1.9423 Low Risk Low Risk -2.1073 Low Risk Low Risk G3 MALE 
TCGA-A3-A6NJ 468 0 -1.8329 Low Risk Low Risk -1.9887 Low Risk Low Risk G1 FEMALE 
TCGA-A3-A6NL 688 0 -1.9185 Low Risk Low Risk -2.0815 Low Risk Low Risk G2 FEMALE 
TCGA-A3-A6NN 3 0 -0.9085 Intermediate Risk Low Risk -0.9857 Intermediate Risk Low Risk G2 MALE 
TCGA-A3-A8CQ 3 0 -2.0304 Low Risk Low Risk -2.2029 Low Risk Low Risk G2 FEMALE 
TCGA-A3-A8OU 0 0 -1.4157 Intermediate Risk Low Risk -1.5360 Intermediate Risk Low Risk G1 FEMALE 
TCGA-A3-A8OV 340 0 -2.1105 Low Risk Low Risk -2.2899 Low Risk Low Risk G2 MALE 
TCGA-A3-A8OW 323 0 -0.9255 Intermediate Risk Low Risk -1.0041 Intermediate Risk Low Risk G2 MALE 
TCGA-A3-A8OX 0 0 -1.3873 Intermediate Risk Low Risk -1.5052 Intermediate Risk Low Risk G3 FEMALE 
TCGA-AK-3425 3340 0 -0.9485 Intermediate Risk Low Risk -1.0291 Intermediate Risk Low Risk G2 MALE 
TCGA-AK-3426 884 1 1.1683 High Risk High Risk 1.2675 High Risk High Risk G3 MALE 
TCGA-AK-3427 3580 0 -0.9834 Intermediate Risk Low Risk -1.0669 Intermediate Risk Low Risk GX MALE 
TCGA-AK-3428 3725 0 -0.2411 Intermediate Risk High Risk -0.2615 Intermediate Risk High Risk G2 MALE 
TCGA-AK-3429 3325 0 -0.2396 Intermediate Risk High Risk -0.2600 Intermediate Risk High Risk G2 FEMALE 
TCGA-AK-3431 2239 0 0.8230 High Risk High Risk 0.8930 High Risk High Risk G3 FEMALE 
TCGA-AK-3433 3406 0 -0.4970 Intermediate Risk High Risk -0.5393 Intermediate Risk High Risk GX FEMALE 
TCGA-AK-3434 2085 0 -1.9926 Low Risk Low Risk -2.1619 Low Risk Low Risk G2 MALE 
TCGA-AK-3436 3328 0 -0.6786 Intermediate Risk High Risk 0.8845 High Risk High Risk G2 MALE 
TCGA-AK-3440 2863 0 -1.5611 Intermediate Risk Low Risk -1.6937 Intermediate Risk Low Risk G3 MALE 
TCGA-AK-3443 1422 0 -0.5340 Intermediate Risk High Risk -0.5794 Intermediate Risk High Risk GX MALE 
TCGA-AK-3444 1470 0 -2.3560 Low Risk Low Risk -2.5563 Low Risk Low Risk G2 FEMALE 
TCGA-AK-3445 2390 0 -0.1280 Intermediate Risk High Risk -0.1389 Intermediate Risk High Risk G3 MALE 
TCGA-AK-3447 1216 0 0.0281 Intermediate Risk High Risk 0.0305 Intermediate Risk High Risk G2 MALE 
TCGA-AK-3450 1778 0 -1.5721 Low Risk Low Risk -1.7057 Low Risk Low Risk G2 FEMALE 
TCGA-AK-3451 2866 0 -0.2055 Intermediate Risk High Risk -0.2230 Intermediate Risk High Risk G3 MALE 
TCGA-AK-3453 2529 0 0.3691 High Risk High Risk 0.4004 Intermediate Risk High Risk G2 FEMALE 
TCGA-AK-3454 873 0 -2.2949 Low Risk Low Risk -2.4899 Low Risk Low Risk G3 MALE 
TCGA-AK-3455 683 0 -0.0201 Intermediate Risk High Risk -0.0218 Intermediate Risk High Risk G3 FEMALE 
TCGA-AK-3456 1142 0 -0.8695 Intermediate Risk Low Risk -0.9434 Intermediate Risk Low Risk G3 MALE 
TCGA-AK-3458 1167 0 -1.2427 Intermediate Risk Low Risk -1.3484 Intermediate Risk Low Risk G3 MALE 
TCGA-AK-3460 2506 0 -1.7010 Low Risk Low Risk -1.8456 Low Risk Low Risk G2 MALE 
TCGA-AK-3461 2215 0 -1.2685 Intermediate Risk Low Risk -1.3763 Intermediate Risk Low Risk G2 MALE 
TCGA-AK-3465 369 0 -0.6426 Intermediate Risk High Risk -0.6972 Intermediate Risk High Risk GX FEMALE 
TCGA-AS-3777 1237 0 -0.2147 Intermediate Risk High Risk -0.2329 Intermediate Risk High Risk [Not Available] MALE 
TCGA-AS-3778 43 0 -2.3841 Low Risk Low Risk -2.5867 Low Risk Low Risk G1 MALE 
TCGA-B0-4688 101 1 1.3040 High Risk High Risk 3.0356 High Risk High Risk G4 MALE 
TCGA-B0-4690 43 1 0.9824 High Risk High Risk 2.6868 High Risk High Risk G3 MALE 
TCGA-B0-4691 139 1 -0.0660 Intermediate Risk High Risk 1.5492 High Risk High Risk G3 MALE 
TCGA-B0-4693 77 0 -0.8734 Intermediate Risk Low Risk -0.9476 Intermediate Risk Low Risk G4 FEMALE 
TCGA-B0-4694 106 0 0.1581 High Risk High Risk 0.1715 Intermediate Risk High Risk G4 MALE 
TCGA-B0-4696 865 1 3.1386 High Risk High Risk 3.4053 High Risk High Risk G3 MALE 
TCGA-B0-4697 578 1 0.8889 High Risk High Risk 2.5853 High Risk High Risk G4 FEMALE 
TCGA-B0-4698 42 1 1.8446 High Risk High Risk 3.6222 High Risk High Risk G4 MALE 
TCGA-B0-4699 110 0 0.8049 High Risk High Risk 2.4942 High Risk High Risk G4 MALE 
TCGA-B0-4700 1979 1 0.7547 High Risk High Risk 2.4397 High Risk High Risk G4 MALE 
TCGA-B0-4701 238 1 0.0261 Intermediate Risk High Risk 1.6491 High Risk High Risk G3 FEMALE 
TCGA-B0-4703 182 1 0.2521 High Risk High Risk 1.8944 High Risk High Risk G4 MALE 
TCGA-B0-4706 65 0 0.3563 High Risk High Risk 0.3866 Intermediate Risk High Risk G4 MALE 
TCGA-B0-4707 600 1 0.8212 High Risk High Risk 0.8909 High Risk High Risk G4 MALE 
TCGA-B0-4710 1754 0 -0.3385 Intermediate Risk High Risk -0.3673 Intermediate Risk High Risk G3 FEMALE 
TCGA-B0-4712 1336 1 1.3250 High Risk High Risk 3.0585 High Risk High Risk G3 MALE 
TCGA-B0-4713 202 1 0.5719 High Risk High Risk 0.6206 High Risk High Risk G2 FEMALE 
TCGA-B0-4714 99 1 0.1173 High Risk High Risk 1.7481 High Risk High Risk G3 MALE 
TCGA-B0-4718 1777 0 0.5897 High Risk High Risk 0.6399 High Risk High Risk G2 MALE 
TCGA-B0-4810 478 1 0.4743 High Risk High Risk 0.5146 High Risk High Risk G3 MALE 
TCGA-B0-4811 1416 1 0.3546 High Risk High Risk 0.3848 Intermediate Risk High Risk G3 MALE 
TCGA-B0-4813 18 0 2.0188 High Risk High Risk 2.1904 High Risk High Risk G3 MALE 
TCGA-B0-4814 168 1 0.0101 Intermediate Risk High Risk 1.6318 High Risk High Risk G3 MALE 
TCGA-B0-4815 1587 1 1.6551 High Risk High Risk 1.7957 High Risk High Risk G4 MALE 
TCGA-B0-4816 1370 1 0.3745 High Risk High Risk 0.4063 Intermediate Risk High Risk G3 MALE 
TCGA-B0-4817 1018 0 1.0691 High Risk High Risk 1.1599 High Risk High Risk G3 MALE 
TCGA-B0-4818 509 1 -0.2116 Intermediate Risk High Risk -0.2296 Intermediate Risk High Risk G3 FEMALE 
TCGA-B0-4819 183 0 0.7898 High Risk High Risk 2.4778 High Risk High Risk G4 FEMALE 
TCGA-B0-4821 1229 1 0.9584 High Risk High Risk 1.0398 High Risk High Risk G3 FEMALE 
TCGA-B0-4822 1110 1 0.4385 High Risk High Risk 0.4757 High Risk High Risk G4 MALE 
TCGA-B0-4823 454 0 -1.7767 Low Risk Low Risk -1.9277 Low Risk Low Risk G2 MALE 
TCGA-B0-4824 1656 0 -1.6055 Low Risk Low Risk -1.7419 Low Risk Low Risk G3 FEMALE 
TCGA-B0-4827 884 1 0.9361 High Risk High Risk 1.0157 High Risk High Risk G4 FEMALE 
TCGA-B0-4828 307 1 -0.4322 Intermediate Risk High Risk 1.1519 High Risk High Risk G3 MALE 
TCGA-B0-4833 2384 1 -1.1976 Intermediate Risk Low Risk -1.2993 Intermediate Risk Low Risk G2 FEMALE 
TCGA-B0-4834 2088 0 -1.0909 Intermediate Risk Low Risk -1.1836 Intermediate Risk Low Risk G3 MALE 
TCGA-B0-4836 1237 1 0.9835 High Risk High Risk 2.6879 High Risk High Risk G3 MALE 
TCGA-B0-4837 1377 1 0.6228 High Risk High Risk 0.6757 High Risk High Risk G3 MALE 
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TCGA-B0-4838 833 0 -1.7009 Low Risk Low Risk -1.8455 Low Risk Low Risk G3 FEMALE 
TCGA-B0-4839 1638 0 -1.1809 Intermediate Risk Low Risk -1.2813 Intermediate Risk Low Risk G2 FEMALE 
TCGA-B0-4841 204 1 0.5836 High Risk High Risk 2.2540 High Risk High Risk G3 MALE 
TCGA-B0-4842 1723 1 0.7983 High Risk High Risk 0.8662 High Risk High Risk G4 FEMALE 
TCGA-B0-4843 320 1 1.3081 High Risk High Risk 1.4193 High Risk High Risk G3 MALE 
TCGA-B0-4844 313 1 0.6625 High Risk High Risk 2.3397 High Risk High Risk G3 MALE 
TCGA-B0-4845 1984 1 0.0528 Intermediate Risk High Risk 1.6781 High Risk High Risk G2 MALE 
TCGA-B0-4846 1199 1 0.0656 High Risk High Risk 1.6920 High Risk High Risk G2 MALE 
TCGA-B0-4847 792 0 -0.0203 Intermediate Risk High Risk 1.5988 High Risk High Risk G3 MALE 
TCGA-B0-4848 882 1 0.8808 High Risk High Risk 0.9556 High Risk High Risk G3 MALE 
TCGA-B0-4849 69 1 -0.0018 Intermediate Risk High Risk -0.0019 Intermediate Risk High Risk G3 MALE 
TCGA-B0-4852 1120 1 -0.1085 Intermediate Risk High Risk -0.1177 Intermediate Risk High Risk G2 FEMALE 
TCGA-B0-4945 2143 0 -1.3919 Intermediate Risk Low Risk -1.5102 Intermediate Risk Low Risk G2 FEMALE 
TCGA-B0-5075 637 0 -0.2105 Intermediate Risk High Risk -0.2284 Intermediate Risk High Risk G2 FEMALE 
TCGA-B0-5077 1316 0 -1.2352 Intermediate Risk Low Risk -1.3401 Intermediate Risk Low Risk G3 MALE 
TCGA-B0-5080 342 1 -0.1186 Intermediate Risk High Risk 1.4922 High Risk High Risk G3 MALE 
TCGA-B0-5081 362 1 0.5210 High Risk High Risk 0.5652 High Risk High Risk G2 FEMALE 
TCGA-B0-5083 1044 1 -0.8838 Intermediate Risk Low Risk -0.9589 Intermediate Risk Low Risk G3 MALE 
TCGA-B0-5084 222 1 1.5728 High Risk High Risk 3.3273 High Risk High Risk G3 MALE 
TCGA-B0-5085 770 0 -0.4087 Intermediate Risk High Risk -0.4434 Intermediate Risk High Risk G3 FEMALE 
TCGA-B0-5088 563 0 -1.7844 Low Risk Low Risk -1.9361 Low Risk Low Risk G3 MALE 
TCGA-B0-5092 459 1 -0.1500 Intermediate Risk High Risk 1.4581 High Risk High Risk G3 FEMALE 
TCGA-B0-5094 333 1 0.6731 High Risk High Risk 2.3511 High Risk High Risk G2 MALE 
TCGA-B0-5095 245 0 0.2816 High Risk High Risk 0.3055 Intermediate Risk High Risk G3 MALE 
TCGA-B0-5096 68 0 1.0803 High Risk High Risk 1.1721 High Risk High Risk GX FEMALE 
TCGA-B0-5097 665 0 0.9733 High Risk High Risk 1.0560 High Risk High Risk G2 FEMALE 
TCGA-B0-5098 1583 0 0.3707 High Risk High Risk 0.4022 Intermediate Risk High Risk G3 FEMALE 
TCGA-B0-5099 485 0 -0.6952 Intermediate Risk High Risk -0.7543 Intermediate Risk High Risk G3 FEMALE 
TCGA-B0-5100 1911 1 0.8562 High Risk High Risk 0.9289 High Risk High Risk G3 MALE 
TCGA-B0-5102 2762 0 -1.3689 Intermediate Risk Low Risk -1.4852 Intermediate Risk Low Risk G3 FEMALE 
TCGA-B0-5104 2750 0 -1.5655 Intermediate Risk Low Risk -1.6985 Intermediate Risk Low Risk G2 FEMALE 
TCGA-B0-5106 1597 0 -1.0251 Intermediate Risk Low Risk -1.1123 Intermediate Risk Low Risk G2 MALE 
TCGA-B0-5107 926 1 0.0043 Intermediate Risk High Risk 1.6255 High Risk High Risk G4 FEMALE 
TCGA-B0-5108 1781 0 0.3549 High Risk High Risk 0.3851 Intermediate Risk High Risk G2 MALE 
TCGA-B0-5109 586 1 2.4685 High Risk High Risk 2.6783 High Risk High Risk G4 MALE 
TCGA-B0-5110 2008 0 -1.4766 Intermediate Risk Low Risk -1.6020 Intermediate Risk Low Risk G2 FEMALE 
TCGA-B0-5113 1174 0 -0.0427 Intermediate Risk High Risk -0.0463 Intermediate Risk High Risk G2 FEMALE 
TCGA-B0-5115 1603 0 -0.0929 Intermediate Risk High Risk 1.5200 High Risk High Risk G3 MALE 
TCGA-B0-5116 1273 0 -0.4293 Intermediate Risk High Risk -0.4658 Intermediate Risk High Risk G3 MALE 
TCGA-B0-5117 1607 0 -1.2101 Intermediate Risk Low Risk -1.3129 Intermediate Risk Low Risk G2 MALE 
TCGA-B0-5119 1551 0 -1.7734 Low Risk Low Risk -1.9242 Low Risk Low Risk G2 FEMALE 
TCGA-B0-5120 1168 0 -1.2359 Intermediate Risk Low Risk -1.3409 Intermediate Risk Low Risk G2 FEMALE 
TCGA-B0-5121 1484 0 -1.4845 Intermediate Risk Low Risk -1.6106 Intermediate Risk Low Risk G2 MALE 
TCGA-B0-5399 1410 0 -1.5174 Intermediate Risk Low Risk -1.6464 Intermediate Risk Low Risk G2 MALE 
TCGA-B0-5400 1732 0 0.8731 High Risk High Risk 0.9473 High Risk High Risk G4 FEMALE 
TCGA-B0-5402 1289 0 -0.8212 Intermediate Risk Low Risk 0.7298 High Risk High Risk G4 MALE 
TCGA-B0-5690 3389 0 -1.4822 Intermediate Risk Low Risk -1.6082 Intermediate Risk Low Risk G1 FEMALE 
TCGA-B0-5691 3428 0 -1.6741 Low Risk Low Risk -1.8164 Low Risk Low Risk G3 FEMALE 
TCGA-B0-5692 3941 0 -0.5727 Intermediate Risk High Risk -0.6214 Intermediate Risk High Risk G3 FEMALE 
TCGA-B0-5693 4071 0 -2.1441 Low Risk Low Risk -2.3263 Low Risk Low Risk G2 FEMALE 
TCGA-B0-5694 480 1 0.6125 High Risk High Risk 0.6646 High Risk High Risk G3 MALE 
TCGA-B0-5695 2148 0 -1.3415 Intermediate Risk Low Risk -1.4555 Intermediate Risk Low Risk G2 FEMALE 
TCGA-B0-5696 2607 0 -0.2390 Intermediate Risk High Risk -0.2593 Intermediate Risk High Risk G4 MALE 
TCGA-B0-5697 2628 0 -0.9564 Intermediate Risk Low Risk -1.0376 Intermediate Risk Low Risk G2 MALE 
TCGA-B0-5698 3628 0 -1.8350 Low Risk Low Risk -1.9909 Low Risk Low Risk G3 MALE 
TCGA-B0-5699 3838 0 -2.3218 Low Risk Low Risk -2.5191 Low Risk Low Risk G2 MALE 
TCGA-B0-5700 1789 0 -1.9618 Low Risk Low Risk -2.1285 Low Risk Low Risk G2 MALE 
TCGA-B0-5701 2459 0 0.4756 High Risk High Risk 0.5161 High Risk High Risk G4 MALE 
TCGA-B0-5702 2170 0 -0.2506 Intermediate Risk High Risk -0.2719 Intermediate Risk High Risk G2 MALE 
TCGA-B0-5703 2244 0 -1.8546 Low Risk Low Risk -2.0122 Low Risk Low Risk G3 MALE 
TCGA-B0-5705 4534 0 -1.7150 Low Risk Low Risk -1.8608 Low Risk Low Risk G2 FEMALE 
TCGA-B0-5706 3203 0 0.5053 High Risk High Risk 0.5482 High Risk High Risk G2 MALE 
TCGA-B0-5707 3741 0 -0.8451 Intermediate Risk Low Risk -0.9169 Intermediate Risk Low Risk G3 FEMALE 
TCGA-B0-5709 3971 0 -0.2541 Intermediate Risk High Risk -0.2757 Intermediate Risk High Risk G3 FEMALE 
TCGA-B0-5710 2428 0 -1.6105 Low Risk Low Risk -1.7473 Low Risk Low Risk G2 MALE 
TCGA-B0-5711 3986 0 -0.6728 Intermediate Risk High Risk -0.7300 Intermediate Risk High Risk G3 MALE 
TCGA-B0-5712 2720 0 -0.6938 Intermediate Risk High Risk 0.8680 High Risk High Risk G3 FEMALE 
TCGA-B0-5713 2780 0 -0.6309 Intermediate Risk High Risk -0.6846 Intermediate Risk High Risk G3 FEMALE 
TCGA-B0-5812 3831 0 -1.4832 Intermediate Risk Low Risk -1.6093 Intermediate Risk Low Risk G3 MALE 
TCGA-B2-3923 991 0 0.1928 High Risk High Risk 0.2092 Intermediate Risk High Risk G2 MALE 
TCGA-B2-3924 1091 0 -1.8982 Low Risk Low Risk -2.0595 Low Risk Low Risk G2 MALE 
TCGA-B2-4098 51 0 -1.4175 Intermediate Risk Low Risk -1.5380 Intermediate Risk Low Risk G2 FEMALE 
TCGA-B2-4099 971 0 -1.3740 Intermediate Risk Low Risk -1.4907 Intermediate Risk Low Risk G3 MALE 
TCGA-B2-4101 648 0 -0.1049 Intermediate Risk High Risk -0.1138 Intermediate Risk High Risk G3 MALE 
TCGA-B2-4102 951 0 -1.9652 Low Risk Low Risk -2.1322 Low Risk Low Risk G2 MALE 
TCGA-B2-5633 962 0 -1.2916 Intermediate Risk Low Risk -1.4014 Intermediate Risk Low Risk G2 MALE 
TCGA-B2-5635 754 0 -1.4462 Intermediate Risk Low Risk -1.5691 Intermediate Risk Low Risk G2 MALE 
TCGA-B2-5636 918 0 -0.4735 Intermediate Risk High Risk -0.5138 Intermediate Risk High Risk G2 MALE 
TCGA-B2-5639 1002 1 -0.3640 Intermediate Risk High Risk 1.2259 High Risk High Risk G3 MALE 
TCGA-B2-5641 655 0 -1.5365 Intermediate Risk Low Risk -1.6671 Intermediate Risk Low Risk G3 MALE 
TCGA-B2-A4SR 507 0 -0.5760 Intermediate Risk High Risk -0.6250 Intermediate Risk High Risk [Not Available] MALE 
TCGA-B4-5377 365 0 -0.8657 Intermediate Risk Low Risk 0.6816 High Risk High Risk G3 FEMALE 
TCGA-B4-5378 175 0 -1.4161 Intermediate Risk Low Risk -1.5365 Intermediate Risk Low Risk G2 MALE 
TCGA-B4-5832 155 0 1.9223 High Risk High Risk 2.0857 High Risk High Risk G2 MALE 
TCGA-B4-5834 38 0 -1.8218 Low Risk Low Risk -1.9767 Low Risk Low Risk G1 MALE 
TCGA-B4-5835 16 0 -1.1715 Intermediate Risk Low Risk -1.2710 Intermediate Risk Low Risk G2 FEMALE 
TCGA-B4-5836 141 0 -0.8484 Intermediate Risk Low Risk -0.9205 Intermediate Risk Low Risk G2 FEMALE 
TCGA-B4-5838 166 0 -0.4999 Intermediate Risk High Risk -0.5424 Intermediate Risk High Risk G2 MALE 
TCGA-B4-5843 11 0 -1.9128 Low Risk Low Risk -2.0753 Low Risk Low Risk G2 MALE 
TCGA-B4-5844 7 0 -0.3725 Intermediate Risk High Risk -0.4042 Intermediate Risk High Risk G1 FEMALE 
TCGA-B8-4143 708 1 0.6450 High Risk High Risk 2.3207 High Risk High Risk G3 FEMALE 
TCGA-B8-4146 511 0 -2.0623 Low Risk Low Risk -2.2376 Low Risk Low Risk G2 FEMALE 
TCGA-B8-4148 1519 0 -1.8958 Low Risk Low Risk -2.0569 Low Risk Low Risk G3 FEMALE 
TCGA-B8-4151 1298 0 -0.3458 Intermediate Risk High Risk -0.3752 Intermediate Risk High Risk G2 FEMALE 
TCGA-B8-4153 761 0 -0.1421 Intermediate Risk High Risk -0.1542 Intermediate Risk High Risk G3 MALE 
TCGA-B8-4154 1379 0 -2.0097 Low Risk Low Risk -2.1805 Low Risk Low Risk G2 FEMALE 
TCGA-B8-4619 523 0 -0.8204 Intermediate Risk Low Risk -0.8902 Intermediate Risk Low Risk G2 MALE 
TCGA-B8-4620 777 0 -0.0014 Intermediate Risk High Risk -0.0016 Intermediate Risk High Risk G2 FEMALE 
TCGA-B8-4621 787 0 -1.5386 Intermediate Risk Low Risk -1.6694 Intermediate Risk Low Risk G3 MALE 
TCGA-B8-4622 1524 0 -0.2343 Intermediate Risk High Risk 1.3666 High Risk High Risk G3 MALE 
TCGA-B8-5158 1217 0 0.5513 High Risk High Risk 0.5981 High Risk High Risk G4 MALE 
TCGA-B8-5159 721 0 -2.2719 Low Risk Low Risk -2.4650 Low Risk Low Risk G3 FEMALE 
TCGA-B8-5162 36 0 0.3234 High Risk High Risk 0.3509 Intermediate Risk High Risk G2 MALE 
TCGA-B8-5163 821 0 0.2027 High Risk High Risk 0.2199 Intermediate Risk High Risk G3 FEMALE 
TCGA-B8-5164 26 0 -0.9700 Intermediate Risk Low Risk -1.0524 Intermediate Risk Low Risk G3 MALE 
TCGA-B8-5165 736 0 -2.1207 Low Risk Low Risk -2.3009 Low Risk Low Risk G2 MALE 
TCGA-B8-5545 1524 0 -1.3593 Intermediate Risk Low Risk -1.4748 Intermediate Risk Low Risk G2 MALE 
TCGA-B8-5546 505 0 -2.2357 Low Risk Low Risk -2.4257 Low Risk Low Risk G2 FEMALE 
TCGA-B8-5549 194 0 -2.6278 Low Risk Low Risk -2.8512 Low Risk Low Risk G3 MALE 
TCGA-B8-5550 1475 0 0.0402 Intermediate Risk High Risk 0.0436 Intermediate Risk High Risk G3 MALE 
TCGA-B8-5551 16 0 -0.2779 Intermediate Risk High Risk -0.3015 Intermediate Risk High Risk G3 FEMALE 
TCGA-B8-5552 1045 0 -1.8082 Low Risk Low Risk -1.9619 Low Risk Low Risk G2 FEMALE 
TCGA-B8-5553 435 0 -1.7956 Low Risk Low Risk -1.9482 Low Risk Low Risk G2 FEMALE 
TCGA-B8-A54D 829 0 -0.1508 Intermediate Risk High Risk -0.1637 Intermediate Risk High Risk G2 MALE 
TCGA-B8-A54E 908 0 -0.7081 Intermediate Risk High Risk -0.7683 Intermediate Risk Low Risk G3 FEMALE 
TCGA-B8-A54F 519 0 -1.7160 Low Risk Low Risk -1.8618 Low Risk Low Risk G2 FEMALE 
TCGA-B8-A54G 53 0 -1.2192 Intermediate Risk Low Risk -1.3228 Intermediate Risk Low Risk G3 MALE 
TCGA-B8-A54H 256 0 -0.5815 Intermediate Risk High Risk -0.6309 Intermediate Risk High Risk G3 FEMALE 
TCGA-B8-A54I 150 0 -0.9119 Intermediate Risk Low Risk -0.9894 Intermediate Risk Low Risk G3 MALE 
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TCGA-B8-A54J 528 0 -0.4135 Intermediate Risk High Risk -0.4487 Intermediate Risk High Risk G2 MALE 
TCGA-B8-A54K 469 0 -0.6169 Intermediate Risk High Risk -0.6693 Intermediate Risk High Risk G1 MALE 
TCGA-B8-A7U6 495 0 -1.2780 Intermediate Risk Low Risk -1.3866 Intermediate Risk Low Risk G3 FEMALE 
TCGA-B8-A8YJ 431 0 -1.8596 Low Risk Low Risk -2.0176 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4158 3374 0 -1.8989 Low Risk Low Risk -2.0603 Low Risk Low Risk G2 MALE 
TCGA-BP-4159 2599 1 -1.1660 Intermediate Risk Low Risk -1.2651 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-4160 2879 0 -0.0213 Intermediate Risk High Risk -0.0231 Intermediate Risk High Risk G2 MALE 
TCGA-BP-4161 2744 0 -1.2300 Intermediate Risk Low Risk -1.3345 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-4162 3072 0 -1.7387 Low Risk Low Risk -1.8864 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4163 2837 0 -0.2725 Intermediate Risk High Risk -0.2957 Intermediate Risk High Risk G3 FEMALE 
TCGA-BP-4164 991 0 -0.6055 Intermediate Risk High Risk -0.6570 Intermediate Risk High Risk G2 FEMALE 
TCGA-BP-4165 3035 0 -1.4046 Intermediate Risk Low Risk -1.5240 Intermediate Risk Low Risk G1 FEMALE 
TCGA-BP-4166 13 0 -0.4254 Intermediate Risk High Risk -0.4616 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4167 2716 0 0.2721 High Risk High Risk 0.2952 Intermediate Risk High Risk G2 MALE 
TCGA-BP-4169 700 1 1.4563 High Risk High Risk 1.5801 High Risk High Risk G2 FEMALE 
TCGA-BP-4170 2341 0 -1.8624 Low Risk Low Risk -2.0207 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4173 1892 0 -0.2207 Intermediate Risk High Risk -0.2395 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4174 1878 0 -0.5086 Intermediate Risk High Risk -0.5518 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4176 1953 0 -0.9938 Intermediate Risk Low Risk -1.0783 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-4177 1669 0 -0.4550 Intermediate Risk High Risk -0.4937 Intermediate Risk High Risk G2 MALE 
TCGA-BP-4325 2962 0 -2.0762 Low Risk Low Risk -2.2526 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4326 1624 0 -0.0847 Intermediate Risk High Risk -0.0919 Intermediate Risk High Risk G2 FEMALE 
TCGA-BP-4327 109 0 -0.2592 Intermediate Risk High Risk -0.2812 Intermediate Risk High Risk G2 FEMALE 
TCGA-BP-4329 844 0 -0.0733 Intermediate Risk High Risk -0.0795 Intermediate Risk High Risk G2 MALE 
TCGA-BP-4330 1886 0 -0.7512 Intermediate Risk Low Risk -0.8151 Intermediate Risk Low Risk G2 FEMALE 
TCGA-BP-4331 2452 1 -1.7862 Low Risk Low Risk -1.9380 Low Risk Low Risk G2 MALE 
TCGA-BP-4332 1132 0 0.0652 High Risk High Risk 0.0707 Intermediate Risk High Risk G2 MALE 
TCGA-BP-4334 645 0 0.3733 High Risk High Risk 0.4050 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4335 475 1 0.1849 High Risk High Risk 1.8215 High Risk High Risk G3 FEMALE 
TCGA-BP-4337 2 0 0.7769 High Risk High Risk 0.8429 High Risk High Risk G4 FEMALE 
TCGA-BP-4338 2857 0 -1.3785 Intermediate Risk Low Risk -1.4957 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-4340 561 0 -2.1099 Low Risk Low Risk -2.2892 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4341 1588 1 -0.2218 Intermediate Risk High Risk -0.2406 Intermediate Risk High Risk G2 MALE 
TCGA-BP-4342 2254 1 1.0171 High Risk High Risk 1.1036 High Risk High Risk G3 MALE 
TCGA-BP-4343 1910 1 0.3103 High Risk High Risk 0.3366 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4344 1665 0 -1.0239 Intermediate Risk Low Risk -1.1110 Intermediate Risk Low Risk G2 FEMALE 
TCGA-BP-4345 1515 0 0.3550 High Risk High Risk 0.3852 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4346 1492 0 -0.2098 Intermediate Risk High Risk -0.2276 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4347 1366 0 -0.8480 Intermediate Risk Low Risk -0.9201 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-4349 372 0 -2.0950 Low Risk Low Risk -2.2730 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4351 969 0 0.4115 High Risk High Risk 0.4465 Intermediate Risk High Risk G2 FEMALE 
TCGA-BP-4352 344 1 1.5285 High Risk High Risk 3.2792 High Risk High Risk G4 FEMALE 
TCGA-BP-4353 375 0 -1.3895 Intermediate Risk Low Risk -1.5075 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-4354 1033 1 0.7575 High Risk High Risk 2.4428 High Risk High Risk G4 MALE 
TCGA-BP-4355 952 0 -0.1941 Intermediate Risk High Risk -0.2106 Intermediate Risk High Risk G4 FEMALE 
TCGA-BP-4756 374 0 -2.0561 Low Risk Low Risk -2.2308 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4758 2206 0 -2.0388 Low Risk Low Risk -2.2121 Low Risk Low Risk G2 MALE 
TCGA-BP-4759 2370 0 -1.6872 Low Risk Low Risk -1.8306 Low Risk Low Risk G2 MALE 
TCGA-BP-4760 2359 0 -0.5428 Intermediate Risk High Risk -0.5889 Intermediate Risk High Risk G2 MALE 
TCGA-BP-4761 182 0 -0.7031 Intermediate Risk High Risk -0.7629 Intermediate Risk Low Risk G4 MALE 
TCGA-BP-4762 1342 0 -1.4495 Intermediate Risk Low Risk -1.5727 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-4763 1269 0 -0.9524 Intermediate Risk Low Risk -1.0333 Intermediate Risk Low Risk G2 FEMALE 
TCGA-BP-4765 2182 0 -1.9144 Low Risk Low Risk -2.0771 Low Risk Low Risk G2 MALE 
TCGA-BP-4766 1461 0 -2.2355 Low Risk Low Risk -2.4254 Low Risk Low Risk G3 FEMALE 
TCGA-BP-4768 400 0 -1.7873 Low Risk Low Risk -1.9392 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4769 1875 0 -0.5652 Intermediate Risk High Risk -0.6133 Intermediate Risk High Risk G2 MALE 
TCGA-BP-4770 329 1 1.2150 High Risk High Risk 2.9391 High Risk High Risk G4 FEMALE 
TCGA-BP-4771 162 0 0.1965 High Risk High Risk 1.8341 High Risk High Risk G4 MALE 
TCGA-BP-4774 1884 0 -1.7002 Low Risk Low Risk -1.8447 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4775 1842 0 -2.7778 Low Risk Low Risk -3.0138 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4776 411 0 -1.5907 Low Risk Low Risk -1.7258 Low Risk Low Risk G2 MALE 
TCGA-BP-4777 1730 0 -1.6858 Low Risk Low Risk -1.8291 Low Risk Low Risk G3 MALE 
TCGA-BP-4781 2078 0 -1.6693 Low Risk Low Risk -1.8111 Low Risk Low Risk G3 MALE 
TCGA-BP-4782 354 0 -1.6054 Low Risk Low Risk -1.7419 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4784 1853 0 -0.5296 Intermediate Risk High Risk -0.5746 Intermediate Risk High Risk G2 FEMALE 
TCGA-BP-4787 480 1 0.0372 Intermediate Risk High Risk 1.6612 High Risk High Risk G4 FEMALE 
TCGA-BP-4789 1488 0 -2.2487 Low Risk Low Risk -2.4398 Low Risk Low Risk G2 MALE 
TCGA-BP-4790 1110 0 -1.5457 Intermediate Risk Low Risk -1.6771 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-4795 620 0 -0.5158 Intermediate Risk High Risk -0.5596 Intermediate Risk High Risk G2 FEMALE 
TCGA-BP-4797 1106 0 -0.3418 Intermediate Risk High Risk -0.3708 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4798 334 1 1.0755 High Risk High Risk 1.1669 High Risk High Risk G4 MALE 
TCGA-BP-4799 1132 1 0.9190 High Risk High Risk 0.9971 High Risk High Risk G3 MALE 
TCGA-BP-4801 1123 0 -1.5464 Intermediate Risk Low Risk -1.6778 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-4803 204 0 0.2845 High Risk High Risk 0.3087 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4804 1458 0 -1.1179 Intermediate Risk Low Risk -1.2129 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-4807 211 0 -1.9918 Low Risk Low Risk -2.1611 Low Risk Low Risk G3 MALE 
TCGA-BP-4959 2658 0 -1.5710 Low Risk Low Risk -1.7045 Low Risk Low Risk G3 MALE 
TCGA-BP-4960 2170 0 -0.1502 Intermediate Risk High Risk -0.1630 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4961 1934 0 -2.2418 Low Risk Low Risk -2.4323 Low Risk Low Risk G2 MALE 
TCGA-BP-4962 1784 0 -0.8955 Intermediate Risk Low Risk -0.9716 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-4963 1833 0 -2.1527 Low Risk Low Risk -2.3356 Low Risk Low Risk G3 MALE 
TCGA-BP-4964 1861 0 -1.6128 Low Risk Low Risk -1.7499 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4965 1870 0 -1.6903 Low Risk Low Risk -1.8340 Low Risk Low Risk G2 MALE 
TCGA-BP-4967 205 0 0.3263 High Risk High Risk 0.3541 Intermediate Risk High Risk G2 MALE 
TCGA-BP-4968 1745 0 -1.6017 Low Risk Low Risk -1.7378 Low Risk Low Risk G3 MALE 
TCGA-BP-4969 1793 0 -1.4585 Intermediate Risk Low Risk -1.5825 Intermediate Risk Low Risk G2 FEMALE 
TCGA-BP-4970 433 0 0.1906 High Risk High Risk 0.2068 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4971 1486 0 0.1744 High Risk High Risk 0.1892 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4972 1501 0 -0.5430 Intermediate Risk High Risk -0.5891 Intermediate Risk High Risk G3 FEMALE 
TCGA-BP-4973 1383 0 -0.3810 Intermediate Risk High Risk -0.4134 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4974 211 1 -0.1869 Intermediate Risk High Risk 1.4180 High Risk High Risk G4 MALE 
TCGA-BP-4975 1432 0 -2.1524 Low Risk Low Risk -2.3353 Low Risk Low Risk G3 MALE 
TCGA-BP-4976 1631 0 -2.6366 Low Risk Low Risk -2.8607 Low Risk Low Risk G3 MALE 
TCGA-BP-4977 454 0 -1.4991 Intermediate Risk Low Risk -1.6265 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-4981 1096 0 0.4061 High Risk High Risk 0.4406 Intermediate Risk High Risk G3 FEMALE 
TCGA-BP-4982 1013 0 -1.9759 Low Risk Low Risk -2.1439 Low Risk Low Risk G3 MALE 
TCGA-BP-4983 1412 0 1.2238 High Risk High Risk 1.3278 High Risk High Risk G4 FEMALE 
TCGA-BP-4985 951 1 0.9043 High Risk High Risk 0.9811 High Risk High Risk G4 MALE 
TCGA-BP-4986 784 0 -1.4374 Intermediate Risk Low Risk -1.5596 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-4987 1123 0 -2.1280 Low Risk Low Risk -2.3088 Low Risk Low Risk G2 FEMALE 
TCGA-BP-4988 827 0 -1.0231 Intermediate Risk Low Risk -1.1100 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-4989 118 0 0.0955 High Risk High Risk 0.1036 Intermediate Risk High Risk G3 MALE 
TCGA-BP-4991 1412 0 -2.3166 Low Risk Low Risk -2.5135 Low Risk Low Risk G2 MALE 
TCGA-BP-4992 501 0 -0.8557 Intermediate Risk Low Risk -0.9285 Intermediate Risk Low Risk G4 MALE 
TCGA-BP-4993 177 0 -1.5259 Intermediate Risk Low Risk -1.6556 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-4994 1307 0 -1.5121 Intermediate Risk Low Risk -1.6407 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-4995 1370 0 -1.5108 Intermediate Risk Low Risk -1.6392 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-4998 931 0 -1.3703 Intermediate Risk Low Risk -1.4867 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-4999 1265 0 -1.8144 Low Risk Low Risk -1.9686 Low Risk Low Risk G2 MALE 
TCGA-BP-5000 563 0 -1.4935 Intermediate Risk Low Risk -1.6204 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-5001 1176 0 -1.6715 Low Risk Low Risk -1.8135 Low Risk Low Risk G2 FEMALE 
TCGA-BP-5004 1125 0 -2.7117 Low Risk Low Risk -2.9422 Low Risk Low Risk G3 MALE 
TCGA-BP-5006 840 0 -1.9452 Low Risk Low Risk -2.1105 Low Risk Low Risk G2 MALE 
TCGA-BP-5007 1139 0 -0.6544 Intermediate Risk High Risk -0.7100 Intermediate Risk High Risk G2 MALE 
TCGA-BP-5008 1070 0 -1.5149 Intermediate Risk Low Risk -1.6437 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-5009 1091 1 -0.7715 Intermediate Risk Low Risk -0.8371 Intermediate Risk Low Risk G3 MALE 
TCGA-BP-5010 877 0 0.7225 High Risk High Risk 0.7839 High Risk High Risk G4 MALE 
TCGA-BP-5168 1462 0 -2.0185 Low Risk Low Risk -2.1901 Low Risk Low Risk G2 MALE 
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TCGA-BP-5169 193 0 -1.0118 Intermediate Risk Low Risk -1.0978 Intermediate Risk Low Risk G4 MALE 
TCGA-BP-5170 2410 0 -1.3256 Intermediate Risk Low Risk -1.4382 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-5173 62 0 -1.8166 Low Risk Low Risk -1.9710 Low Risk Low Risk G2 MALE 
TCGA-BP-5174 2255 0 -1.5729 Low Risk Low Risk -1.7066 Low Risk Low Risk G2 FEMALE 
TCGA-BP-5175 931 0 -0.6631 Intermediate Risk High Risk -0.7195 Intermediate Risk High Risk G3 MALE 
TCGA-BP-5176 1589 0 -1.1979 Intermediate Risk Low Risk -1.2997 Intermediate Risk Low Risk G2 FEMALE 
TCGA-BP-5177 293 0 -1.6415 Low Risk Low Risk -1.7810 Low Risk Low Risk G3 FEMALE 
TCGA-BP-5178 1910 1 -0.5342 Intermediate Risk High Risk 1.0413 High Risk High Risk G4 MALE 
TCGA-BP-5180 2261 0 -1.3825 Intermediate Risk Low Risk -1.5000 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-5181 1494 0 -1.8567 Low Risk Low Risk -2.0145 Low Risk Low Risk G2 FEMALE 
TCGA-BP-5182 1164 0 -1.8998 Low Risk Low Risk -2.0613 Low Risk Low Risk G3 MALE 
TCGA-BP-5183 1290 0 -0.3644 Intermediate Risk High Risk -0.3953 Intermediate Risk High Risk G3 MALE 
TCGA-BP-5184 1132 0 -1.9604 Low Risk Low Risk -2.1270 Low Risk Low Risk G3 MALE 
TCGA-BP-5185 1131 0 -2.0698 Low Risk Low Risk -2.2457 Low Risk Low Risk G3 MALE 
TCGA-BP-5186 693 0 -1.8407 Low Risk Low Risk -1.9971 Low Risk Low Risk G2 FEMALE 
TCGA-BP-5187 406 0 -1.3701 Intermediate Risk Low Risk -1.4865 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-5189 821 1 -1.2617 Intermediate Risk Low Risk -1.3690 Intermediate Risk Low Risk G4 MALE 
TCGA-BP-5190 1010 0 -2.5437 Low Risk Low Risk -2.7599 Low Risk Low Risk G3 MALE 
TCGA-BP-5191 966 0 0.4054 High Risk High Risk 0.4398 Intermediate Risk High Risk G2 MALE 
TCGA-BP-5192 714 0 -2.4756 Low Risk Low Risk -2.6859 Low Risk Low Risk G2 MALE 
TCGA-BP-5194 408 0 -1.9481 Low Risk Low Risk -2.1136 Low Risk Low Risk G2 MALE 
TCGA-BP-5195 749 0 -1.4136 Intermediate Risk Low Risk -1.5338 Intermediate Risk Low Risk G2 MALE 
TCGA-BP-5196 1017 0 -1.7957 Low Risk Low Risk -1.9483 Low Risk Low Risk G2 MALE 
TCGA-BP-5198 603 0 0.4274 High Risk High Risk 0.4637 High Risk High Risk G3 MALE 
TCGA-BP-5199 1354 0 0.3112 High Risk High Risk 0.3377 Intermediate Risk High Risk G4 MALE 
TCGA-BP-5200 1062 0 -0.0123 Intermediate Risk High Risk -0.0133 Intermediate Risk High Risk G4 MALE 
TCGA-BP-5201 950 0 0.1804 High Risk High Risk 1.8166 High Risk High Risk G4 MALE 
TCGA-BP-5202 29 0 -0.2198 Intermediate Risk High Risk -0.2385 Intermediate Risk High Risk G2 MALE 
TCGA-CJ-4634 3495 0 -1.7592 Low Risk Low Risk -1.9087 Low Risk Low Risk G2 FEMALE 
TCGA-CJ-4635 1415 0 -1.0602 Intermediate Risk Low Risk -1.1503 Intermediate Risk Low Risk G3 MALE 
TCGA-CJ-4636 1923 0 -0.1124 Intermediate Risk High Risk -0.1220 Intermediate Risk High Risk G3 MALE 
TCGA-CJ-4637 2225 1 0.6830 High Risk High Risk 2.3619 High Risk High Risk G4 FEMALE 
TCGA-CJ-4638 431 1 0.4311 High Risk High Risk 2.0886 High Risk High Risk G4 FEMALE 
TCGA-CJ-4639 3227 0 -0.6030 Intermediate Risk High Risk -0.6543 Intermediate Risk High Risk G2 FEMALE 
TCGA-CJ-4640 3477 0 -0.2735 Intermediate Risk High Risk -0.2968 Intermediate Risk High Risk G4 MALE 
TCGA-CJ-4641 1660 1 -0.1106 Intermediate Risk High Risk 1.5008 High Risk High Risk G4 FEMALE 
TCGA-CJ-4642 3203 0 0.4197 High Risk High Risk 0.4553 High Risk High Risk G2 MALE 
TCGA-CJ-4643 1792 0 0.3683 High Risk High Risk 0.3996 Intermediate Risk High Risk G3 FEMALE 
TCGA-CJ-4644 336 1 0.0798 High Risk High Risk 1.7074 High Risk High Risk G3 FEMALE 
TCGA-CJ-4868 645 1 0.8004 High Risk High Risk 2.4893 High Risk High Risk G3 MALE 
TCGA-CJ-4869 2552 0 -0.9575 Intermediate Risk Low Risk -1.0389 Intermediate Risk Low Risk G2 MALE 
TCGA-CJ-4870 1497 0 -0.6147 Intermediate Risk High Risk -0.6669 Intermediate Risk High Risk G2 FEMALE 
TCGA-CJ-4871 2421 0 0.6348 High Risk High Risk 2.3096 High Risk High Risk G4 MALE 
TCGA-CJ-4872 1434 0 -0.8853 Intermediate Risk Low Risk -0.9605 Intermediate Risk Low Risk G4 MALE 
TCGA-CJ-4873 2257 0 0.0591 High Risk High Risk 0.0642 Intermediate Risk High Risk G3 FEMALE 
TCGA-CJ-4874 2281 0 -1.8579 Low Risk Low Risk -2.0157 Low Risk Low Risk G3 FEMALE 
TCGA-CJ-4875 3551 1 -0.0049 Intermediate Risk High Risk 1.6155 High Risk High Risk G3 MALE 
TCGA-CJ-4876 1953 0 -0.6946 Intermediate Risk High Risk -0.7537 Intermediate Risk High Risk G3 MALE 
TCGA-CJ-4878 2184 0 0.0928 High Risk High Risk 0.1007 Intermediate Risk High Risk G2 FEMALE 
TCGA-CJ-4881 2012 0 0.6844 High Risk High Risk 0.7426 High Risk High Risk G3 MALE 
TCGA-CJ-4882 1882 0 1.3792 High Risk High Risk 1.4964 High Risk High Risk G3 MALE 
TCGA-CJ-4884 1758 0 -0.1432 Intermediate Risk High Risk -0.1554 Intermediate Risk High Risk G3 FEMALE 
TCGA-CJ-4885 3448 0 0.7291 High Risk High Risk 2.4118 High Risk High Risk G3 MALE 
TCGA-CJ-4886 1951 0 -1.5931 Low Risk Low Risk -1.7285 Low Risk Low Risk G3 FEMALE 
TCGA-CJ-4887 931 1 -1.0172 Intermediate Risk Low Risk 0.5172 High Risk High Risk G3 MALE 
TCGA-CJ-4888 1566 1 0.7347 High Risk High Risk 2.4180 High Risk High Risk G4 MALE 
TCGA-CJ-4889 1945 0 -1.1045 Intermediate Risk Low Risk -1.1984 Intermediate Risk Low Risk G4 FEMALE 
TCGA-CJ-4890 3516 0 0.6313 High Risk High Risk 2.3058 High Risk High Risk G4 MALE 
TCGA-CJ-4891 819 0 0.7890 High Risk High Risk 0.8561 High Risk High Risk G4 FEMALE 
TCGA-CJ-4892 1520 0 -1.9200 Low Risk Low Risk -2.0831 Low Risk Low Risk G2 FEMALE 
TCGA-CJ-4893 749 0 -2.0463 Low Risk Low Risk -2.2202 Low Risk Low Risk G3 FEMALE 
TCGA-CJ-4894 840 1 0.1029 High Risk High Risk 0.1117 Intermediate Risk High Risk G3 MALE 
TCGA-CJ-4895 1199 1 -0.0073 Intermediate Risk High Risk 1.6129 High Risk High Risk G4 MALE 
TCGA-CJ-4897 3339 0 -0.9566 Intermediate Risk Low Risk -1.0379 Intermediate Risk Low Risk G3 FEMALE 
TCGA-CJ-4899 1527 0 -1.9723 Low Risk Low Risk -2.1400 Low Risk Low Risk G2 MALE 
TCGA-CJ-4900 1713 1 0.9613 High Risk High Risk 2.6638 High Risk High Risk G4 FEMALE 
TCGA-CJ-4901 1449 0 -0.0917 Intermediate Risk High Risk -0.0995 Intermediate Risk High Risk G3 MALE 
TCGA-CJ-4902 1519 0 -0.0132 Intermediate Risk High Risk -0.0143 Intermediate Risk High Risk G3 MALE 
TCGA-CJ-4903 1559 0 -1.5654 Intermediate Risk Low Risk -1.6984 Intermediate Risk Low Risk G3 MALE 
TCGA-CJ-4904 3300 0 -0.0709 Intermediate Risk High Risk 1.5439 High Risk High Risk G3 FEMALE 
TCGA-CJ-4905 1495 0 -1.2563 Intermediate Risk Low Risk -1.3630 Intermediate Risk Low Risk G2 FEMALE 
TCGA-CJ-4907 1498 0 -0.5526 Intermediate Risk High Risk -0.5996 Intermediate Risk High Risk G3 MALE 
TCGA-CJ-4908 1530 0 -1.4288 Intermediate Risk Low Risk -1.5502 Intermediate Risk Low Risk G2 MALE 
TCGA-CJ-4912 1656 0 0.4655 High Risk High Risk 0.5051 High Risk High Risk G3 MALE 
TCGA-CJ-4916 1372 0 0.0327 Intermediate Risk High Risk 0.0355 Intermediate Risk High Risk G3 FEMALE 
TCGA-CJ-4918 93 1 0.0331 Intermediate Risk High Risk 1.6567 High Risk High Risk G4 MALE 
TCGA-CJ-4920 139 0 -1.2932 Intermediate Risk Low Risk -1.4031 Intermediate Risk Low Risk G2 FEMALE 
TCGA-CJ-4923 572 1 1.3184 High Risk High Risk 3.0512 High Risk High Risk G4 FEMALE 
TCGA-CJ-5671 3984 0 -1.1644 Intermediate Risk Low Risk -1.2633 Intermediate Risk Low Risk G3 MALE 
TCGA-CJ-5672 2188 0 -1.7282 Low Risk Low Risk -1.8751 Low Risk Low Risk G3 MALE 
TCGA-CJ-5675 3933 0 -0.9015 Intermediate Risk Low Risk -0.9781 Intermediate Risk Low Risk G3 MALE 
TCGA-CJ-5676 4064 0 -0.1420 Intermediate Risk High Risk -0.1541 Intermediate Risk High Risk G3 MALE 
TCGA-CJ-5677 781 1 0.1121 High Risk High Risk 1.7425 High Risk High Risk G4 FEMALE 
TCGA-CJ-5678 574 1 -0.6390 Intermediate Risk High Risk 0.9275 High Risk High Risk G3 MALE 
TCGA-CJ-5679 679 1 0.8832 High Risk High Risk 0.9582 High Risk High Risk G4 MALE 
TCGA-CJ-5680 767 1 0.1630 High Risk High Risk 1.7977 High Risk High Risk G4 FEMALE 
TCGA-CJ-5681 551 1 -0.2523 Intermediate Risk High Risk 1.3471 High Risk High Risk G3 FEMALE 
TCGA-CJ-5682 3733 0 0.0603 High Risk High Risk 1.6863 High Risk High Risk G4 MALE 
TCGA-CJ-5683 1888 0 -0.8006 Intermediate Risk Low Risk -0.8687 Intermediate Risk Low Risk G3 MALE 
TCGA-CJ-5684 2229 0 -0.5402 Intermediate Risk High Risk -0.5861 Intermediate Risk High Risk G2 MALE 
TCGA-CJ-5686 2036 0 -1.9800 Low Risk Low Risk -2.1482 Low Risk Low Risk G3 FEMALE 
TCGA-CJ-5689 1619 0 -1.3122 Intermediate Risk Low Risk -1.4237 Intermediate Risk Low Risk G4 MALE 
TCGA-CJ-6027 3612 0 -0.9297 Intermediate Risk Low Risk -1.0087 Intermediate Risk Low Risk G4 MALE 
TCGA-CJ-6028 1624 1 0.2164 High Risk High Risk 1.8556 High Risk High Risk G4 MALE 
TCGA-CJ-6030 2297 0 -0.7560 Intermediate Risk Low Risk -0.8202 Intermediate Risk Low Risk G3 MALE 
TCGA-CJ-6031 1904 0 -1.1167 Intermediate Risk Low Risk -1.2116 Intermediate Risk Low Risk G3 MALE 
TCGA-CJ-6032 3636 0 -0.7508 Intermediate Risk High Risk -0.8146 Intermediate Risk Low Risk G3 FEMALE 
TCGA-CJ-6033 224 1 1.3472 High Risk High Risk 3.0825 High Risk High Risk G4 FEMALE 
TCGA-CW-5580 1962 0 -0.2751 Intermediate Risk High Risk 1.3223 High Risk High Risk G3 FEMALE 
TCGA-CW-5581 2797 0 -2.2405 Low Risk Low Risk -2.4310 Low Risk Low Risk G3 MALE 
TCGA-CW-5583 2487 0 -2.2297 Low Risk Low Risk -2.4192 Low Risk Low Risk G2 FEMALE 
TCGA-CW-5584 164 0 -0.2657 Intermediate Risk High Risk -0.2883 Intermediate Risk High Risk G3 MALE 
TCGA-CW-5585 2607 0 -1.2824 Intermediate Risk Low Risk 0.2294 Intermediate Risk High Risk G2 MALE 
TCGA-CW-5587 2224 0 -0.9119 Intermediate Risk Low Risk -0.9893 Intermediate Risk Low Risk G2 FEMALE 
TCGA-CW-5588 2015 0 -1.3696 Intermediate Risk Low Risk -1.4860 Intermediate Risk Low Risk G2 FEMALE 
TCGA-CW-5589 2376 0 -1.6644 Low Risk Low Risk -1.8059 Low Risk Low Risk G2 MALE 
TCGA-CW-5590 1074 0 -0.7284 Intermediate Risk High Risk 0.8305 High Risk High Risk G3 MALE 
TCGA-CW-5591 2269 0 -0.7161 Intermediate Risk High Risk 0.8439 High Risk High Risk G2 MALE 
TCGA-CW-6087 41 0 0.7379 High Risk High Risk 2.4214 High Risk High Risk G4 MALE 
TCGA-CW-6088 3220 0 -1.9818 Low Risk Low Risk -2.1503 Low Risk Low Risk G2 MALE 
TCGA-CW-6090 2550 0 -1.1864 Intermediate Risk Low Risk -1.2872 Intermediate Risk Low Risk G3 MALE 
TCGA-CW-6093 3144 0 -1.6907 Low Risk Low Risk -1.8344 Low Risk Low Risk G1 MALE 
TCGA-CW-6097 571 1 0.2541 High Risk High Risk 0.2757 Intermediate Risk High Risk G4 MALE 
TCGA-CZ-4853 773 0 -2.1728 Low Risk Low Risk -2.3574 Low Risk Low Risk G2 MALE 
TCGA-CZ-4854 1403 0 -0.8379 Intermediate Risk Low Risk -0.9091 Intermediate Risk Low Risk G2 MALE 
TCGA-CZ-4856 18 0 -1.5576 Intermediate Risk Low Risk -1.6900 Intermediate Risk Low Risk G2 FEMALE 
TCGA-CZ-4857 1431 1 0.7263 High Risk High Risk 2.4089 High Risk High Risk G3 MALE 
TCGA-CZ-4858 2103 1 1.8190 High Risk High Risk 1.9736 High Risk High Risk G4 MALE 
TCGA-CZ-4859 1786 0 -2.4463 Low Risk Low Risk -2.6542 Low Risk Low Risk G2 FEMALE 
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TCGA-CZ-4860 206 1 1.4880 High Risk High Risk 3.2353 High Risk High Risk G4 MALE 
TCGA-CZ-4861 446 1 0.1347 High Risk High Risk 0.1461 Intermediate Risk High Risk G2 MALE 
TCGA-CZ-4862 3269 0 -1.6899 Low Risk Low Risk -1.8336 Low Risk Low Risk G2 MALE 
TCGA-CZ-4863 1927 0 -0.5059 Intermediate Risk High Risk -0.5489 Intermediate Risk High Risk G3 FEMALE 
TCGA-CZ-4864 2828 0 -1.1484 Intermediate Risk Low Risk -1.2460 Intermediate Risk Low Risk G3 MALE 
TCGA-CZ-4865 166 0 -1.2758 Intermediate Risk Low Risk -1.3843 Intermediate Risk Low Risk G2 FEMALE 
TCGA-CZ-4866 3265 0 -1.3097 Intermediate Risk Low Risk -1.4210 Intermediate Risk Low Risk G3 FEMALE 
TCGA-CZ-5451 1928 0 -0.5649 Intermediate Risk High Risk -0.6129 Intermediate Risk High Risk G3 MALE 
TCGA-CZ-5452 1788 0 -0.4140 Intermediate Risk High Risk -0.4492 Intermediate Risk High Risk G2 MALE 
TCGA-CZ-5453 2417 0 -0.7078 Intermediate Risk High Risk -0.7680 Intermediate Risk Low Risk G2 MALE 
TCGA-CZ-5454 721 1 -0.1581 Intermediate Risk High Risk 1.4493 High Risk High Risk G2 MALE 
TCGA-CZ-5455 561 1 -0.2002 Intermediate Risk High Risk 1.4036 High Risk High Risk G4 MALE 
TCGA-CZ-5456 2420 0 -0.2187 Intermediate Risk High Risk -0.2372 Intermediate Risk High Risk G3 MALE 
TCGA-CZ-5457 2752 0 -0.8906 Intermediate Risk Low Risk -0.9663 Intermediate Risk Low Risk G4 MALE 
TCGA-CZ-5458 2787 0 -0.8219 Intermediate Risk Low Risk -0.8918 Intermediate Risk Low Risk G3 MALE 
TCGA-CZ-5459 1682 0 0.0366 Intermediate Risk High Risk 0.0397 Intermediate Risk High Risk G3 MALE 
TCGA-CZ-5460 2871 0 -0.2667 Intermediate Risk High Risk 1.3314 High Risk High Risk G2 MALE 
TCGA-CZ-5461 330 1 0.2691 High Risk High Risk 1.9128 High Risk High Risk G4 MALE 
TCGA-CZ-5462 311 1 -0.7214 Intermediate Risk High Risk 0.8382 High Risk High Risk G3 MALE 
TCGA-CZ-5463 662 0 -0.2070 Intermediate Risk High Risk -0.2246 Intermediate Risk High Risk G2 MALE 
TCGA-CZ-5464 2126 0 0.1349 High Risk High Risk 1.7672 High Risk High Risk G2 MALE 
TCGA-CZ-5465 2562 0 -0.2107 Intermediate Risk High Risk -0.2287 Intermediate Risk High Risk G2 FEMALE 
TCGA-CZ-5466 684 0 -0.4363 Intermediate Risk High Risk -0.4734 Intermediate Risk High Risk G2 MALE 
TCGA-CZ-5467 73 1 0.1462 High Risk High Risk 0.1586 Intermediate Risk High Risk G4 FEMALE 
TCGA-CZ-5468 59 1 0.4091 High Risk High Risk 2.0647 High Risk High Risk G4 MALE 
TCGA-CZ-5469 945 1 0.3671 High Risk High Risk 0.3983 Intermediate Risk High Risk G2 MALE 
TCGA-CZ-5470 386 0 0.1560 High Risk High Risk 0.1692 Intermediate Risk High Risk G3 FEMALE 
TCGA-CZ-5982 2437 0 -2.1271 Low Risk Low Risk -2.3079 Low Risk Low Risk G2 FEMALE 
TCGA-CZ-5984 2065 0 -1.3594 Intermediate Risk Low Risk -1.4749 Intermediate Risk Low Risk G3 MALE 
TCGA-CZ-5985 1995 0 -0.8297 Intermediate Risk Low Risk -0.9002 Intermediate Risk Low Risk G2 MALE 
TCGA-CZ-5986 373 0 -2.4471 Low Risk Low Risk -2.6551 Low Risk Low Risk G3 MALE 
TCGA-CZ-5987 445 1 0.5565 High Risk High Risk 2.2246 High Risk High Risk G2 MALE 
TCGA-CZ-5988 693 0 -1.3559 Intermediate Risk Low Risk -1.4711 Intermediate Risk Low Risk G2 MALE 
TCGA-CZ-5989 1903 0 0.4452 High Risk High Risk 0.4830 High Risk High Risk G2 MALE 
TCGA-DV-5565 1328 0 -1.4028 Intermediate Risk Low Risk -1.5220 Intermediate Risk Low Risk G2 MALE 
TCGA-DV-5566 1397 0 -1.3074 Intermediate Risk Low Risk -1.4186 Intermediate Risk Low Risk G2 FEMALE 
TCGA-DV-5567 2002 0 -0.8350 Intermediate Risk Low Risk -0.9060 Intermediate Risk Low Risk G2 FEMALE 
TCGA-DV-5568 370 0 -1.1709 Intermediate Risk Low Risk -1.2704 Intermediate Risk Low Risk G2 MALE 
TCGA-DV-5569 355 0 -1.7009 Low Risk Low Risk -1.8455 Low Risk Low Risk G2 FEMALE 
TCGA-DV-5573 1129 0 -1.7872 Low Risk Low Risk -1.9391 Low Risk Low Risk G2 MALE 
TCGA-DV-5574 2014 0 -0.9975 Intermediate Risk Low Risk -1.0823 Intermediate Risk Low Risk G2 MALE 
TCGA-DV-5575 1728 0 -1.9738 Low Risk Low Risk -2.1416 Low Risk Low Risk G2 FEMALE 
TCGA-DV-5576 726 1 -0.9260 Intermediate Risk Low Risk -1.0047 Intermediate Risk Low Risk G2 FEMALE 
TCGA-DV-A4VX 1625 1 -0.4520 Intermediate Risk High Risk 1.1304 High Risk High Risk G4 MALE 
TCGA-DV-A4VZ 365 0 -0.2393 Intermediate Risk High Risk -0.2596 Intermediate Risk High Risk G2 MALE 
TCGA-DV-A4W0 2468 0 -1.1585 Intermediate Risk Low Risk -1.2570 Intermediate Risk Low Risk G3 MALE 
TCGA-EU-5904 551 0 -1.6399 Low Risk Low Risk -1.7792 Low Risk Low Risk G1 FEMALE 
TCGA-EU-5905 119 0 -1.9689 Low Risk Low Risk -2.1362 Low Risk Low Risk G3 FEMALE 
TCGA-EU-5906 206 0 -1.9905 Low Risk Low Risk -2.1597 Low Risk Low Risk G2 MALE 
TCGA-EU-5907 127 0 -0.1297 Intermediate Risk High Risk -0.1407 Intermediate Risk High Risk G3 MALE 
TCGA-G6-A5PC 242 1 0.0795 High Risk High Risk 1.7071 High Risk High Risk G4 FEMALE 
TCGA-G6-A8L6 313 1 -0.3322 Intermediate Risk High Risk 1.2604 High Risk High Risk G3 MALE 
TCGA-G6-A8L7 2131 0 -0.6502 Intermediate Risk High Risk -0.7055 Intermediate Risk High Risk G3 FEMALE 
TCGA-G6-A8L8 1090 0 -1.1994 Intermediate Risk Low Risk -1.3014 Intermediate Risk Low Risk G3 FEMALE 
TCGA-GK-A6C7 61 0 -2.1249 Low Risk Low Risk -2.3055 Low Risk Low Risk [Not Available] FEMALE 
TCGA-MM-A563 591 0 0.4284 High Risk High Risk 0.4648 High Risk High Risk G2 MALE 
TCGA-MM-A564 607 0 0.7728 High Risk High Risk 0.8385 High Risk High Risk G2 MALE 
TCGA-MM-A84U 700 0 -0.8557 Intermediate Risk Low Risk -0.9284 Intermediate Risk Low Risk G2 FEMALE 
TCGA-MW-A4EC 498 0 -1.6150 Low Risk Low Risk -1.7523 Low Risk Low Risk G2 FEMALE 
TCGA-T7-A92I 356 0 -1.7467 Low Risk Low Risk -1.8951 Low Risk Low Risk G1 FEMALE 
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Patient Stage 
Standardized 
Age 
VHL mutation 
SSIGN 
Score 
Beleut signature (A 
vs. B vs. C) 
Bostrom signature ClearCode34 signature Kosari signature Lane signature Zhao signature 
TCGA-6D-AA2E Stage I 0.608 not mutated 4 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-A3-3306 Stage I 0.526 not mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3307 Stage III 0.444 not mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3308 Stage III 1.349 mutated 4 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-A3-3311 Stage I -0.297 not mutated 2 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3313 Stage I -0.133 not mutated 3 Cluster B TGF-b signature score high ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-A3-3316 Stage II -0.297 mutated 4 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-A3-3317 Stage II 0.526 not mutated 3 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3319 Stage I 0.773 not mutated 2 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-A3-3320 Stage I -0.709 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3322 Stage I -0.791 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3323 Stage I -0.627 not mutated 2 Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3324 Stage I -0.791 not mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3325 Stage I -0.709 not mutated 0 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3326 Stage I -1.120 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3328 Stage I 1.514 not mutated 4 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-A3-3329 Stage I 1.184 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3331 Stage I 2.090 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3335 Stage II -1.614 not mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-A3-3343 Stage II 1.514 not mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3346 Stage I 0.608 not mutated 3 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-A3-3347 Stage III 1.267 not mutated 4 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-A3-3349 Stage I -2.191 mutated 2 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-A3-3351 Stage II -1.532 not mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3352 Stage III 1.102 not mutated 5 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3357 Stage II 0.114 not mutated 4 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3358 Stage I -0.297 not mutated 2 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-A3-3359 Stage I 1.761 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3362 Stage I -0.050 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3363 Stage II -0.873 not mutated 3 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-A3-3365 Stage I -1.203 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3367 Stage I 0.938 not mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3370 Stage I -1.038 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3372 Stage III 0.279 mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3373 Stage I -0.544 mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3374 Stage I -0.791 not mutated 2 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-A3-3376 Stage I -0.791 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3378 Stage I -0.050 mutated 3 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-A3-3380 Stage I -0.544 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3382 Stage I 0.691 mutated 3 Cluster B TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-A3-3383 Stage I -0.709 mutated 2 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-A3-3385 Stage I -1.203 mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-3387 Stage I -0.956 not mutated 2 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-A3-A6NI Stage I -1.120 not mutated 3 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-A3-A6NJ Stage I -0.297 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-A6NL Stage I -0.956 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-A3-A6NN Stage I 1.431 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-A8CQ Stage I -0.133 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-A8OU Stage I 1.102 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-A8OV Stage I 1.184 not mutated 2 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-A8OW Stage III -1.944 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-A3-A8OX Stage I 0.361 not mutated 3 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-AK-3425 Stage I 0.608 not mutated 2 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-AK-3426 Stage III -1.944 not mutated 9 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-AK-3427 Stage I 0.361 not mutated 2 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3428 Stage III 0.114 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-AK-3429 Stage II -0.544 not mutated 5 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3431 Stage II 0.114 not mutated 4 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-AK-3433 Stage II -1.038 not mutated 3 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3434 Stage I 0.938 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-AK-3436 Stage IV -1.697 not mutated 7 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-AK-3440 Stage I -0.215 not mutated 3 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3443 Stage II -1.285 not mutated 3 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3444 Stage I 1.596 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-AK-3445 Stage III 0.691 mutated 7 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-AK-3447 Stage II 1.843 not mutated 3 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3450 Stage I 2.008 mutated 2 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-AK-3451 Stage II -1.038 mutated 4 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3453 Stage II -0.215 not mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3454 Stage I 1.925 not mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-AK-3455 Stage III 0.855 mutated 5 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3456 Stage II -1.038 not mutated 4 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3458 Stage I -1.038 mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AK-3460 Stage I -0.215 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-AK-3461 Stage I 0.938 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-AK-3465 Stage I 0.855 not mutated 2 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AS-3777 Stage I 0.197 not mutated 2 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-AS-3778 Stage I -2.108 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-4688 Stage IV -1.203 not mutated 12 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4690 Stage IV 0.361 mutated 13 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4691 Stage IV -0.462 not mutated 10 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4693 Stage III 0.938 not mutated 6 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4694 Stage III 0.938 not mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4696 Stage III -0.215 not mutated 7 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4697 Stage IV -1.203 not mutated 10 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4698 Stage IV 1.184 not mutated 8 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4699 Stage IV 1.102 not mutated 12 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4700 Stage IV -0.050 mutated 12 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4701 Stage IV 0.444 not mutated 11 Cluster C TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-4703 Stage IV -0.791 mutated 10 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4706 Stage III 0.032 mutated 6 Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4707 Stage III 0.197 not mutated 6 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4710 Stage III 1.184 mutated 7 Cluster C TGF-b signature score low ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4712 Stage IV 1.267 mutated 11 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4713 Stage III 1.267 mutated 6 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4714 Stage IV 1.678 mutated 11 Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B0-4718 Stage III -0.297 not mutated 6 Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-4810 Stage III -1.120 mutated 9 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4811 Stage III -1.038 not mutated 7 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4813 Stage III 0.608 not mutated 7 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4814 Stage IV -0.215 mutated 13 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-4815 Stage III 0.361 not mutated 6 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4816 Stage II -0.956 mutated 6 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-4817 Stage III 1.678 not mutated 7 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4818 Stage II 0.608 mutated 6 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4819 Stage IV -0.050 mutated 10 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4821 Stage III 0.608 not mutated 7 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4822 Stage II 1.431 mutated 5 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4823 Stage I 2.255 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4824 Stage I -0.956 mutated 5 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4827 Stage III 1.349 mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4828 Stage IV 1.514 mutated 10 Cluster C TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4833 Stage I 1.761 mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4834 Stage I -0.956 not mutated 5 Cluster B TGF-b signature score low ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4836 Stage IV 0.032 not mutated 11 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4837 Stage I 0.197 not mutated 5 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4838 Stage I 0.691 not mutated 5 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
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TCGA-B0-4839 Stage I 1.596 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4841 Stage IV 0.197 not mutated 10 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-4842 Stage III 1.020 mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4843 Stage III -0.297 not mutated 7 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4844 Stage IV -0.050 not mutated 11 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4845 Stage IV 0.773 mutated 10 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4846 Stage IV -0.709 not mutated 10 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4847 Stage IV -0.050 mutated 11 Cluster C TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4848 Stage III -0.544 not mutated 7 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-4849 Stage III -0.791 not mutated 7 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4852 Stage II 1.431 mutated 5 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-4945 Stage I 1.184 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5075 Stage III 1.349 mutated 6 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5077 Stage I 1.349 mutated 5 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5080 Stage IV 0.197 not mutated 11 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-5081 Stage III 1.514 mutated 6 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5083 Stage I 0.197 not mutated 5 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B0-5084 Stage IV -2.273 not mutated 13 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5085 Stage III 1.267 mutated 7 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B0-5088 Stage I -0.627 mutated 5 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5092 Stage IV -0.627 not mutated 9 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5094 Stage IV 0.114 not mutated 10 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5095 Stage III 1.678 mutated 7 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-5096 Stage III 0.938 mutated 8 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5097 Stage III -0.133 mutated 6 Cluster A TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-5098 Stage I -0.627 not mutated 5 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5099 Stage III 2.255 mutated 7 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5100 Stage III 0.938 not mutated 7 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5102 Stage I 1.102 mutated 5 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5104 Stage I 2.419 mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5106 Stage I 0.279 mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5107 Stage IV 0.361 mutated 9 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5108 Stage III -0.544 mutated 6 Cluster A TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5109 Stage III 0.691 not mutated 8 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5110 Stage I 0.855 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5113 Stage III 0.691 mutated 6 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5115 Stage IV -1.450 mutated 10 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5116 Stage III -0.709 mutated 7 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-5117 Stage I -1.697 not mutated 4 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B0-5119 Stage I 0.032 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5120 Stage I 0.938 not mutated 4 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-5121 Stage I -0.380 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-5399 Stage I -1.203 mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5400 Stage III -0.133 not mutated 4 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5402 Stage IV 0.279 mutated 6 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5690 Stage I -0.627 not mutated 4 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5691 Stage I 0.444 mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-5692 Stage III 0.444 mutated 7 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5693 Stage I -1.120 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5694 Stage III 0.855 not mutated 7 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-5695 Stage I 0.032 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5696 Stage III 0.691 mutated 6 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5697 Stage I -0.873 not mutated 4 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5698 Stage I 1.349 not mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5699 Stage I -0.627 mutated 4 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5700 Stage I 1.349 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5701 Stage III 0.361 not mutated 6 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5702 Stage I 0.855 not mutated 4 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5703 Stage I 1.020 mutated 5 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5705 Stage I 0.361 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5706 Stage II -1.285 not mutated 5 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5707 Stage I -1.779 not mutated 5 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B0-5709 Stage III 0.114 mutated 7 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B0-5710 Stage I -0.297 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5711 Stage III -0.873 mutated 7 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5712 Stage IV 0.608 not mutated 10 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5713 Stage III 1.184 mutated 7 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B0-5812 Stage I -0.627 mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B2-3923 Stage II -0.133 not mutated 5 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B2-3924 Stage I 1.020 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B2-4098 Stage I 0.938 not mutated 4 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B2-4099 Stage I 1.843 not mutated 5 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B2-4101 Stage II -0.709 not mutated 6 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B2-4102 Stage I 0.032 not mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B2-5633 Stage I -0.380 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B2-5635 Stage I 1.102 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B2-5636 Stage I 1.514 not mutated 4 Cluster A TGF-b signature score low ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B2-5639 Stage IV -1.203 not mutated 11 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B2-5641 Stage I 1.514 not mutated 5 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B2-A4SR Stage II 0.032 not mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B4-5377 Stage IV 0.608 not mutated 11 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B4-5378 Stage I 0.114 not mutated 4 Cluster A TGF-b signature score low ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B4-5832 Stage III 0.361 mutated 4 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B4-5834 Stage I -0.133 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B4-5835 Stage I 0.279 not mutated 2 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B4-5836 Stage I 0.032 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B4-5838 [Discrepancy] -0.709 not mutated 6 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B4-5843 Stage I -1.285 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B4-5844 Stage II 0.032 not mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-4143 Stage IV 0.444 not mutated 9 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B8-4146 Stage I -1.614 not mutated 0 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-4148 Stage I 0.197 mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-4151 Stage III -0.791 mutated 4 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-4153 Stage III 1.102 mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B8-4154 Stage I 1.020 mutated 2 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-4619 Stage I -0.215 not mutated 4 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B8-4620 Stage III 0.773 not mutated 6 Cluster B TGF-b signature score high ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B8-4621 Stage I 0.197 mutated 5 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B8-4622 Stage IV -0.297 not mutated 11 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-5158 Stage III -0.380 not mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B8-5159 Stage I 0.032 mutated 3 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-5162 Stage II 0.114 mutated 3 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B8-5163 Stage III 0.197 mutated 5 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B8-5164 Stage III 0.361 mutated 5 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B8-5165 Stage I -1.450 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-5545 Stage I -1.532 not mutated 2 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-5546 Stage I -1.861 not mutated 2 Cluster B TGF-b signature score low ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-5549 Stage I -0.627 mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-5550 Stage III 0.855 mutated 5 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B8-5551 Stage I 0.361 mutated 3 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B8-5552 Stage I -1.614 not mutated 0 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-5553 Stage I 0.526 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-A54D Stage III 0.691 not mutated 6 Cluster C TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B8-A54E Stage I 0.114 not mutated 5 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-B8-A54F Stage I -0.956 not mutated 2 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B8-A54G Stage I -0.873 not mutated 5 Cluster C TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-B8-A54H Stage II 0.691 not mutated 6 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-B8-A54I Stage I -1.038 not mutated 3 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
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TCGA-B8-A54J Stage II -0.050 not mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B8-A54K Stage I 0.032 not mutated 4 Cluster C TGF-b signature score low ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B8-A7U6 Stage I -0.544 not mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-B8-A8YJ Stage I -0.050 not mutated 4 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4158 Stage I 0.691 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4159 Stage I 0.773 mutated 2 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4160 Stage III 0.526 not mutated 6 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4161 Stage I 1.102 mutated 5 Cluster C TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4162 Stage I 0.361 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4163 Stage III -0.050 not mutated 7 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4164 Stage III -0.791 mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4165 Stage I 0.279 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4166 Stage III 0.691 mutated 5 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4167 Stage III -0.133 mutated 4 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4169 Stage II 1.267 not mutated 5 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4170 Stage I 0.938 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4173 Stage II -1.120 not mutated 6 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4174 Stage II -0.956 not mutated 4 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4176 Stage I 0.279 not mutated 2 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4177 Stage I 0.361 not mutated 2 Cluster A TGF-b signature score low ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4325 Stage I 0.279 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4326 Stage I -0.627 not mutated 2 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4327 Stage II 1.184 not mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4329 Stage III 1.184 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4330 Stage III -0.050 not mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4331 Stage I -0.709 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4332 Stage III -2.026 not mutated 4 Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4334 Stage III -0.380 not mutated 5 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4335 Stage IV 0.361 not mutated 11 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4337 Stage III 1.267 not mutated 6 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4338 Stage I -1.450 not mutated 3 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4340 Stage I 0.773 mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4341 Stage III 0.526 mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4342 Stage II 1.514 mutated 6 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4343 Stage III 0.279 not mutated 7 Cluster B TGF-b signature score high ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4344 Stage I 1.184 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4345 Stage III 0.114 not mutated 7 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4346 Stage III -0.297 not mutated 7 Cluster C TGF-b signature score low ccB signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4347 Stage III 1.102 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4349 Stage I 0.608 mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4351 Stage III -0.791 not mutated 4 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4352 Stage IV 1.102 not mutated 10 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4353 Stage I 0.032 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4354 Stage IV -1.697 not mutated 14 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4355 Stage III -0.133 mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4756 Stage I 0.114 not mutated 2 Cluster B TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4758 Stage I -1.697 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4759 Stage I -0.873 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4760 Stage I 0.691 not mutated 0 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4761 Stage III -0.297 not mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4762 Stage I -1.532 mutated 5 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4763 Stage I 1.514 mutated 2 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4765 Stage I -1.450 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4766 Stage I -1.450 not mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4768 Stage I 0.938 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4769 Stage I 0.197 not mutated 2 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4770 Stage IV 1.020 not mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4771 Stage IV 0.114 mutated 10 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4774 Stage I -0.297 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4775 Stage I -0.462 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4776 Stage I -0.709 not mutated 2 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4777 Stage I -1.203 not mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4781 Stage I 1.431 not mutated 3 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4782 Stage I -0.462 mutated 2 Cluster B TGF-b signature score low ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4784 Stage I 0.526 not mutated 2 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4787 Stage IV -0.133 not mutated 10 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4789 Stage I -1.038 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4790 Stage I 1.267 not mutated 2 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4795 Stage I 1.102 not mutated 2 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4797 Stage III -2.191 not mutated 5 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4798 [Discrepancy] 1.102 mutated 8 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4799 Stage III 0.773 not mutated 7 Cluster B TGF-b signature score high ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4801 Stage I -0.297 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4803 Stage III 1.514 not mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4804 Stage I -0.133 not mutated 2 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4807 Stage I -1.532 mutated 3 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4959 Stage I -0.956 not mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4960 Stage II -1.203 mutated 4 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4961 Stage I -1.120 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4962 Stage II -0.215 not mutated 5 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4963 Stage I 0.197 mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4964 Stage I -0.544 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4965 Stage I -1.203 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4967 Stage III 1.267 mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4968 Stage I -1.697 mutated 5 Cluster A TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4969 Stage I 0.197 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4970 Stage III -1.367 mutated 7 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4971 Stage III -1.697 not mutated 5 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4972 Stage III -1.450 not mutated 7 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4973 Stage III -1.120 mutated 5 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4974 Stage IV -0.215 mutated 10 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4975 Stage I -1.697 mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4976 Stage I 1.349 mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4977 Stage I -0.297 mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4981 Stage III 1.184 not mutated 5 Cluster C TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4982 Stage I -1.532 mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4983 Stage III 0.526 not mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4985 Stage III 0.938 not mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4986 Stage I 1.184 mutated 3 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4987 Stage I -1.614 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4988 Stage I 0.938 mutated 4 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4989 Stage III -0.215 mutated 7 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4991 Stage I -0.544 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4992 Stage I 0.444 mutated 2 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-4993 Stage I -0.215 not mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4994 Stage I -0.544 not mutated 5 Cluster B TGF-b signature score low ccB signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-4995 Stage I 0.608 mutated 5 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-4998 Stage I -0.956 mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-4999 Stage I -0.380 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5000 Stage I -1.697 not mutated 3 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5001 Stage I -1.450 mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5004 Stage I -0.627 mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5006 Stage I 0.032 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5007 Stage II -1.285 mutated 5 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5008 Stage I -1.203 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5009 Stage I -0.709 mutated 5 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5010 Stage III 0.197 not mutated 4 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5168 Stage I 1.184 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5169 Stage I 0.773 mutated 2 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
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TCGA-BP-5170 Stage I -0.462 mutated 2 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-5173 Stage I 1.184 mutated 2 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5174 Stage I -1.285 mutated 2 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-5175 Stage I -0.050 mutated 3 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5176 Stage I 1.431 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5177 Stage I -1.203 mutated 3 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5178 Stage IV 0.855 not mutated 10 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5180 Stage I -0.627 mutated 2 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5181 Stage I -0.215 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5182 Stage I -0.380 not mutated 3 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5183 Stage III -0.297 mutated 5 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5184 Stage I -0.544 mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5185 Stage I -0.380 not mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-BP-5186 Stage I -0.873 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5187 Stage I -0.544 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5189 Stage I -0.050 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-BP-5190 Stage I 0.032 mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5191 Stage III 1.514 not mutated 4 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5192 Stage I -0.133 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5194 Stage I -1.779 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5195 Stage I 1.184 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5196 Stage I -0.627 mutated 2 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5198 Stage III 0.938 mutated 7 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5199 Stage II -0.215 mutated 3 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5200 Stage II -1.367 mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-BP-5201 Stage IV 0.197 not mutated 8 Cluster C TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-BP-5202 Stage III 1.184 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4634 Stage I -0.050 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4635 Stage I -1.038 not mutated 3 Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4636 Stage III -0.791 mutated 5 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4637 Stage IV -0.709 mutated 7 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4638 Stage IV -1.203 mutated 10 Cluster C TGF-b signature score low ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-CJ-4639 Stage II -0.956 not mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4640 Stage III -0.956 not mutated 4 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4641 Stage IV -0.462 not mutated 8 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4642 Stage II -1.120 not mutated 1 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4643 Stage II 0.526 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4644 Stage IV -1.038 mutated 9 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4868 Stage IV -1.532 not mutated 11 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4869 Stage III -0.956 not mutated 7 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4870 Stage III -0.215 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4871 Stage IV 0.197 not mutated 8 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4872 Stage I -0.791 mutated 2 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CJ-4873 Stage III 2.008 not mutated 7 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4874 Stage I 1.020 not mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4875 Stage IV 0.526 mutated 9 Cluster C TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4876 Stage II -0.297 not mutated 4 Cluster C TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-CJ-4878 Stage III 0.855 not mutated 4 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4881 Stage III -1.614 not mutated 7 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4882 Stage III -0.297 not mutated 7 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4884 Stage III 0.938 mutated 5 Cluster C TGF-b signature score low ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-CJ-4885 Stage IV 0.279 mutated 11 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4886 Stage I -1.532 not mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4887 Stage IV -1.038 not mutated 9 Cluster C TGF-b signature score high ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4888 Stage IV -0.133 not mutated 10 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4889 Stage I 0.197 not mutated 2 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CJ-4890 Stage IV 0.938 not mutated 8 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4891 Stage III -0.297 not mutated 6 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4892 Stage I 0.361 mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4893 Stage I 1.267 not mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4894 Stage III -0.215 mutated 5 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4895 Stage IV 0.114 not mutated 8 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4897 Stage III 1.514 not mutated 7 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4899 Stage I -1.532 not mutated 4 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4900 Stage IV 0.691 mutated 14 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4901 Stage III -1.120 not mutated 7 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4902 Stage III 0.032 not mutated 7 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CJ-4903 Stage I -0.873 mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4904 Stage IV -0.050 not mutated 9 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4905 Stage I 0.114 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4907 Stage III -0.215 not mutated 5 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4908 Stage I -1.861 mutated 2 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-4912 Stage II 0.032 mutated 4 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4916 Stage III 0.691 mutated 5 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-4918 Stage IV 0.279 mutated 10 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CJ-4920 Stage I 0.279 mutated 4 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CJ-4923 Stage IV 0.197 not mutated 10 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-5671 Stage I -0.791 not mutated 3 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-5672 Stage I 1.925 mutated 3 Cluster B TGF-b signature score low ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-5675 Stage II 0.773 mutated 6 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-5676 Stage III -1.120 mutated 7 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-5677 Stage IV -0.544 mutated 10 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-5678 Stage IV 0.114 not mutated 8 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-5679 Stage III 1.020 mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-5680 Stage IV 0.361 mutated 10 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-5681 Stage IV -1.367 not mutated 11 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-5682 Stage IV -0.050 not mutated 10 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-5683 Stage I 1.431 not mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CJ-5684 Stage III 0.032 mutated 6 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-5686 Stage I -0.133 mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-5689 Stage I 2.419 not mutated 4 Cluster A TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-6027 Stage I 1.349 mutated 2 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-6028 Stage IV -0.215 not mutated 10 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-CJ-6030 Stage I 0.361 mutated 5 Cluster B TGF-b signature score high ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-6031 Stage I -0.544 mutated 3 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CJ-6032 Stage II 0.197 mutated 6 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CJ-6033 Stage IV -0.544 mutated 10 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CW-5580 Stage IV 1.020 mutated 9 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CW-5581 Stage I -1.367 mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CW-5583 Stage I -0.791 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CW-5584 Stage III 1.102 not mutated 7 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CW-5585 Stage IV -0.791 not mutated 8 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CW-5587 Stage III 0.114 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CW-5588 Stage I 1.431 mutated 2 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CW-5589 Stage I -0.709 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CW-5590 Stage IV -0.791 not mutated 9 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CW-5591 Stage IV -0.380 mutated 8 Cluster B TGF-b signature score low ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CW-6087 Stage IV 0.032 not mutated 12 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CW-6088 Stage I -0.050 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CW-6090 Stage I 0.608 mutated 5 Cluster B TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CW-6093 Stage I 1.020 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CW-6097 Stage III -2.355 not mutated 6 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-4853 Stage I 1.761 mutated 2 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-4854 Stage I 0.608 not mutated 2 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-4856 Stage I 0.114 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-4857 Stage IV -0.380 not mutated 9 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-4858 Stage II -1.779 mutated 5 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-4859 Stage I -0.133 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
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TCGA-CZ-4860 Stage IV -0.050 not mutated 12 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-4861 Stage II 0.197 mutated 3 Cluster B TGF-b signature score high ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-4862 Stage I -1.203 not mutated 2 Cluster C TGF-b signature score low ccB signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-CZ-4863 Stage III -0.791 not mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-CZ-4864 Stage II 2.090 not mutated 2 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CZ-4865 Stage I 0.773 not mutated 2 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-4866 Stage I 1.514 not mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-CZ-5451 Stage II 1.102 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5452 Stage II 0.691 not mutated 5 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-5453 Stage II 0.526 not mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5454 Stage IV 0.197 not mutated 9 Cluster A TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-5455 Stage IV 0.197 mutated 8 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5456 Stage II -0.297 not mutated 4 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-5457 Stage III 0.114 mutated 6 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5458 Stage III -1.450 mutated 5 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5459 Stage III 0.197 not mutated 5 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CZ-5460 Stage IV -0.462 mutated 8 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5461 Stage IV -0.709 not mutated 6 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5462 Stage IV 1.843 not mutated 9 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-CZ-5463 Stage II 1.267 not mutated 3 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5464 Stage IV 0.691 not mutated 8 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-5465 Stage III 1.267 mutated 4 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5466 Stage III 0.526 mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-5467 Stage III 2.090 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5468 Stage IV 1.925 not mutated 8 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-5469 Stage II -1.614 mutated 5 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-5470 Stage II 0.938 mutated 4 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-CZ-5982 Stage I -0.133 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5984 Stage I -0.791 mutated 3 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-5985 Stage II -0.215 mutated 3 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-CZ-5986 Stage I 0.032 mutated 3 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-CZ-5987 Stage IV -0.050 mutated 8 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-CZ-5988 Stage I -1.861 not mutated 2 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-CZ-5989 Stage II -0.050 mutated 3 Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-DV-5565 Stage I -0.133 not mutated 4 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-DV-5566 Stage I 0.526 not mutated 2 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-DV-5567 Stage I -1.697 not mutated 2 Cluster A TGF-b signature score low ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-DV-5568 Stage I -2.849 not mutated 4 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-DV-5569 Stage I -2.602 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-DV-5573 Stage I -1.614 not mutated 2 Cluster B TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-DV-5574 Stage I -1.944 not mutated 4 Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-DV-5575 Stage I -0.709 not mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-DV-5576 Stage I -0.462 not mutated 2 Cluster A TGF-b signature score low ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-DV-A4VX Stage IV -0.133 not mutated 4 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-DV-A4VZ Stage I -0.627 not mutated 2 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-DV-A4W0 Stage I -0.462 not mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-EU-5904 Stage I -1.120 mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-EU-5905 Stage I 0.526 mutated 5 Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-EU-5906 Stage I -0.462 mutated 4 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-EU-5907 Stage III 1.678 mutated 7 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-G6-A5PC Stage IV -0.544 not mutated 6 Cluster B TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
TCGA-G6-A8L6 Stage IV -0.462 not mutated 4 Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-G6-A8L7 Stage I 1.678 not mutated 5 Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-G6-A8L8 Stage I 0.114 not mutated 3 Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-GK-A6C7 Stage I 1.267 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-MM-A563 [Discrepancy] -1.614 not mutated 4 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-MM-A564 Stage II 0.608 not mutated 3 Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
TCGA-MM-A84U Stage I -0.215 not mutated 4 Cluster C TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
TCGA-MW-A4EC Stage I 0.938 not mutated 2 Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
TCGA-T7-A92I Stage I -1.120 not mutated 2 Cluster B TGF-b signature score low ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
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Patient 
CSS 
months 
CSS 
event 
ccRCC 
early 
score 
ccRCC early Score - 3 risk 
groups 
ccRCC early Score - 2 
risk groups 
ccRCC score ccRCC Score - 3 risk groups 
ccRCC Score - 2 risk 
groups 
Grade Gender 
EGAR00001121490_ccRCC-1-tumor 111 0 -1.3265 Intermediate Risk Low Risk -1.4392 Intermediate Risk Low Risk G3 F 
EGAR00001121491_ccRCC-2-tumor 73 1 -1.6033 Low Risk Low Risk -0.1187 Intermediate Risk High Risk G3 M 
EGAR00001121492_ccRCC-3-tumor 8 1 0.0812 High Risk High Risk 0.0881 Intermediate Risk High Risk G1 + G2 M 
EGAR00001121493_ccRCC-4-tumor 9 1 -1.2060 Intermediate Risk Low Risk -1.3085 Intermediate Risk Low Risk G3 M 
EGAR00001121494_ccRCC-5-tumor 98 0 -1.6090 Low Risk Low Risk -1.7457 Low Risk Low Risk G1 + G2 M 
EGAR00001121495_ccRCC-6-tumor 94 0 -1.6239 Low Risk Low Risk -1.7620 Low Risk Low Risk G1 + G2 M 
EGAR00001121496_ccRCC-7-tumor 11 0 -0.9036 Intermediate Risk Low Risk -0.9804 Intermediate Risk Low Risk G4 F 
EGAR00001121497_ccRCC-8-tumor 80 0 -1.4044 Intermediate Risk Low Risk -1.5238 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121498_ccRCC-9-tumor 12 1 1.0406 High Risk High Risk 2.7498 High Risk High Risk G4 M 
EGAR00001121499_ccRCC-10-tumor 3 1 1.3218 High Risk High Risk 3.0550 High Risk High Risk G4 M 
EGAR00001121500_ccRCC-11-tumor 79 0 -1.7124 Low Risk Low Risk -1.8579 Low Risk Low Risk G1 + G2 M 
EGAR00001121501_ccRCC-12-tumor 30 0 -1.5725 Low Risk Low Risk -1.7062 Low Risk Low Risk G1 + G2 M 
EGAR00001121502_ccRCC-13-tumor 18 1 0.8895 High Risk High Risk 0.9651 High Risk High Risk G3 F 
EGAR00001121503_ccRCC-14-tumor 76 0 -0.2040 Intermediate Risk High Risk -0.2213 Intermediate Risk High Risk G1 + G2 M 
EGAR00001121504_ccRCC-15-tumor 69 1 -0.9072 Intermediate Risk Low Risk -0.9844 Intermediate Risk Low Risk G1 + G2 F 
EGAR00001121505_ccRCC-16-tumor 73 0 -0.9638 Intermediate Risk Low Risk -1.0457 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121506_ccRCC-17-tumor 74 0 -2.3761 Low Risk Low Risk -2.5781 Low Risk Low Risk G1 + G2 F 
EGAR00001121507_ccRCC-18-tumor 71 0 -1.4420 Intermediate Risk Low Risk -1.5645 Intermediate Risk Low Risk G1 + G2 F 
EGAR00001121508_ccRCC-19-tumor 70 0 -0.2870 Intermediate Risk High Risk -0.3114 Intermediate Risk High Risk NA F 
EGAR00001121509_ccRCC-20-tumor 31 0 -0.4391 Intermediate Risk High Risk 1.1445 High Risk High Risk G1 + G2 F 
EGAR00001121510_ccRCC-21-tumor 36 0 -1.6970 Low Risk Low Risk -1.8412 Low Risk Low Risk G1 + G2 M 
EGAR00001121511_ccRCC-22-tumor 11 1 -0.8584 Intermediate Risk Low Risk -0.9313 Intermediate Risk Low Risk G3 M 
EGAR00001121512_ccRCC-23-tumor 39 0 -1.5013 Intermediate Risk Low Risk -1.6289 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121513_ccRCC-24-tumor 25 1 0.1708 High Risk High Risk 0.1853 Intermediate Risk High Risk G1 + G2 M 
EGAR00001121514_ccRCC-25-tumor 45 0 -2.3976 Low Risk Low Risk -2.6014 Low Risk Low Risk G1 + G2 M 
EGAR00001121515_ccRCC-26-tumor 60 0 -1.7103 Low Risk Low Risk -1.8557 Low Risk Low Risk G1 + G2 M 
EGAR00001121516_ccRCC-27-tumor 53 0 -1.5494 Intermediate Risk Low Risk -1.6811 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121517_ccRCC-28-tumor 51 0 -1.2005 Intermediate Risk Low Risk -1.3025 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121518_ccRCC-29-tumor 57 0 -2.0845 Low Risk Low Risk -2.2616 Low Risk Low Risk G1 + G2 F 
EGAR00001121519_ccRCC-30-tumor 14 1 0.3192 High Risk High Risk 0.3463 Intermediate Risk High Risk G3 M 
EGAR00001121520_ccRCC-31-tumor 52 0 -2.0950 Low Risk Low Risk -2.2731 Low Risk Low Risk G1 + G2 M 
EGAR00001121521_ccRCC-32-tumor 44 1 0.2350 High Risk High Risk 0.2550 Intermediate Risk High Risk G1 + G2 M 
EGAR00001121522_ccRCC-34-tumor 51 0 -0.0921 Intermediate Risk High Risk 1.5209 High Risk High Risk G1 + G2 M 
EGAR00001121523_ccRCC-35-tumor 46 0 -1.2225 Intermediate Risk Low Risk -1.3264 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121524_ccRCC-36-tumor 47 0 0.3039 High Risk High Risk 0.3297 Intermediate Risk High Risk G1 + G2 M 
EGAR00001121525_ccRCC-37-tumor 50 0 -1.6083 Low Risk Low Risk -1.7449 Low Risk Low Risk G1 + G2 F 
EGAR00001121526_ccRCC-38-tumor 46 0 -2.0146 Low Risk Low Risk -2.1858 Low Risk Low Risk G1 + G2 M 
EGAR00001121527_ccRCC-39-tumor 30 0 -0.7494 Intermediate Risk High Risk -0.8131 Intermediate Risk Low Risk NA M 
EGAR00001121528_ccRCC-40-tumor 34 0 -1.8199 Low Risk Low Risk -1.9746 Low Risk Low Risk G1 + G2 M 
EGAR00001121529_ccRCC-41-tumor 18 1 1.8056 High Risk High Risk 1.9591 High Risk High Risk G4 M 
EGAR00001121530_ccRCC-42-tumor 39 0 0.3163 High Risk High Risk 0.3432 Intermediate Risk High Risk G1 + G2 M 
EGAR00001121531_ccRCC-43-tumor 35 0 -1.7597 Low Risk Low Risk -1.9093 Low Risk Low Risk G1 + G2 F 
EGAR00001121532_ccRCC-44-tumor 35 0 -1.5379 Intermediate Risk Low Risk -1.6686 Intermediate Risk Low Risk G1 + G2 F 
EGAR00001121533_ccRCC-45-tumor 34 0 -1.9776 Low Risk Low Risk -2.1457 Low Risk Low Risk G4 M 
EGAR00001121534_ccRCC-46-tumor 33 0 -1.2122 Intermediate Risk Low Risk -1.3152 Intermediate Risk Low Risk G3 M 
EGAR00001121535_ccRCC-48-tumor 33 0 -1.7549 Low Risk Low Risk -1.9041 Low Risk Low Risk G1 + G2 M 
EGAR00001121536_ccRCC-49-tumor 43 0 -0.8568 Intermediate Risk Low Risk -0.9297 Intermediate Risk Low Risk G3 M 
EGAR00001121537_ccRCC-50-tumor 30 0 0.4298 High Risk High Risk 0.4663 High Risk High Risk G1 + G2 M 
EGAR00001121538_ccRCC-51-tumor 47 0 -0.7865 Intermediate Risk Low Risk -0.8534 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121539_ccRCC-52-tumor 45 0 -0.9151 Intermediate Risk Low Risk 0.6280 High Risk High Risk G3 F 
EGAR00001121540_ccRCC-53-tumor 42 0 -2.2533 Low Risk Low Risk -2.4448 Low Risk Low Risk G1 + G2 M 
EGAR00001121541_ccRCC-54-tumor 40 0 -2.0502 Low Risk Low Risk -2.2245 Low Risk Low Risk G1 + G2 M 
EGAR00001121542_ccRCC-55-tumor 42 0 0.7395 High Risk High Risk 0.8024 High Risk High Risk G1 + G2 F 
EGAR00001121543_ccRCC-56-tumor 65 0 -1.1911 Intermediate Risk Low Risk -1.2923 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121544_ccRCC-58-tumor 37 0 -1.1287 Intermediate Risk Low Risk -1.2246 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121545_ccRCC-59-tumor 31 0 -1.7811 Low Risk Low Risk -1.9325 Low Risk Low Risk G1 + G2 M 
EGAR00001121546_ccRCC-60-tumor 49 0 -1.9838 Low Risk Low Risk -2.1524 Low Risk Low Risk G1 + G2 F 
EGAR00001121547_ccRCC-61-tumor 49 0 -1.3827 Intermediate Risk Low Risk -1.5002 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121548_ccRCC-62-tumor 54 0 -1.2249 Intermediate Risk Low Risk -1.3290 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121549_ccRCC-64-tumor 81 0 0.9335 High Risk High Risk 1.0128 High Risk High Risk G3 M 
EGAR00001121550_ccRCC-65-tumor 10 1 1.5244 High Risk High Risk 3.2747 High Risk High Risk G3 M 
EGAR00001121551_ccRCC-66-tumor 84 0 0.3397 High Risk High Risk 1.9894 High Risk High Risk G1 + G2 F 
EGAR00001121552_ccRCC-67-tumor 42 1 -2.0308 Low Risk Low Risk -2.2034 Low Risk Low Risk G3 M 
EGAR00001121553_ccRCC-68-tumor 88 0 -1.5059 Intermediate Risk Low Risk -1.6339 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121554_ccRCC-69-tumor 89 0 -1.1978 Intermediate Risk Low Risk -1.2996 Intermediate Risk Low Risk G3 M 
EGAR00001121555_ccRCC-70-tumor 18 1 0.3527 High Risk High Risk 2.0035 High Risk High Risk G3 M 
EGAR00001121556_ccRCC-71-tumor 72 0 -2.3644 Low Risk Low Risk -2.5654 Low Risk Low Risk G1 + G2 M 
EGAR00001121557_ccRCC-72-tumor 92 0 -1.8876 Low Risk Low Risk -2.0481 Low Risk Low Risk G3 M 
EGAR00001121558_ccRCC-73-tumor 88 0 -1.8685 Low Risk Low Risk -2.0273 Low Risk Low Risk G1 + G2 M 
EGAR00001121559_ccRCC-75-tumor 6 1 0.8896 High Risk High Risk 2.5860 High Risk High Risk G1 + G2 M 
EGAR00001121560_ccRCC-76-tumor 32 1 -0.5258 Intermediate Risk High Risk 1.0503 High Risk High Risk G1 + G2 F 
EGAR00001121561_ccRCC-77-tumor 62 0 -1.7710 Low Risk Low Risk -1.9215 Low Risk Low Risk G1 + G2 M 
EGAR00001121562_ccRCC-78-tumor 87 0 -1.7984 Low Risk Low Risk -1.9512 Low Risk Low Risk G1 + G2 F 
EGAR00001121563_ccRCC-79-tumor 89 0 -1.9604 Low Risk Low Risk -2.1271 Low Risk Low Risk G3 M 
EGAR00001121564_ccRCC-80-tumor 100 0 -0.8139 Intermediate Risk Low Risk -0.8830 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121565_ccRCC-81-tumor 43 1 0.7416 High Risk High Risk 0.8047 High Risk High Risk G3 M 
EGAR00001121566_ccRCC-82-tumor 103 0 -1.8542 Low Risk Low Risk -2.0118 Low Risk Low Risk G3 M 
EGAR00001121567_ccRCC-83-tumor 10 0 -2.4165 Low Risk Low Risk -2.6218 Low Risk Low Risk G1 + G2 M 
EGAR00001121568_ccRCC-84-tumor 67 0 -1.9731 Low Risk Low Risk -2.1408 Low Risk Low Risk G3 M 
EGAR00001121569_ccRCC-85-tumor 111 0 -1.5051 Intermediate Risk Low Risk -1.6330 Intermediate Risk Low Risk G3 F 
EGAR00001121570_ccRCC-86-tumor 113 0 -2.6369 Low Risk Low Risk -2.8610 Low Risk Low Risk G3 F 
EGAR00001121571_ccRCC-87-tumor 79 0 -2.3586 Low Risk Low Risk -2.5591 Low Risk Low Risk G1 + G2 M 
EGAR00001121572_ccRCC-88-tumor 96 0 -1.6339 Low Risk Low Risk -1.7727 Low Risk Low Risk G1 + G2 M 
EGAR00001121573_ccRCC-89-tumor 117 0 -1.3530 Intermediate Risk Low Risk -1.4680 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121574_ccRCC-90-tumor 39 1 -0.8332 Intermediate Risk Low Risk -0.9040 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121575_ccRCC-91-tumor 63 1 -1.3065 Intermediate Risk Low Risk -1.4175 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121576_ccRCC-92-tumor 122 0 -1.8884 Low Risk Low Risk -2.0489 Low Risk Low Risk G1 + G2 M 
EGAR00001121577_ccRCC-93-tumor 122 0 -2.5353 Low Risk Low Risk -2.7508 Low Risk Low Risk G1 + G2 M 
EGAR00001121578_ccRCC-94-tumor 16 1 -1.5433 Intermediate Risk Low Risk -1.6745 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121579_ccRCC-95-tumor 132 0 -0.3513 Intermediate Risk High Risk -0.3812 Intermediate Risk High Risk G1 + G2 M 
EGAR00001121580_ccRCC-96-tumor 131 0 -2.0787 Low Risk Low Risk -2.2554 Low Risk Low Risk G1 + G2 M 
EGAR00001121581_ccRCC-97-tumor 33 1 -0.3882 Intermediate Risk High Risk 1.1996 High Risk High Risk G1 + G2 M 
EGAR00001121582_ccRCC-98-tumor 1 0 -2.6796 Low Risk Low Risk -2.9073 Low Risk Low Risk G3 M 
EGAR00001121583_ccRCC-99-tumor 111 0 0.4573 High Risk High Risk 0.4962 High Risk High Risk G1 + G2 F 
EGAR00001121584_ccRCC-100-tumor 142 0 -1.6210 Low Risk Low Risk -1.7587 Low Risk Low Risk G1 + G2 M 
EGAR00001121585_ccRCC-102-tumor 142 0 -1.5620 Intermediate Risk Low Risk -1.6948 Intermediate Risk Low Risk G1 + G2 M 
EGAR00001121586_ccRCC-103-tumor 145 0 -1.4122 Intermediate Risk Low Risk -1.5322 Intermediate Risk Low Risk G1 + G2 F 
EGAR00001121587_ccRCC-104-tumor 116 0 -2.0876 Low Risk Low Risk -2.2650 Low Risk Low Risk G1 + G2 F 
EGAR00001121588_ccRCC-105-tumor 73 0 -2.0656 Low Risk Low Risk -2.2411 Low Risk Low Risk G1 + G2 M 
EGAR00001121589_ccRCC-106-tumor 63 1 -1.6829 Low Risk Low Risk -1.8259 Low Risk Low Risk G1 + G2 M 
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Patient Stage 
Standardized 
Age 
New 
Metastases 
VHL nonsyn 
mutation 
Beleut 
signature (A 
vs. B vs. C) 
Boström signature 
ClearCode34 
signature 
Kosari signature Lane signature Zhao signature 
EGAR00001121490_ccRCC-1-tumor I -0.215 yes mutated Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121491_ccRCC-2-tumor IV 0.855 yes not mutated Cluster B TGF-b signature score high ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121492_ccRCC-3-tumor III 0.855 yes mutated Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121493_ccRCC-4-tumor I 1.761 yes not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121494_ccRCC-5-tumor I 1.349 yes mutated Cluster C TGF-b signature score high ccA signature Aggressive subgroup Aggressive subgroup Cluster 1 (good) 
EGAR00001121495_ccRCC-6-tumor I 1.184 no mutated Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121496_ccRCC-7-tumor II 2.172 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121497_ccRCC-8-tumor I 1.020 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121498_ccRCC-9-tumor IV 1.184 yes mutated Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121499_ccRCC-10-tumor IV 1.267 yes mutated Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121500_ccRCC-11-tumor I 1.267 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121501_ccRCC-12-tumor I 1.596 no mutated Cluster B TGF-b signature score low ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121502_ccRCC-13-tumor III -1.367 yes mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121503_ccRCC-14-tumor III -0.215 yes mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121504_ccRCC-15-tumor II 0.361 no mutated Cluster B TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121505_ccRCC-16-tumor II -1.038 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121506_ccRCC-17-tumor I -0.544 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121507_ccRCC-18-tumor I -0.380 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121508_ccRCC-19-tumor II -1.779 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121509_ccRCC-20-tumor IV -0.380 yes mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121510_ccRCC-21-tumor I 0.773 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121511_ccRCC-22-tumor III 0.279 yes mutated Cluster C TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121512_ccRCC-23-tumor I 0.938 no not mutated Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121513_ccRCC-24-tumor III 2.502 no mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121514_ccRCC-25-tumor I 0.361 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121515_ccRCC-26-tumor I -0.791 no mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121516_ccRCC-27-tumor I -0.380 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121517_ccRCC-28-tumor I -0.133 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121518_ccRCC-29-tumor I 1.020 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121519_ccRCC-30-tumor II 0.279 yes mutated Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121520_ccRCC-31-tumor I 1.184 no not mutated Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121521_ccRCC-32-tumor II -0.462 yes not mutated Cluster C TGF-b signature score high ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121522_ccRCC-34-tumor IV 0.361 yes mutated Cluster B TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121523_ccRCC-35-tumor I 0.526 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121524_ccRCC-36-tumor II -0.133 no mutated Cluster C TGF-b signature score high ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
EGAR00001121525_ccRCC-37-tumor I 1.020 no not mutated Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121526_ccRCC-38-tumor I -0.050 yes not mutated Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121527_ccRCC-39-tumor II 1.020 no mutated Cluster B TGF-b signature score high ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
EGAR00001121528_ccRCC-40-tumor I 0.361 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121529_ccRCC-41-tumor III 1.761 yes not mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121530_ccRCC-42-tumor III 1.020 no not mutated Cluster A TGF-b signature score high ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121531_ccRCC-43-tumor I -0.462 no not mutated Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121532_ccRCC-44-tumor I -0.380 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121533_ccRCC-45-tumor I 0.032 no not mutated Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121534_ccRCC-46-tumor I 0.032 no mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121535_ccRCC-48-tumor I -1.532 no not mutated Cluster A TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121536_ccRCC-49-tumor III 0.279 no mutated Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121537_ccRCC-50-tumor III 0.608 no mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121538_ccRCC-51-tumor III 0.773 no mutated Cluster B TGF-b signature score high ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
EGAR00001121539_ccRCC-52-tumor IV 0.444 yes mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121540_ccRCC-53-tumor I 0.691 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121541_ccRCC-54-tumor I -0.297 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
EGAR00001121542_ccRCC-55-tumor III -0.215 yes mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121543_ccRCC-56-tumor I 1.431 no mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121544_ccRCC-58-tumor I 0.114 no mutated Cluster B TGF-b signature score high ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121545_ccRCC-59-tumor I -0.380 no mutated Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
EGAR00001121546_ccRCC-60-tumor I 1.431 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121547_ccRCC-61-tumor I -0.380 no mutated Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121548_ccRCC-62-tumor I 1.431 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121549_ccRCC-64-tumor III -0.215 no mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121550_ccRCC-65-tumor IV 0.197 yes mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121551_ccRCC-66-tumor IV 1.020 yes mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
EGAR00001121552_ccRCC-67-tumor I -0.133 yes mutated Cluster B TGF-b signature score high ccA signature Aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121553_ccRCC-68-tumor I 0.691 no mutated Cluster C TGF-b signature score high ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121554_ccRCC-69-tumor I 1.596 yes mutated Cluster B TGF-b signature score high ccA signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121555_ccRCC-70-tumor IV 0.773 yes not mutated Cluster A TGF-b signature score low ccB signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
EGAR00001121556_ccRCC-71-tumor I 0.938 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121557_ccRCC-72-tumor I -2.108 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121558_ccRCC-73-tumor I -0.380 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121559_ccRCC-75-tumor IV -0.215 yes mutated Cluster C TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121560_ccRCC-76-tumor IV 1.678 yes not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121561_ccRCC-77-tumor I -1.614 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121562_ccRCC-78-tumor I 0.773 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121563_ccRCC-79-tumor I -2.108 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121564_ccRCC-80-tumor II 0.773 yes mutated Cluster B TGF-b signature score high ccA signature Aggressive subgroup Indolent subgroup Cluster 2 (poor) 
EGAR00001121565_ccRCC-81-tumor III 1.020 yes not mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121566_ccRCC-82-tumor I -0.627 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121567_ccRCC-83-tumor I 0.938 no mutated Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121568_ccRCC-84-tumor I 0.691 no not mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121569_ccRCC-85-tumor I 1.020 yes mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121570_ccRCC-86-tumor I 1.102 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121571_ccRCC-87-tumor I -1.697 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121572_ccRCC-88-tumor I 0.279 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121573_ccRCC-89-tumor I -0.133 no not mutated Cluster B TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 2 (poor) 
EGAR00001121574_ccRCC-90-tumor I 0.938 no not mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121575_ccRCC-91-tumor I 0.526 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121576_ccRCC-92-tumor I -0.133 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121577_ccRCC-93-tumor I -0.050 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121578_ccRCC-94-tumor I 0.691 yes mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121579_ccRCC-95-tumor I -0.133 yes mutated Cluster A TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121580_ccRCC-96-tumor I -0.709 no not mutated Cluster B TGF-b signature score high ccA signature Non-aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121581_ccRCC-97-tumor IV -1.697 yes mutated Cluster C TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121582_ccRCC-98-tumor I -0.544 no not mutated Cluster B TGF-b signature score high ccB signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121583_ccRCC-99-tumor II -0.050 no mutated Cluster A TGF-b signature score low ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121584_ccRCC-100-tumor I 0.361 yes mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121585_ccRCC-102-tumor I -0.627 no mutated Cluster B TGF-b signature score high ccB signature Aggressive subgroup Aggressive subgroup Cluster 2 (poor) 
EGAR00001121586_ccRCC-103-tumor I -0.462 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121587_ccRCC-104-tumor I -0.709 no not mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121588_ccRCC-105-tumor I -0.133 no mutated Cluster A TGF-b signature score low ccA signature Non-aggressive subgroup Indolent subgroup Cluster 1 (good) 
EGAR00001121589_ccRCC-106-tumor I -0.215 no mutated Cluster A TGF-b signature score low ccB signature Non-aggressive subgroup Aggressive subgroup Cluster 1 (good) 
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